EA046405B1 - FUNGICIDAL COMPOSITIONS - Google Patents

Description

The present invention relates to new fungicidal compositions, their use in agriculture or plant production for the control of diseases caused by phytopathogens, especially phytopathogenic fungi, and methods for controlling diseases of beneficial plants.

WO 2010/012793, WO 2017/207362 and WO 2019/105933 describe thiazole derivatives as pesticides.

Although many fungicidal compounds and compositions belonging to various distinct chemical classes have been/continue to be developed for use as fungicides on crops of beneficial plants, crop tolerance and activity against certain plant pathogenic fungi has not always met the needs of agricultural practices in many respects. Therefore, there is a constant need to find new compounds and compositions characterized by superior biological properties for use in controlling or preventing plant infestation by phytopathogenic fungi. For example, compounds with higher biological activity, a preferred spectrum of activity, an increased safety profile, improved physicochemical properties, and increased biodegradability. Or in other words, compositions having a broader spectrum of activity, improved crop tolerance, synergistic interactions or potentiating properties, or compositions that exhibit a faster onset of action, or that have a longer residual activity, or that provide reduced application rates and/or reducing application rates of compounds and compositions required for effective plant pathogen control, thereby enabling effective resistance management practices, reducing environmental impact and reducing operator exposure.

The use of compositions containing mixtures of different fungicidal compounds having different mechanisms of action may address some of these needs (eg, by combining fungicides with different activity spectra).

According to the present invention, there is provided a fungicidal composition containing a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I):

where X represents N;

Y represents C-F or C-H;

R ¹ represents hydrogen, ^-^-alkyl, ^-^-alkoxy, C ₁ -C ₃ -haloalkyl, C1-C3-hydroxyalkyl, C ₁ -C ₃ -alkoxy-C ₁ -C ₄ -alkyl, ^-^- cycloalkyl, ^^-alkoxy-^^-alkoxy, C1-C3al^^^arbon^^^-alkyl, ^^-alkoxycarbonyloxy-^^-alkyl, ^^-alkycarbonyloxy-^^alkyl, ^-^-alkynyloxy, C ₁ -C ₃ -alkylsulfanyl, diethylamino, phenyl, benzyl, phenoxy, benzyloxy-^^-alkyl, thienyl or furanyl;

R ² represents ^-^-alkyl, ^-^-alkoxy, C ₁ -C ₄ -haloalkyl or HC(O)NH-;

R ³ represents C ₃ -C ₆ -cycloalkyl, where the cycloalkyl groups are optionally substituted by 1 or 2 groups represented by R ⁴ , or R ³ represents a 6-10 membered non-aromatic spirocyclic carbobicyclyl ring system;

R ⁴ represents ^-^-alkyl;

or a salt or N-oxide thereof; and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole, raz, fenpropidine, fenpropimorph, fluxapyroxade , fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, trinexepak-ethyl, fosetyl-aluminum chloride, lonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]- M-ethyl-Mmethylformamidine (this compound can be obtained using the methods described in WO 2016/202742); N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-M-ethyl-M-methylformamidine (this compound can be prepared using the methods described in WO 2016/202688); N-(1-benzyl-1,3- 1 046405 dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide (these compounds can be prepared using the methods described in WO 2017/153380); 1-(6,7dimethylpyrazolo[1,5-pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline (these compounds can be obtained using the methods described in WO 2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3, 3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl1-(4-methylbenzimidazol-1-yl)isoquinoline (these compounds can be prepared using the methods described in WO 2016/156085); N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-( 1 -methyl-2-propoxyethoxy)-3-pyridyl]-N-tth.i-Nmethylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N -isopropyl-Nmethylformamidine (these compounds can be obtained using the methods described in WO 2015/155075); N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-Nmethylformamidine (this compound can be prepared using the methods described in WO 2018/228896); Nmethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy -1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazol- 4-carboxylate, N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol-3-amine (data the compounds can be prepared using the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689); methyl (2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3methoxy-2-[ 2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate (these compounds can be prepared using the methods described in WO 2020/079111); methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl(2)-2-[5-[4(ethoxymethyl)thiazole -2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate , methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO® (i.e. Bacillus amyloliquefaciens, strain FZB24), Timorex Gold™ (a plant extract containing tea tree oil) and methylpicoxamide.

Generally, the weight ratio of component (A) to component (B) may preferably be 100:1 to 1:100, 50:1 to 1:50, 20:1 to 1:40, 15:1 to 1 :30, 12:1 to 1:25, 10:1 to 1:20, 5:1 to 1:15, 3:1 to 1:10 or 2:1 to 1:5.

Additionally, the present invention provides a method for controlling or preventing phytopathogenic diseases of useful plants or their propagation material, especially those caused by phytopathogenic fungi, which includes applying a fungicidal composition in accordance with the present invention to useful plants, their habitat or their propagation material. reproduction.

The benefits provided by certain fungicide mixture compositions according to the present invention may also include, inter alia, preferential levels of biological activity for plant protection against diseases caused by fungi, or superior properties for use as agrochemical active ingredients (e.g., more high biological activity, preferred spectrum of activity, improved safety profile, improved physicochemical properties or increased biodegradability).

The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compounds may occur in optically isomeric forms, i.e. enantiomeric or diastereomeric forms. Also, as a result of limited rotation around a single bond, atropisomers can occur. The present invention includes all such possible isomeric forms of the compound of formula (I) (eg geometric isomers) and mixtures thereof. The present invention includes all possible tautomeric forms of the compound of formula (I), as well as the racemic compound, i.e. a mixture of at least two enantiomers in a ratio of approximately 50:50.

In each case, the compounds of formula (I) according to the present invention are in free form, in oxidized form as an N-oxide or in salt form, for example an agronomically useful salt.

- 2 046405

N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen-containing heteroaromatic compounds. They are described, for example, in the book Heterocyclic N-oxides by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.

Preferred groups and meanings for substituents in the compounds of formula (I) in any combination thereof are as follows.

Y represents C-F or C-H. In one set of embodiments, Y is C-F. In another set of embodiments, Y is C-H.

X represents N.

R ¹ represents hydrogen, C ₁ -C ₃ -alkyl, C ₁ -C ₃ -alkoxy, C ₁ -C ₃ -haloalkyl, C ₁ -C ₃ hydroxyalkyl, C ₁ -C ₃ -alkoxy-C ₁ -C ₄ -alkyl, C ₃ -C ₄ -cycloalkyl, C ₁ -C ₂ -alkoxy-C ₁ -C ₂ -alkoxy, C ₁ -C ₃ alkoxycarbonyl-C ₁ -C ₃ -alkyl, C ₁ -C ₂ -alkoxycarbonyloxy- C ₁ -C ₂ -alkyl, C ₁ -C ₂ -alkycarbonyloxy-C ₁ -C ₂ alkyl, C ₃ -C ₄ -alkynyloxy, C ₁ -C ₃ -alkylsulfanyl, diethylamino, phenyl, benzyl, phenoxy, benzyloxy-Cr C ₂ click, thienyl or furanyl.

Preferably R ¹ is hydrogen, methyl, ethyl, isopropyl, methoxy, ethoxy, fluoromethyl, chloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-hydroxyethyl, methoxymethyl, 1-methoxyethyl, 1-ethoxymethyl, 1-methoxy-1-methylethyl , cyclopropyl, methoxyethoxy, ethoxycarbonyl, 2-methoxy-2oxoethyl, 2-methoxyoxoethyl, 2-methoxyoxopropyl, propargyloxy, 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl, 1-methylcarbonyloxyethyl, methylcarbonyloxymethyl, methylsulfanyl, ethylsulfanyl, isopropylsulfanyl, , phenyl, benzyl, phenoxy, benzyloxymethyl , 1benzyloxyethyl, 2-furanyl or 2-thiophenyl.

More preferably, R ¹ is hydrogen, methyl, ethyl, isopropyl, methoxy, ethoxy, fluoromethyl, 2,2,2-trifluoroethyl, 1-hydroxyethyl, 1-ethoxymethyl, cyclopropyl, methoxyethoxy, 2-methoxy2-oxoethyl, 2-methoxyoxoethyl, 2-methoxyoxopropyl, propargyloxy, 1-methoxycarbonyloxyethyl, 1ethoxycarbonyloxyethyl, 1-methylcarbonyloxyethyl, methylcarbonyloxymethyl, isopropylsulfanyl, diethylamino, phenyl, benzyl, phenoxy, benzyloxymethyl, 1-benzyloxyethyl, 2-furanyl or 2-thiophenyl.

R ² represents ^-^-alkyl, ^-^-alkoxy, C ₁ -C ₄ -haloalkyl or HC(O)NH-. Preferably R ¹ represents ^-^-alkyl or ^-^-alkoxy. More preferably, R ¹ is methyl or methoxy.

R ³ represents C ₃ -C ₆ -cycloalkyl, where the cycloalkyl groups are optionally substituted by 1 or 2 groups represented by R ⁴ , or R ³ represents a 6-10 membered non-aromatic spirocyclic carbobicyclyl ring system.

Preferably, R ³ is C ₃ -C ₄ -cycloalkyl, wherein the cycloalkyl groups are optionally substituted by 1 or 2 groups represented by R ⁴ , or R ³ is a 6-8 membered non-aromatic spirocyclic carbobicyclyl ring system.

More preferably, R ³ is cyclobutyl, 2,2-dimethylcyclobutyl or spiro[3.4]octanyl and most preferably cyclobutyl, 2,2-dimethylcyclobutyl or spiro[3.4]octan-3yl.

R ⁴ represents ^-^-alkyl. Preferably R ⁴ is methyl, ethyl or isopropyl. More preferably, R ⁴ is methyl.

Preferably component (A) is a compound selected from:

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]acetate (connection X.01);

[2-[[4-(cyclobutylcarbamoyl)-5-methylthiazol-2-yl]-(2,6-difluoro-4pyridyl)amino]-1-methyl-2-oxoethyl]ethyl carbonate (compound X. 02);

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]methyl carbonate (H.OZ connection);

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate (connection X.04);

2-[(2,6-difluoro-4-pyridyl)-(2-hydroxypropanoyl)amino]-5-methyl-7Uspiro[3.4]octan-3-ylthiazol-4-carboxamide (compound X.05);

2-[2-benzyloxypropanoyl-(2,6-difluoro-4-pyridyl)amino]-A-cyclobutyl-5methylthiazol-4-carboxamide (compound X.06);

TV ring of butyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxypropanoyl)amino]-5methylthiazol-4-carboxamide (compound X.07);

- 3 046405

[2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2-oxoethyl]acetate (compound X.08) ;

2-[(2,6-difluoro-4-pyridyl)-(2-phenylacetyl)amino]-A-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.09);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methoxy-7Y-spiro[3.4]octan-3ylthiazol-4-carboxamide (compound X.10);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-7Y-spiro[3.4]octan3-ylthiazol-4-carboxamide (compound X.11);

TV ring of butyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5methylthiazol-4-carboxamide (compound X.12);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-A-cyclobutyl-5-methylthiazol-4carboxamide (compound X.13);

2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-A-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 14);

2-[(2,6-difluoro-4-pyridyl)-(2-ethoxyacetyl)amino]-A-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.15);

2-[diethylcarbamoyl-(2,6-difluoro-4-pyridyl)amino]-A-(2,2-dimethylcyclobutyl)5-methylthiazole-4-carboxamide (compound X.16);

2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-A-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.17);

methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-3-oxopropanoate (compound X.18);

2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 19);

methyl 5-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-5-oxopentanoate (compound X.20);

2-[(2,6-difluoro-4-pyridyl)-(3,3,3-trifluoropropanoyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (compound X.21);

8-isopropyl-M-(2,6-difluoro-4-pyridyl)-M-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2-yl]carbamothioate (compound X.22); methyl 4-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-4-oxobutanoate (compound X.23);

2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.24);

2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.25);

phenyl-X-(2,6-difluoro-4-pyridyl)-M-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate (compound X.26);

2-[(2,6-difluoro-4-pyridyl)-(2-fluoroacetyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.27);

2-methoxyethyl-M-(2,6-difluoro-4-pyridyl)-18G-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2-yl]carbamate (compound X.28);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-M-(2,2-dimethylcyclobutyl)5-methylthiazole-4-carboxamide (compound X.29);

ethyl-X-(2,6-difluoro-4-pyridyl)-M-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate (compound X.3O);

- 4 046405

2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.31);

methyl X-(2,6-difluoro-4-pyridyl)-X-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate (compound X.32);

2-[(2,6-difluoro-4-pyridyl)formylamino]-X-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.33);

ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2-oxoacetate (compound X.34);

2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-X-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.35);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-X-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.36);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-X-spiro[3.4]octan-3-ylthiazol4-carboxamide (compound X.37) and

2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (X. 3 8).

More preferably, component (A) is a compound selected from:

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]acetate (connection X.01);

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate (connection X.04);

L ^g -cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxypropanoyl)amino]-5methylthiazol-4-carboxamide (compound X.07);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-A-spiro[3.4]octan3-ylthiazol-4-carboxamide (compound C.I);

L ^g -cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5methylthiazol-4-carboxamide (compound X.12);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-7U-cyclobutyl-5-methylthiazol-4carboxamide (compound X.13);

2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-A-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 14);

2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-L ^g -(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.17);

methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-3-oxopropanoate (compound X.18);

2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 19);

8-isopropyl-T4-(2,6-difluoro-4-pyridyl)-M-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2-yl]carbamothioate (compound X.22);

2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-HS-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.24);

phenyl-M-(2,6-difluoro-4-pyridyl)-M-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate (compound X.26);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-M-(2,2-dimethylcyclobutyl)5-methylthiazole-4-carboxamide (compound X.29);

- 5 046405

2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-I-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.31);

2-[(2,6-difluoro-4-pyridyl)formylamino]-I-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.33);

ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2-oxoacetate (compound X.34);

2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-I-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.35);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-I-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.36);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-spiro[3.4]octan-3-ylthiazol4-carboxamide (compound X.37) and

2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (X. 3 8).

Even more preferably, component (A) is a compound selected from: [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol- 2yl]amino]-1-methyl-2-oxoethyl]acetate (compound X.01);

[2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate (connection X.04);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-A-spiro[3.4]octan3-ylthiazol-4-carboxamide (compound X. 11);

TV ring of butyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5methylthiazol-4-carboxamide (compound X.12);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-TU-cyclobutyl-5-methylthiazol-4carboxamide (compound X.13);

2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-A-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.17);

methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-3-oxopropanoate (compound X. 18);

2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-bT-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 19);

2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X.24);

- 6 046405

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-M-(2,2-dimethylcyclobutyl)5-methylthiazol-4-carboxamide a (compound X.29);

2-[(2,6-difluoro-4-pyridyl)formylamino]-M-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.33);

ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2-oxoacetate (compound X.34);

2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.35);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.36);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-M-spiro[3.4]octan-3-ylthiazol4-carboxamide (compound X.37) and

2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (X. 3 8).

Even more preferably, component (A) is a compound selected from: [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazole -2yl]amino]-1-methyl-2-oxoethyl]acetate (compound X.01);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-7Y-spiro[3.4]octan3-ylthiazol-4-carboxamide (compound X.11);

TV ring of butyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5methylthiazol-4-carboxamide (compound X.12);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-TU-cyclobutyl-5-methylthiazol-4carboxamide (compound X.13);

2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (compound X. 19);

2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-M-(2,2-dimethylcyclobutyl)5-methylthiazole-4-carboxamide (compound X.29);

2-[(2,6-difluoro-4-pyridyl)formylamino]-M-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.33);

2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide (compound X.35);

2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-M-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.36);

2-[acetyl-(2,6-d iforo-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-ylthiazol4-carboxamide (compound X.37) and

2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-M-(2,2dimethylcyclobutyl)-5-methylthiazol-4-carboxamide (X.38).

- 7 046405

Table X

Connection number Connection structure Name according to ShRAS X.01 J °\ n L/ 7/ / N—/ ⁿ 7/ H N-''^ _c /^CH ₃ H ₃ C / ^S / ^x o 0 H ₃ C [2 - [(2,6-difluoro-4-pyridyl) - [5 -methyl-4 (spiro [3,4]octan-3 -ylcarbamoyl)thiazol2-i l] amino] -1 -methyl-2-o xoethyl] acetate X.02 j °vP иА ζ~~ ^{Ν F} jv Ν-^Χς/^-СНз Н ₃ С / ^s / ^Х О О Н ₃ s [2-[[4-(cyclobutylcarbamoyl)-5methylthiazo l-2 -yl]-(2,6-difluoro-4 pyridyl)amino]-1-methyl-2oxoethyl]ethyl carbonate H.OZ 1 °\ Rkl N\ U—NL/ 7/ / Ν—( ^N L K ^N ₃ C / ^S / ^X o O o ^Ch CH ₃ [2 - [(2,6-difluoro-4-pyridyl) - [5 -methyl-4 (spiro[3,4]octan-3-ylcarbamoyl)thiazol- 2 -yl]amino]-1 -methyl-2 oxoethyl]methyl carbonate

- 8 046405

X.04 J °\ ja У—NL/ 7/ / N—( ^H A to Ν-^Χς/^СНз H ₃ C / ^S / ^X o O O H ₃ c [2 - [(2,6-difluoro-4-pyridyl) - [5 -methyl-4 (spiro [3,4]octan-3 -ylcarbamoyl)thiazol l2 -yl] amino] -1 -methyl-2 oxoethyl] ethyl carbonate X.05 I °\ Pr\ йА У—NL/ 7/ / N—/ ^{H f} ^aa to νΆ-/^ΟΗ ₃ H ₃ C / ^S / ^x o HO 2-[(2,6-difluoro-4-pyridyl)-(2hydroxypropanoyl)amino]-5-methyl-Aspiro[3,4]octan-3-ylthiazol-4carboxamide X.06 J °\ P N-Чч У-N ^ρ Ά=Α 7/Al d„/^CH ₃ ^H 3 ^C \7 O 2-[2-benzyloxypropanoyl-(2,6-difluoro4-pyridyl)amino]-\'-cyclobutyl-5methylthiazol-4-carboxamide X.07 I\___ ω /^Z ABOUT / \ '° A V o \ /—S iF o\ ω I x ω \ ____ V-ts and to the forehead til-2-[(2,6-difluoro-4 pyridyl)-(2-methoxypropanoyl)amino]5-methylthiazol-4-carboxamide X.08 /°^v to I°\ ω ω I X ZZ ω\ —> °\ ω I ω [2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2oxoethyl] acetate

- 9 046405

X.09 T O co i ^s . T ⁵ 1 ^w 2-[(2,6-difluoro-4-pyridyl)-(2phenylacetyl)amino]-A-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.10 J °\ /--NL / // / N—/ ^H J \YF ^Нз Ν^\θ/^Ο НзС-А _o 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]5-methoxy-A-spiro[3.4]octan-3-ylthiazol4-carboxamide X.ll I \ w \ 4P^ >Z-- ^z o ___ ω 1 ι xz ω \ ____ 2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5-venstyl-\spiro[3,4]octan-3-ylthiazol-4carboxamide X.12 /°^ C3— o \ Z—~ °V ω I I xz w\__-I V-ts and to the forehead til-2-[(2,6-difluoro-4 pyridyl)-(2-methoxyacetyl)amino]-5 methylthiazol-4-carboxamide X.13 *— *4 co 1 ⁵ 1 ^ω y° ^Ζ ***Ύ * 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]A-cyclobutyl-5-methylthiazol-4carboxamide

- 10 046405

X.14 O ___ ω 1 I IZ ω —i o—T ωq ZE ω 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4pyridyl)amino]-V-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.15 I ° J--^ ^{cH3 hCH} sn ^fAs 3^~ ^ch /yu H ₃ C 2-[(2,6-difluoro-4-pyridyl)-(2ethoxyacetyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.16 co I O co ^L—O 1— ”*4. с ⁵ 1 ^w z° /л ^Ζ \ О £ \ τ' 2 - [diethylcarbamoyl-(2,6-difluoro-4 pyridyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.17 ^Ω Λ >z^ ^z о ω 1 'у== ^: _Х ^о Z ^IZ ω \ - ° 1 « o I ω 2-[(2-chloroacetyl)-(2,6-difluoro-4pyridyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.18 £ ° ZK o I CO 1 °^v ^ZT I \_ VJ ^z f3^ ^zA C. °^-° _x o o co T methyl-3-[(2,6-difluoro-4-pyridyl)-[4[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino] -3 - oxopropanoate

- 11 046405

X.19 F N F [ΓΥ ppp/ 2-[(2,6-difluoro-4-pyridyl)-(furan-2carbonyl)amino]-X-(2,2dimethylcyclobutyl)-5-methylhyazol-4carboxamide X.20 I o o \ // °—¥ '-----i Ο -π /Ху Jpz 'τι I ^ω 1 o \/ ^x o <? methyl-5 - [(2,6-difluoro-4-pyridyl) - [4 [(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl] amino] -5 - oxopentanoate X.21 FNF XX N ,?H ₃ C - ^снз У 4V> ^F 1 СНз 2-[(2,6-difluoro-4-pyridyl)-(3,3,3trifluoropropanoyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.22 F _,hL _F XT ο^^,ν^^,ν__Л ⁵ n ₃ с .сз H ₃ CS ^S ~~\ X--<(y> 1 CH ₃ СНз 8-isopropyl-X-(2,6-difluoro-4-pyridyl)N-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamothioate X.23 :£ o /\ O ] τ' I °^χ ^ΗΙ \ τ' ο—ο methyl-4 - [(2,6-difluoro-4-pyridyl) - [4 [(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-4-oxobutanoate X.24 Ο -Π /Xu 1 o >Z ^x o t? 2 - [cyclopropanecarbonyl-(2,6-difluoro-4 pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide

- 12 046405

X.25 FX t ud / 7 ⁿ z ^s \/ ^СНз j τχνχ ιΐι ^СНз prop-2-ynyl-M-(2,6-difluoro-4-pyridyl)N-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate X.26 o O 1 £ 1 °^ ^ZI \ \T ZV b fsnyl-M-(2.6-difluoro-4-pyridyl)-M-|4[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate X.27 £ o /H o Ύ °<^ ^ΖΙ mg i_ o U- 2-[(2,6-difluoro-4-pyridyl)-(2fluoroacetyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.28 А А χτ ^Ο ·^ ^/Νχ ^· ^Ν \__ ^Н 3 ^С >у^ ^Нз 1 СНз СГ 1 СНз 2-methoxyethyl-M-(2,6-difluoro-4pyridyl)-N-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate X.29 ^F Ν ^F χτ °·^^· ^Ν \ ^-N /? ^N 3S SNz J CV L 1 SNz SNz 2-[(2,6-difluoro-4-pyridyl)-(2- methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide H.ZO ^F N. .P xt /?H ₃ C CHz .TALA 1 CHz H ₃ s^ eth and l-N-(2,6-difluoro-4-pyridyl)-N-[4 [(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate

- 13 046405

X.31 XX 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2carbonyl)amino]-KG-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.32 ___,NF XX H ₃ C ΓΊ3Ό \ ΓΊ CH3 methyl-N-(2,6-difluoro-4-pyridyl)-N-[4 [(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate H.ZZ FN .F XX °x/N. _N /7 ^НзС \/ ^СНз T Хр _йх > СНз 2-[(2,6-difluoro-4pyridyl)formylamino]-N-(2,2 dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.34 F N F XX o 1 SPr СНз ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]amino]-2-oxoacetate X.35 FNF χχ °X /°H ₃ C, ^CH 3 HI СНз 2-[benzoyl-(2,6-difluoro-4pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide X.36 FNF XX °<Y' ^N 'X^ ^N 4 ^Н з ^с к/ ^Нз CH ₃ \ СНз 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]N-(2,2-dimethylcyclobutyl)-5 methylthiazol-4-carboxamide X.37 XX °γ ^Ν 'γ' ^Ν , _ СНз N--/ \ η X/ ^CH 3 / ) 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]5-methyl-M-spiro[3.4]octan-3-ylthiazol-4carboxamide X.38 __Рн ₃ s H ₃ CT CH ₃ \ H Nz СНз 2-[(2,6-difluoro-4-pyridyl)-(2methylpropanoyl)amino]-N-(2,2dimethylcyclobutyl)-5-methylthiazol-4carboxamide

Preferably, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole, raz, fenpropidine, fenpropimorph, fluxapyroxade , fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bik-14 046405 safen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, trinexepak-ethyl, fosetyl aluminum, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, No-[2-chloro-4-(2-fluorophenoxy)- 5 -methylphenyl]-N-ethyl-Nmethylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1benzyl-1,3-dimethylbutyl)- 8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut- 3-enyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4, 4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4 ,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 - yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, I-[5-bromo -2-methyl-6(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)- 3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N- isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1- methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, N,N-dimethyl -1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy -2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-( 3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5 -[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-( 2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2- [5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3methoxyprop-2-enoate and methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazole -2-yl]phenoxy]prop2-enoate.

In another set of embodiments, component (B) is selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole, prochloraz, fenpropidine, fenpropimorph, fluxapyroxade , fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, trinexepak-ethyl, fosetyl-aluminum chloride, lonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl] -N-ethyl-Nmethylformamidine, N'-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1benzyl-1,3-dimethylbutyl)-8 - fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3 - enyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro- 3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4 ,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl) -4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, ^-^-bromo^-methyl -b(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl ]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N '-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy- 3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4- 15 046405 carboxylate, ^Ndimethyl-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2- [2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazole -1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2) -3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4 -(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2- (5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4 -bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl] phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide.

More preferably, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, , pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline tri, cyclazole, pyroquilone, cyflufenamide, metrafenone, ^ -[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-Nmethylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N -methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4 ,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7 -dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3, 3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazole -1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-χλορ- 2methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)-3 - pyridyl]-Ni-isopropyl-N-methylformamidine, N-isopropyl-N-[5-methoxy-2methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-[[4-[5(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy -3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5- (trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3- yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[ 2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1- yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy -2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl) triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5- cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol- 2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop- 2-enoate.

In another set of embodiments, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, flupyra, pidiflumetofen , isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, acibenzolarS-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, , quinofumelin, tricyclazole, pyroquilone, cyflufenamide, metrafenone , No.-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-No.ethyl-No. methylformamidine, No.-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-No.ethyl- N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4 ,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7 -dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5- 16 046405 trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1- (4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[ 5-χΛορ-2methyl-6 -(1 -methyl-2-propoxyethoxy)-3-pyridyl] -N -ethyl-N-methylformamidine, N'-[5 -bromo-2-methyl-6 -(1methyl-2- propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl] -N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-||4-|5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3- dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-( trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol- 4-carboxylate, N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2 -methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate , methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy ]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2 )-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5( trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide.

Even more preferably, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflu pyra, pidiflumetofen, isoflucipram , isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, she, No(1-benzyl1,3-dimethylbutyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a ]pyridin-3-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl )isoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3, 3-dimethylisoquinoline.

In a particularly preferred set of embodiments, component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyra , pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, vinofumelin, tricyclazole, pyroquilone, N-(1 - benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7 -dimethylpyrazolo[1,5-a]pyridin-3-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5dimethylbenzimidazol-1-yl)- 4,4-difluoro-3,3-dimethylisoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-isopropyl-N '-[5-methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methyl-picoxamide, methyl-(2)-3methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3 -methoxy-2-[2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate , methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy ]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)- 3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, Nmethoxy-N-[[4-[5-(trifluoromethyl)-1, 2,4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl -2-methyl-H-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea and

- 17 046405 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate.

The compounds constituting component (B) are listed herein and above under the so-called ISO common name or other common name used in individual cases or trade name. The compounds representing component (B) are well known and commercially available and/or can be prepared using procedures known in the art and/or procedures described in the literature.

In a preferred composition according to the present invention, component (A) is Compound No. X.01, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane- 3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]acetate, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprol, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide , oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N -ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline- 3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl) -8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3 ,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4, 6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4, 4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6- (1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl -N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy- 2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, No. ethyl-2 -methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl ]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol- 1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)- 2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazole -2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate , methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl) thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.04, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane -3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]tyl carbonate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin , trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pona, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl ]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl) -8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3 -enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro-3,3-dimethyl- 18 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro -3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1- methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N- methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl -4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, H-meth-oxy-H-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimeth-oxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, No. ethyl -2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 -yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, NH-dimethyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl )pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-( 2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-( 4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2 -enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop- 2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4 (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop -2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.07, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxypropanoyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, dinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5 -chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro -1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [^^ pyridinA -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4, 4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl- 1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[ 5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy )-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl] -N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N-2-dimethoxy-N-[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1, 3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl] pyrazole-4-carboxylate, N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine , methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2- [2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3 - methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy -2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2 -enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 19 046405 (2)-2-[5-(4-cyclohexylthiazol-2-yl )-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate , methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl- 5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1: thirty.

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-[(2,6-fluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-Mspiro[ 3.4]octan-3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorine otalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5chloro-2-methylphenyl]-M-ethyl-M-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1- (7-methylpyrazolo[1,5-a]pyridin3-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3 -dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl -2-propoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-ethyl- Nmethylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2-nropoxyethoxy)-3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isonropyl-N'-[5-methoxy-2 -methyl-4-(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4 -oxαdiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxαdiazol-3yl]phenyl]methyl]propanamide, N-ethyl- 2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol- 1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl- (2) -2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-( 4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2- enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl )thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.12, N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5-methylthiazol- 4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph , fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-( 2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformαmidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3 ,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6, 7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl

- 20 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline,

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy )-3-pyridyl]-Nethyl-Nmethylformamidine, propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine,

I-[5-chloro-2-methyl-6-(1-methyl-2I-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl|-H-isopropyl-H- methyl(|yurmamidine, N-isopropyl-N-[5-methoxy-2-methyl-4 (2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine,

N-MeTOKCn-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-[[4-[5(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide,

N-ethyl-2-methyl-N-[[4-[51-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, oxadiazol-3-yl]phenyl]methyl]urea , yl](enyl]methyl]pyrazole-4-carboxylate,

-ethyl-1-methoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 HNi dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3- methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3 -propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[ 4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)- 2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5- (4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl ]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-Ncyclobutyl-5methylthiazol-4-carboxamide, or its salt, enantiomer, tautomer or N-oxide, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, la-M, aminopyrifene, folpeta, ipflufenoquin, quinofumeline , tricyclazole, pyroquilone, cyflufenamide, metrafenone, I-[2-chloro-4-(2fluorophenoxy)-5-methylphenyl]-Nethyl-Nmethylformamidine, I-[4-(2-bromophenoxy)-5-chloro-2methylphenyl] -Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridine-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylyurazolo[1,5-a]pyridin3 -yl)isoquinoline, 1 - (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4, 4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3- dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-No.ethyl-No. methylformamidine, No. [5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nethyl-N methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl- 2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl] -Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide , 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, ^Ndimethyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2 -[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5 -(3 - propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2 )-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[ 4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2- (5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 21 046405 (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5 -(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2- yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N' -[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo [1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline , 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3 -pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5 -bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2 ,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]cyclopropanecarboxamide, K2-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Naethyl-2-methyl-N-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3- ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate , methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl (2)-2-[5-(3-isopropylpyrazole -1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-( 5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[ 5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3 -methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component ( B) ranges from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N' -[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl

- 22 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline,

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy )-3-pyridyl]-Nethyl-Nmethylformamidine, propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine,

I-[5-chloro-2-methyl-6-(1-methyl-2I-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl|-H-isopropyl-H- methyl(|yurmamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4 (2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine,

N-MeTOKCn-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-[[4-[5(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide,

N-ethyl-2-methyl-N-[[4-[51-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, oxadiazol-3-yl]phenyl]methyl]urea , yl](enyl]methyl]pyrazole-4-carboxylate,

-ethyl-1-methoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 HNi dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3- methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3 -propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[ 4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)- 2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl^)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-( 4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl] phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.18, methyl-3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-3-oxopropanoate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine , N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3dimethyl-1-( 7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3yl)-4,4,6-trifluoro-3,3 -dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3 ,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[[5-bromo-2-methyl-6-(1-methyl -2propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[ 5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4(2,2,2 -trifluoro-1-hydroxy-1-phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2 -dimethoxy^-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy- 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2, 4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z) -3-methoxy-2-[2-methyl-5-(3-πpropyliurazol-1-yl)phenoxy]prop-2enoate, methyl-^)-2-[5-(3-isopropylpyrazol-1-yl)-2 -methylphenoxy]-3-methoxyprop-2-enoate, methyl-^)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-^) -3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-^)-2-(5-cyclohexyl-2-methylphenoxy)3- methoxyprop-2-enoate, methyl-^)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 23 046405 (2)-2-[5-(4-cyclohexylthiazol-2 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2- methyl 5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorine otalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7dimethylpyrazolo[^^pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-( 4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6 -chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl ]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo -2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2 -trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide , K2-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl- 1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]- 1,2,4-triazol-3-amine, methyl (2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl -(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2- enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5- cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5- (4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy -2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) ranges from 15:1 to 1:30.

In a preferred composition according to the present invention, component (A) is Compound No. X.22, S-isopropyl-N-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl)carbamoyl ]-5-methylthiazol-2-yl]carbamothioate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole , hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide florilpicoxamide, yes, acibenzolarS-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-Nmethylformamidine , N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N -(1-benzyl-3,3,3-trifluoro-1-methylpropyl)8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline- 3 carboxamides, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4- 24 046405 difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,6- trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4, 4-difluoro-3,3dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5bromo-2-methyl-6-( 1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, Ν'-[5-χΛορ-2methyl-6 -(1 -methyl-2-propoxyethoxy)-3-pyridyl]-Ν -ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6 -(1methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, N-isopropyl-N-[5-methoxy- 2methyl-4-(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazole-3 -yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, No. ethyl-2-methyl-No. [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5- (3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2) -2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2) -2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy|-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl ]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of the component (A ) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.24, 2-[cyclopropanecarbonyl-(2,6-difluoro-4-ppripdyl)amino]-No.(2,2dimethylcyclobutyl)-5-methylthiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, acibenzolarD-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, uazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy )-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3, 3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a ]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5- dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4 -difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isopnoline, ^-^-bromo^-methyl-b-D-methyl^propoxyethoxy)-3-pyridyl]-N-ethyl-H -methylformamidine, ^-^-chloro^-methyl-b-D-methyl^propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, ^-^-bromo^-methyl-b-D-methyl^propoxyethoxy )-3-pyridyl]-N-isopropyl-N-methylformamidine, ^isopropyl-N'^-methoxy^-methylM(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3- dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-( trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol- 4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl (2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[ 2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop -2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy- 2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2- enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 25 046405 (2)-2-[5-(4-cyclohexylthiazol-2-yl) -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5 -[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30 .

In another preferred composition according to the present invention, component (A) is Compound No. X.26, phenyl-H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2dimethylcyclobutyl)carbamoyl] -5-methylthiazol-2-yl]carbamate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar-methyl chloride, lonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil N '-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 -benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7- methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)- 3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[ 5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2, 2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[ 4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2 -(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2 -[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2) -3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.29, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N' -[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl- 26 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro -3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1- methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N- methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl -4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, H-methoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl -N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl ]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl] phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2- [5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2 -yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl- (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4(ethoxymethyl)thiazol- 2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the ratio by weight component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.31, 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorine otalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7dimethylpyrazolo[1,5-3]pyridium-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7 -methylpyrazolo[1,5-a]pyrugin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline , 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy) -3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N- [5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2 ,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl ]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[ [4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea , 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl] phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-( 3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy ]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)- 2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 27 046405 ( 2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4(ethoxymethyl)thiazol-2 -yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl -(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of the component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.33, 2-[(2,6-difluoro-4-pyridyl)formylamino]-H-(2,2dimethylcyclobutyl)-5-methylthiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, uazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-( 2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3 ,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6, 7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5- a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5 -dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4, 4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H -ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2- methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro- 1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2- dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy -1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2 ,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2 )-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl) -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl -(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2 -methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4- cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2- [2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is between 15 :1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.34, ethyl-2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-2-oxoacetate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-S -methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline -3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl - 28 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro -3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1- methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N- methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl -4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, H-methoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]cyclopropanecarboxamide, N.2-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl- 2-methyl-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, ^H-dimethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl) pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4( ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide , where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.35, 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, oxathiapiproline, , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4 ,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]- N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2 -methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro -1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl -1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^H-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate , methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl (2)-2-[5-(3-isopropylpyrazole) -1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-( 5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 29 046405 (2)- 2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl] -2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2 )-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylarylpicoxamide, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.36, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, oxathiapiproline, , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, ^-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4 ,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]- N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2 -methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro -1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2 -dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1- methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2, 4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1, 2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl) )-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl- 2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4 -cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.37, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Spiro[3.4]octane- 3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole , fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, xathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl- M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, No.-[4 -(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl- 3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridine- 30 046405

-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol- 1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4 -difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-K -ethyl-Kmethylformamidine, K'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-K-ethyl-Kmethylformamidine, K'-[5-bromo-2- methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-K-isopropyl-Kmethylformamidine, K-isopropyl-K'-[5-methoxy-2-methyl-4-(2,2,2- trifluoro-1-hydroxy-1 phenylethyl)phenyl]-K-methylformamidine, K-methoxy-K-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, K ,2-dimethoxy-K-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, K-ethyl-2-methyl-K-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy -1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]pyrazol-4carboxylate, K,K-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] -1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol- 1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2- enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5 -cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5- (4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy -2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide, where the weight ratio of component (A) and component (B) ranges from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.38, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-K-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, K'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-K-ethyl-K-methylformamidine, N '-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-K-ethyl-K-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 -benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7- methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy) -3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N '-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl- 4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazole-3 -yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2 -methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl ]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl) pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4 -propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2- enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl- 31 046405 (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5- [4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold ™ and methylpicoxamide, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In a more preferred composition according to the present invention, component (A) is Compound No. X.01, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane -3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]acetate, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin , methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, , fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3 ,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3 -dimethyluzoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4, 5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15: 1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.04, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane -3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin , trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pona, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3 ,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3 ,3-dimethylusoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4, 4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.07, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxypropanoyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol- 1-yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-Nspiro[ 3.4]octan-3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpeta, ipflufenoquine,

- 32 046405 quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[^^pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5- dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.12, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5- dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, rifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3 dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflu- 33 046405 fenoquin, quinofumelin, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro -3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3, 3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.18, methyl-3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-3-oxopropanoate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3,dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1-methylpropyl)-8fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 4,4-difluoro -3,3-dimethyl-1-(7-methylpyrazolo[^^pyridin-3-yl)isoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3D -dimethyl-L^-methylpyrazoloCD^pyridin-3-yl^zoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazole -1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.22, S-isopropyl-N-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl) carbamoyl]-5-methylthiazol-2-yl]carbamothioate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, coseba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl- M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1- methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro- 3D-dimethyl-L^-methylpyrazoloCD^pyridin-3-yl^zoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5- dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.24, 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluin- 34 046405 dapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, lin, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8 -fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3- dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.26, phenyl-H-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl)carbamoyl] -5-methylthiazol-2-yl]carbamate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, propamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3, 3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.29, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.31, 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro3,3-dimethyl-1-(7-methylpyrazolo[N^pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.33, 2-[(2,6-difluoro-4-pyridyl)formylamino]-N-(2,2dimethylcyclobutyl)-5-methylthiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole,

- 35 046405 mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, ba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylnirazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro-3, 3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.34, ethyl-2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-2-oxoacetate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4, 4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30 .

In another preferred composition according to the present invention, component (A) is Compound No. X.35, 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, sonyl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 - (4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.36, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, sonyl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.37, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Spiro[3.4]octane- 3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloc

- 36 046405 systrobin, methyltetraprol, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, amide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide , oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl -3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [^^pyridinA -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5 -trifluoro3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 until 1:30.

In another preferred composition according to the present invention, component (A) is Compound No. X.38, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30.

In a preferred composition according to the present invention, component (A) is Compound No. X.01, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane- 3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]acetate, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprol, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide , oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N -ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline- 3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl) -8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [^^pyridinA -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-( 7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3- dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3, 3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy )-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine , Na-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-H-isopropyl-N-methylformamidine, Na-isopropyl-N'-[5-methoxy-2-methyl- 4-(2,2,2-trifluoro-1hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl] phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol3 -yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3 yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea , 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5 -(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate, N.N-dimethyl1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3 -yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3 methoxy-2-[2-methyl-5-[3 -(trifluoromethyl)pyrazol-1 -yl ]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate), methyl-(2)- 2-[5-(3-isopropylpyrazol-1-yl)-2methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl -(2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl-(2)-2-(5

- 37 046405 cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-cyclohexylthiazol-2-yl)-2methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4-(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]3-methoxyprop-2-enoate, methyl (2)-2-[5-(4- bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl ]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.04, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane -3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin , trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pona, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, ^-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl ]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl) -8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3 -enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4- difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4 ,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl) -4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl -6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl ]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'- [5-methoxy-2-methyl-4-(2,2,2-trifluoro-1hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, ^2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, No. ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3 -yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[ [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazole -1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl -(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5- (4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2 -enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2 -enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4( ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate and methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.07, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxypropanoyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, dinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5 -chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro -1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [1, 5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl

- 38 046405

1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3 ,3-dimethylisoquinoline,

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy )-3-pyridyl]-Nethyl-Nmethylformamidine, propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine,

I-[5-chloro-2-methyl-6-(1-methyl-2I-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl|-H-isopropyl-H- methyl(|yurmamidine, N-isopropyl-N-[5-methoxy-2-methyl-4 (2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine,

N-MeTOKCn-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy^-[[4-[5(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide,

N-ethyl-2-methyl-N-[[4-[51-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, oxadiazol-3-yl]phenyl]methyl]urea , yl](enyl]methyl]pyrazole-4-carboxylate,

-ethyl-1-methoxy-1-[[4-[5 -(trifluoromethyl)-1,2,4ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 HNi dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3- methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3 -propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[ 4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)- 2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5- (4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl ]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-[(2,6-fluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-No. spiro [3.4]octan-3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide acibenzolar^- methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil , cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-Nethyl-Nmethylformamidine, And -[4-(2-bromophenoxy)-5chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl -3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 - (6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7- methylirazolo[1,5-a]pyridin3 -yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3 -yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl-2- propoxyethoxy)-3-pyridyl]-N-'Trna-Nmethylformamidine, No.-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-No.ethyl-No. methylformamidine, No. -[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-( 2,2,2-trifluoro-1 -hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl] cyclopropanecarboxamide, N2-dimethoxy-N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl )-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl ]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]pyrazol-4carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2, 4-triazol3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2) -3-methoxy-2-[2-methyl-5 -(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-( 2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2- methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl- 39 046405 (2)-2-[5-(4 -cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2 -[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.12, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, oxonyl, cyprodinil, metalaxyl-M, aminopyrifene, folpet , ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-Nethyl-Nmethylformamidine, N'-[4-(2bromophenoxy)-5 -chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[^^pyridine^ -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4 ,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1 -(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5 -chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy) -3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]- N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, D2-dimethoxy-N-[[4-[5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3- dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-( trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea,ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol- 4-carboxylate, DNdimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl- (2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2- methyl 5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl (2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2 -enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2- [2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy] -3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2) -2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl )thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5) .

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[acetyl-(2,6-fluoro-4-pyridyl)amino]-N-cyclobutyl-5methylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, laxila-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-χλορ-4-(2fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N-[4-(2-bromophenoxy)-5- chloro-2methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo [N^pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylnirazolo[1,5-a]pyridin3 -yl)isoquinoline, 1 - (6,7-dimethylpyrazolo[1,5]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline,

- 40 046405

1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5 -bromo-2-methyl-6-( 1 -methyl-2- propoxyethoxy)-3-pyridyl] -Ν-μήλ-Νmethylformamidine, I-|5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|A-ethylAmethylformamidine, I-|5- bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl|A-isopropylAmethylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-(2,2,2-trifluoro -1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy- N[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[4-[5-(trifluoromethyl)-1,2,4 -oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1, 3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]pyrazol-4carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2- [2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3- methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy- 2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2- enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-( 2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5-[5 (trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1: 5).

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-No.(2,2dimethylcyclobutyl) -5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar-methyl, chlorothalonil, , mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-Nethyl-Nmethylformamidine, N'-[4 -(2bromophenoxy)-5-chloro-2-methylphenyl]-Nethyl-Nmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3 ,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6, 7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5- a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5 -dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4, 4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, No.-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-No. ethyl-Nmethylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-Nethyl-Nmethylformamidine, N-[5-bromo-2-methyl-6- (1-methyl-2propoxyethoxy)-3-pyridyl]-Nisopropyl-Nmethylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl )phenyl]-Nmethylformamidine, N-methoxy-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N-2-dimethoxy-N[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1.3 -dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole -4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl -(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2 -methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2 -[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate , methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy ]-3-methoxyprop-2-enoate, methyl-(/)-2-[5-[4- 41 046405 (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl -(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3-methoxy-2-[2-methyl-5- [5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-H-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolarD-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'- [4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl -3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1- (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3- pyridyl]-N-ethyl-N-methylformamidine, No-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, No-[5- bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridish ^l -N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2, 2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl] cyclopropanecarboxamide, K2-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3- ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, KH-dimethyl-1-[[4-[5-(tri(|)tormethyl)-1.2.4-oxadiazol-3yl]phenyl ]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2 -enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5-(3 -isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2 -(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2 -[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]- 2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2) -3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.18, methyl-3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-3-oxopropanoate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, acibenzolarD-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N- methylformamidine, N-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline- 3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3yl)-4,4,6-trifluoro- 3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4,5-trifluoro-3,3- 42 046405 dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)- 4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl- 6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H -ethyl-N-methylformamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridshL-N-isopropyl-N-methylformamidine, N-isopropyl-H'-[5-methoxy -2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-H-methylformamidine, N-methoxy-H-||4-|5(trifluoromethyl)-1,2, 4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N- ethyl-2-methyl-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1.3-dimethoxy-1-||4-|5-(tri(|)toromethyl)1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl -1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3-methoxy-2-[2-methyl-5-[ 3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate , methyl-^)-?-^-^-isopropylpyrazol-1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(^)3-methoxy-2-|2-methyl-5- (4-propyltriazol-2-yl)(()enoxy|prop-2-enoate. methyl-(^)-3-methoxy-2-|2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-^)-2-(5-cyclohexyl-2 -methylphenoxy)3-methoxyprop-2-enoate, methyl-^)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazole -2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop -2-enoate, methyl-^)-2-|5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-(^)-3-methoxy-2-|2 -methyl-5-|5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole , hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a), (luxapyroxad, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone) , (luindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, cyflufenamide, metrafenone, N'- [2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-(4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N -methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo 11,5-a]pyridin-3-yl)-4,4 ,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo [1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3, 3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2- methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl ]-H-isopropyl-N-methylformamidine, H-isopropyl-H'-|5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-H-methylformamidine , N-methoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3 -yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, C3-dimethoxyC -^-^-Cgrifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2, 4oxadiazol-3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, N,N -dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3 -methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-( 3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-^)-2-|5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-^ )3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl5-[4 -(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-^)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-^)-2-( 5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-(4- bromothiazol-2- 43 046405 yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2- yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.22, S-isopropyl-N-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl) carbamoyl]-5-methylthiazol-2-yl]carbamothioate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide acibenzolar^- methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil , cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine , N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N- (1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 -carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-( 7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3- dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3, 3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy )-3-pyridyl]-N-ethyl-N-methylformamidine, No.-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, No. -[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4( 2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N- [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5- (3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2) -2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2) -2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl ]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-( 2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is from 10 :1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.24, 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, oxathiapiproline, , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro - 44 046405

4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl] -N-ethyl-N-methyl(ormamidine, No-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, No-[ 5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methyl(ormamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4( 2,2,2-tri(|)tor-1-hydroxy-1-(|)enylethyl)(|)enyl|-H-methyl(|yurmamidine, N-MemoKcu-N-[[4-[5(trifluoromethyl )-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-guMeTOKCu-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3- methyl-1-[[4-[5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5- (trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3- yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-| |4-|5-(tri(|)tormethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3-methoxy-2 -[2-methyl-5-[3-(tri(tormethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1-yl)(enoxy]prop-2-enoate, methyl-^)-?-^^-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-O3-methoxy-2 -[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(^)-3-methoxy-2-|2-methyl5-[4-(trifluoromethyl)triazol- 2-yl]phenoxy]prop-2-enoate, methyl-(Z)-2-(5-cyclohexyl-2-methyl(enoxy)3-methoxyprop-2-enoate, methyl-(Z)-2-(5- cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methyl(enoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-(4- bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-(^)-3-methoxy-2-|2-methyl-5-|5(trifluoromethyl)thiazol-2-yl]phenoxy] prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.26, Phenyl-N-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl)carbamoyl| -5-methylthiazol-2-yl|carbamate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(loxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a, (luxapyroxad), (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapir, (enpicoxamide, (lorilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, (luazinam, (ludioxonil, cyprodinil, metalaxyl-M, aminopyri(ene, (olpeta, ip(lu(enoquina, quino(umelina) , tricyclazole, pyroquilone, cy(lu(enamide, metra(enone, N'-[2-chloro-4-(2-(tor(enoxy)-5-methyl(enyl]-N-ethyl-N-methyl(ormamidine , N'-(4-(2bromo(enoxy)-5-chloro-2-methyl(enyl]-N-ethyl-N-methyl(ormamidine, N-(1-benzyl-1,3-dimethylbutyl)-8( torquinoline-3-carboxamide, N-(1-benzyl-3,3,3-tri(tor-1-methylpropyl)-8-(torquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut -3-enyl)-8 -(torquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo|1,5-a]pyridin-3-yl)-4,4,5-tri(tor-3,3-dimethylisoquinoline , 4,4-di(tor-3,3-dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridine -3-yl)-4,4,6tri(tor-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-tri(tor-3,3-dimethylisoquinoline, 1 - (4,5-dimethylbenzimidazol-1 -yl)-4,4-di(tor-3,3-dimethylisoquinoline, 6-chloro4,4-di(tor-3,3-dimethyl-1-(4-methylbenzimidazol-1 -yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-chloro- 2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy) -3-pyridyl]-H-isopropyl-N-methyl(ormamidine, H-isopropyl-H'-|5-methoxy-2-methyl-4(2,2,2-tri(tor-1-hydroxy-1- (enylethyl)(enyl]-H-methyl(ormamidine, N-methoxy-H-||4-|5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]propanamide, N-ethyl-2-methyl-N-| |4-|5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]propanamide, 1-methoxy-3-methyl-1-||4-|5(tri(tormethyl )-1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(tri(tormethyl)1,2,4-oxadiazol-3 -yl](enyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(Ίri(tormethyl)-1,2,4oxadiazol-3-yl](enyl]methyl]urea, ethyl 1-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3yl](enyl]methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4- [5-(tri(tormethyl)-1,2,4-oxadiazol-3yl](enyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3-methoxy-2-[ 2-methyl-5-[3-(tri(tormethyl)pyrazol-1yl](enoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazole -1-yl)(enoxy]prop-2-enoate, methyl-O^-^-^-isopropylpyrazol-1 -yl)-2-methyl(enoxy]-3-methoxyprop-2-enoate, methyl-O3-methoxy-2 -[2-methyl-5-(4-propyltriazol-2-yl)(enoxy]prop-2-enoate, methyl-(^)-3-methoxy-2-|2-methyl5-[4-(tri(tormethyl )triazol-2-yl](enoxy]prop-2-enoate, methyl-O-2-(5-cyclohexyl-2-methyl(enoxy)3-methoxyprop-2-enoate, methyl-O-2-(5- cyclopentyl-2-methyl(enoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methyl(enoxy]-3-methoxyprop-2- enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methyl(enoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5 -(4-bromothiazol-2yl)-2-methyl(enoxy]-3-methoxyprop-2-enoate and methyl-(Z)-3-methoxy-2-[2-methyl-5-[5

- 45 046405 (trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 up to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.29, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-H-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N' -[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 - benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo [1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline , 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3 -pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5 -bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2-methyl-4(2,2 ,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]cyclopropanecarboxamide, K2-dimethoxy-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3- ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate , methyl (2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl (2)-2-[5-(3-isopropylpyrazole -1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop- 2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-( 5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[ 5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2- methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl (2)-3 -methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.31, 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorine otalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-( 1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3 - carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline , 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 -dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2- 46 046405 propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl- N-methyl(ormamidine, N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-N-methyl(ormamidine, Isopropyl-N'-N-methoxy ^-methylM(2,2,2-tri(|)tor-1-hydroxy-1-(|)enylethyl)(|)enyl|-H-methyl(|yurmamidine, N-MemoKcu-N-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, 102-dimethoxy-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy- 3-methyl-1-[[4-[5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 1,3-dimethoxy-1-[[4-[ 5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol- 3-yl]phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1 -||4-|5-(tri(|)tormethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3-methoxy -2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-^)-?-^^-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(^)3-methoxy -2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(^)-3-methoxy-2-|2-methyl5-[4-(trifluoromethyl) triαzol-2-yl]phenoxy]prop-2-enoate, methyl-(Z)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(Z)-2-(5- cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl- (Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-(4-bromothiαzol- 2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-(^)-3-methoxy-2-|2-methyl-5-|5(trifluoromethyl)thiazol-2-yl]phenoxy]prop- 2-enoate, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.33, 2-[(2,6-difluoro-4-pyridyl)formylamino]-N-(2,2dimethylcyclobutyl)-5-methylthiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a, (luxapyroxade, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapyra, (enpicoxamide) (lorilpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, (luazinam, (ludioxonil, cyprodinil, metalaxyl-M, aminopyri(ene, (olpeta, ip(lu(enoquina, quino(umelina, tricyclazole, pyroquilone, (lu(enamide, metra(enone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-(4-(2bromo(enoxy)- 5-chloro-2-methyl(enyl]-N-ethyl-N-methyl(ormamidine, N-(1-benzyl-1,3-dimethylbutyl)-8(torquinoline-3-carboxamide, N-(1-benzyl- 3,3,3-tri(tor-1-methylpropyl)-8-(torquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-(torquinoline-3 - carboxamide, 1-(6,7dimethylpyrazolo|1,5-a]pyridin-3-yl)-4,4,5-tri(tor-3,3-dimethylisoquinoline, 4,4-di(tor-3,3- dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6tri(tor -3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-tri(tor-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4 ,4-di(tor-3,3-dimethylisoquinoline, 6-chloro4,4-di(tor-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[[5-bromo -2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy )-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-H- methyl(ormamidine, N-isopropyl-H'-|5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformαmidine, N-methoxy-H -||4-|5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(tri(tormethyl )-1,2,4-oxadiazol-3-yl](enyl]methyl]propanamide, Eethyl^-methyl-H-^-^(tri(tormethyl)-1,2,4-oxadiazol-3-yl]( enyl]methyl]propanamide, 1-methoxy-3-methyl-1-||4-|5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 1,3 -dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5 -(Ίrifluoromethyl)-1,2,4oxadiazol-3-yl](enyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl](enyl] methyl]pyrazole-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiαzol-3yl](enyl]methyl]-1,2,4-triazole -3-amine, methyl-(Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl](enoxy]prop-2-enoate, methyl-(Z)-3 -methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-^)-2-|5-(3-isopropylpyrazol-1-yl)-2-methyl (enoxy]-3-methoxyprop-2-enoate, methyl-^)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(^ )-3-methoxy-2-|2-methyl5-[4-(trifluoromethyl)triαzol-2-yl]phenoxy]prop-2-enoate, methyl-^)-2-(5-cyclohexyl-2-methyl(enoxy )3-methoxyprop-2-enoate, methyl-^)-2-(5-cyclopentyl-2-methyl(enoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazole -2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methyl(enoxy]-3 -methoxyprop-2-enoate, methyl-^)-2-|5-(4-bromothiazol-2yl)-2-methyl(enoxy]-3-methoxyprop-2-enoate and methyl-(^)-3-methoxy- 2-|2-methyl-5-|5(tri(tormethyl)thiazol-2-yl](enoxy]prop-2-enoate, where the weight ratio of component (A) and component

- 47 046405 nent (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.34, ethyl-2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-2-oxoacetate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam , fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, ^-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-H-ethyl-H -methylformamidine, N'-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline -3-carboxamide, 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3, 3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro- 3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N-[5-bromo-2-methyl-6-(1-methyl -2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine , Na-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl-N-isopropyl-N-methylformamidine, Na-isopropyl-N'-[5-methoxy-2-methyl-4 (2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, Nmethoxy-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]cyclopropanecarboxamide, K2-dimethoxy-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, Nethyl-2-methyl-N- [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl] urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazol-4-carboxylate, ^Ndimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-(2)-2-[5- (3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl) phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2) -2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2) -2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl ]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl-( 2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is from 10 :1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.35, 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, oxathiapiproline, , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-[4- (2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3, 3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6 ,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7-methylpyrazolo[1,5 -a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4 ,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, ^-^-bromo^-methyl-b-C-methyl^propoxyethoxy)-3-pyridyl]-N-ethyl -N-methylformamidine, No-[5-chloro-2-methyl-6-(1-methyl-2- 48 046405 propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, No-[5- bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-H-methyl(ormamidine, N isopropyl-H'-[5-methoxy-2-methyl-4(2, 2,2-tri(|)tor-1-hydroxy-1-(|)enylethyl)(|)enyl|-H-methyl(|yurmamidine, N-MemoKcu-N-[[4-[5(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-guMeTOKCu-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl] methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl- 1-[[4-[5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl )1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl] phenyl]methyl]urea, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, KH-dimethyl-1-||4 -|5-(tri(|)tormethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(Z)-3-methoxy-2-[ 2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1- yl)phenoxy]prop-2-enoate, methyl-^)-?-^^-isopropylpyrazol-1 -yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(/)3-methoxy-2-[ 2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(/)-3-methoxy-2-|2-methyl5-[4-(trifluoromethyl)triazol-2- yl]phenoxy]prop-2-enoate, methyl-(Z)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(Z)-2-(5-cyclopentyl-2- methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-^^-p -p(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate and methyl-(/)-.3-methoxy-2-|2-methyl-5-|5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of the component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.36, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri(oxystrobin, methyltetraprole, di(enoconazole, hexaconazole, propiconazole, prothioconazole , me(entri(luconazole, (enpropidine, (enpropimor(a), (luxapyroxad, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapir, (enpicoxamide) , (lorilpicoxamide, acibenzolar-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, (luazinam, (ludioxonil, cyprodinil, metalaxyl-M, aminopyri(ene, (olpeta, ip(lu(enoquina, quino(umelina, tricyclazole, pyroquilone, cy(lu(enamide, metra(enone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N'-(4-(2bromo(enoxy) -5-chloro-2-methyl(enyl]-N-ethyl-N-methyl(ormamidine, N-(1-benzyl-1,3-dimethylbutyl)-8(torquinoline-3-carboxamide, N-(1-benzyl -3,3,3-tri(tor-1-methylpropyl)-8-(torquinoline-3 carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-(torquinoline-3 -carboxamide, 1-(6,7dimethylpyrazolo|1,5-a]pyridin-3-yl)-4,4,5-tri(tor-3,3-dimethylisoquinoline, 4,4-di(tor-3,3 -dimethyl1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6tri( tor-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-tri(tor-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)- 4,4-di(tor-3,3-dimethylisoquinoline, 6-chloro4,4-di(tor-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5-bromo -2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy )-3-pyridyl]-N-ethyl-N-methyl(ormamidine, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-H-isopropyl-H- methyl(ormamidine, N-isopropyl-H'-|5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-methoxy-H -||4-|5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5(tri(tormethyl )-1,2,4-oxadiazol-3-yl](enyl]methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(tri(tormethyl)-1,2,4-oxadiazole -3-yl](enyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(tri(tormethyl)-1,2,4-oxadiazol-3-yl](enyl]methyl ]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl](enyl]methyl]urea, 3-ethyl-1-methoxy-1- [[4-[5-(Ίfluoromethyl)-1,2,4oxadiazol-3-yl](enyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole -3yl](enyl]methyl]pyrazol-4-carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl](enyl]methyl]-1 ,2,4-triazol-3-amine, methyl-(Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1yl](enoxy]prop-2-enoate, methyl -(Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-^^-rD3-isopropylpyrazol-1-yl)-2-methyl (enoxy]-3-methoxyprop-2-enoate, methyl-^)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(Z )-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-^)-2-(5-cyclohexyl-2-methyl(enoxy )3-methoxyprop-2-enoate, methyl-^)-2-(5-cyclopentyl-2-methyl(enoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazole -2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-^)^-^(ethoxymethyl)thiazol-2-yl]-2-methyl(enoxy]-3-methoxyprop-2-enoate , methyl-(Z)-2-[5-(4-bromothiazol-2yl)-2-methyl(enoxy]-3-methoxyprop-2-enoate and methyl-(Z)-3-methoxy-2-[2- methyl 5-[5(tri(tormethyl)thiazol-2-yl](enoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

- 49 046405

In another preferred composition according to the present invention, component (A) is Compound No. X.37, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Mspiro[3.4]octane- 3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole , fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, xathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl- M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, ^-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, No.-[4 -(2-bromophenoxy)-5chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3 carboxamide, N-(1-benzyl- 3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide, 1 -( 6,7-dimethylpyrazolo[1,5-a]pyridin-3 yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo [1,5-a]pyridin3-yl)isoquinoline, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline , 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy )-3-pyridyl] ^-31^^methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-ethyl-Nmethylformamidine, N' -[5-bromo-2-methyl-6-(1-methyl-2-npropoxyethoxy)-3-pyridyl]-N-isopropyl-Nmethylformamidine, N-isonropyl-N'-[5-methoxy-2-methyl-4 -(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine, N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, N-ethyl-2-methyl- N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea , 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4-[5-( trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4carboxylate, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl]phenyl]methyl]-1,2,4-triazol3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl] phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2) - 2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2- yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl- (2)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl( 2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-[4(ethoxymethyl)thiazol-2 -yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl -(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) to component (B) is 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.38, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-M-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florilpicoxamide, acibenzolar^-methyl, chlorothalonil, zeba, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylformamidine, N '-[4-(2bromophenoxy)-5-chloro-2-methylphenyl]-N-ethyl-N-methylformamidine, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1 -benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide , 1-(6,7dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7- methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3- dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, N'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy) -3-pyridyl]-N-ethyl-N-methylformamidine, N'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, N '-[5-bromo-2-methyl-6-(1-methyl-2-50 046405 propoxyethoxy)-3-pyridyl]-N-isopropyl-N-methylformamidine, N-isopropyl-N'-[5-methoxy-2 -methyl-4(2,2,2-trifluoro-1-hydroxy-1-phenylethyl)phenyl]-N-methylformamidine, N-MemoKCu-N-[[4-[5(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-guMeTOKCu-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, H- ethyl-2-methyl-H-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4- [5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol- 3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate, HH-dimethyl-1-[[4-[5-(trifluoromethyl) -1.2.4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3-amine, methyl-(2)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl )pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-( 2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)3-methoxy-2-[2-methyl-5-( 4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2 -enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop- 2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2-[5-[4 (ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop -2-enoate and methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In a preferred composition according to the present invention, component (A) is Compound No. X.01, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane- 3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]acetate, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, tri( loxystrobin, methyltetraprol, di(enoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine, (enpropimor(a), (luxapyroxad, (luopyram, isopyrazam, sedaxane, benzovindi(lupira, pidi(lumeto(ene), iso() lucipram, iso(etamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, , pyroquilone, No.(1-benzyl- 1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1 ,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridine -3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4 -difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.04, [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octane -3ylcarbamoyl)thiazol-2-yl]amino]-1-methyl-2-oxoethyl]ethyl carbonate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin , trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pona, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline , fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3 ,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4, 4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.07, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxypropanoyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or Noxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8- 51 046405 fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3 carboxamides, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 up to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.11, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-Nspiro[ 3.4]octan-3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo [^^pyridinA -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1- (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4, 5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5: 1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.12, No. Cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5-methylthiazol-4 -carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5- dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1: 5).

In another preferred composition according to the present invention, component (A) is Compound No. X.13, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram , isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, rifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone , N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, 1- (6,7-dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl-1 -(7 methylpyrazolo[ 1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.14, 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapi- 52 046405 proline, fluazinam, fludioxonil, cyprodinil, metalaxyl -M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1 -methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro -3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3, 3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 ( or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.17, 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.18, methyl-3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-3-oxopropanoate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1.3dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1-methylpropyl)-8fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 4,4-difluoro -3,3-dimethyl-1-(7-methylpyrazolo[^^pyridin-3-yl)isoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazol1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.19, 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3 carboxamide, L^D-dimethylpyrazoloC^^pyridin-3-yl^D^-trifluoro-3-dimethylisoquinoline, 4,4difluoro-3-dimethylL-^-methylpyrazoloCD^pyridin-3-yl^zoquinoline , 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3 dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.22, S-isopropyl-N-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl) carbamoyl]-5-methylthiazol-2-yl]carbamothioate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram,

- 53 046405 isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, xyla-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole , pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1 -(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7- methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1-(4,5-dimethylbenzimidazole -1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5 ).

In another preferred composition according to the present invention, component (A) is Compound No. X.24, 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, sonyl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3 carboxamides, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 up to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.26, phenyl-H-(2,6-difluoro-4-pyridyl)-N-[4-[(2,2dimethylcyclobutyl)carbamoyl] -5-methylthiazol-2-yl]carbamate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, propamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3, 3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.29, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)- 8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3 -dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.31, 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-N-(2 ,2dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin,

- 54 046405 trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide , oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl -3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro -3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)- 4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) and component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.33, 2-[(2,6-difluoro-4-pyridyl)formylamino]-N-(2,2dimethylcyclobutyl)-5-methylthiazole -4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, , cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1- (7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4, 5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.34, ethyl-2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]- 5-methylthiazol-2-yl]amino]-2-oxoacetate, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro- 1-methylpropyl)-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4, 4difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3 ,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, where the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.35, 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5- methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine , fenpropimorpha, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, sonyl, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin , quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline- 3 carboxamides, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl-1 -(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4 ,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3 dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5: 1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.36, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-55 046405 dimethylcyclobutyl )-5-methylthiazole-4-carboxamide or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, tiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpeta, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8 -fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro-3,3- dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.37, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-Spiro[3.4]octane- 3-ylthiazol-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole , fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, inama, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet , ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8- fluoroquinoline-3-carboxamide, 1-(6,7dimethylpyrazolo[^^pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl1-(7 -methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro3,3-dimethylisoquinoline and 1-(4,5- dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In another preferred composition according to the present invention, component (A) is Compound No. X.38, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole , mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, Oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene , folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl) -8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro-3, 3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably from 5:1 to 1:5).

In a preferred composition according to the present invention, component (A) is Compound No. X.29, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl )-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of: azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapyroxade, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, propamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8-fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylusoquinoline, 4,4difluoro-3 ,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3- dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 -pyridyl]-H-ethyl-Nmethylformamidine, N-[isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1- 56 046405 (|)enylethyl )(|)enyl|-H-methyl(|yurmamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methyl-(2)-3-methoxy-2-[2- methyl 5-[3(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy ]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl-(2)-2-(5-cyclopentyl-2-methylphenoxy)-3 -methoxyprop-2-enoate, methyl(2)-2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy- 2-[2methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol- 2-yl]phenoxy]prop-2-enoate, H-methoxy-H-||4-|5-(trifluoromethyl)-1.2.4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N- [[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, K-ethyl-2-methyl-K-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol3 -yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl] urea, 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea and ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]phenyl]methyl]pyrazole4-carboxylate, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10:1 to 1:10 or even more preferably 5:1 to 1:5.

In another preferred composition according to the present invention, component (A) is Compound No. X.36, 2-[adetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5 -methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of: azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, mefentrifluconazole , fenpropidine, fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, inama, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet , ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8- fluoroquinoline-3 carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4difluoro-3,3-dimethyl -1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(4,5-dimethylbenzimidazol1 -yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1 - (4,5-dimethylbenzimidazol-1 -yl)-4,4-difluoro-3,3dimethylisoquinoline, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]- N-ethyl-Nmethylformamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-N-methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methylpicoxamide, methyl-(2)-3-methoxy-2-[2-methyl-5-[3(trifluoromethyl)pyrazol-1-yl]phenoxy]prop -2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-(5- cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-( 3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl (2)-3-methoxy-2-[2methyl-5-(4-propyltriazol-2-yl)phenoxy] prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, Nmethoxy-N-[ [4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol- 3-yl]phenyl]methyl]propanamide, K-ethyl-2-methyl-K-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3 -yl]phenyl]methyl]propanamide, 1-methoxy -3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea, 1,3-dimethoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl ]phenyl]methyl]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate, where the weight ratio of component (A) and component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10:1 to 1:10, or even more preferably 5:1 to 1:5.

In a further preferred composition according to the present invention, component (A) is Compound No. X.38, 2-[(2,6-difluoro-4-pyridyl)-(2methylpropanoyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methylthiazole-4-carboxamide, or a salt, enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of: azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole , prothioconazole, mefentrifluconazole, fenpropidine, fenpropimorph, fluxapiroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupir, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florilpicoxamide, chlorothalonil, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M , aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N(1-benzyl-3,3,3-trifluoro-1-methylpropyl )-8- 57 046405 fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 4,4- difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1 (4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro- 3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1yl)-4,4-difluoro-3,3-dimethylisoquinoline, N-[5-bromo-2-methyl-6-( 1 -methyl-2- propoxyethoxy)-3-pyridyl] N-ethyl-N-methylformamidine, N-isopropyl-H'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N -methylformamidine, TAEGRO®, Timorex GoldTM, acibenzolar^-methyl, cyflufenamide, metrafenone, fosetyl-aluminum, methylpicoxamide, methyl-(2)-3-methoxy-2-[2-methyl-5-[3(trifluoromethyl)pyrazol- 1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(3propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2 )-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2) -2-[5-(3-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2methyl-5-(4-propyltriazole -2-yl)phenoxy]prop-2-enoate, methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate , Nmethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N2-dimethoxy-N-[[4-[5-(trifluoromethyl) -1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, K-ethyl-2-methyl-K-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol3 -yl]phenyl] methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea, 1,3-dimethoxy-1- [[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3yl]phenyl]methyl]urea and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate, where the weight ratio of component (A) to component (B) is from 15:1 to 1:30, where preferably the weight ratio of component (A) to component (B) is from 10:1 to 1:10, or even more preferably 5:1 up to 1:5.

The term fungicide as used herein means a compound that controls, modifies or prevents the growth of fungi. The term fungicidal effective amount means an amount of such a compound or combination of such compounds that is capable of providing an effect on the growth of fungi. Controlling or modifying effects include all deviations from natural development, such as destruction, inhibition of development, etc., and prevention includes a barrier or other protective formation in or on the plant to prevent infection by the fungus.

The term plant refers to all the physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, petioles, leaves and fruits.

The term plant propagation material refers to all generative parts of a plant, such as seeds or vegetative parts of plants such as cuttings and tubers. It includes seeds in the narrow sense, as well as roots, fruits, tubers, bulbs, rhizomes and plant parts.

The term growing site as used herein means the fields in or on which plants are grown, or where the seeds of cultivated plants are sown, or where the seeds will be placed in the soil. It includes soil, seeds and seedlings, as well as established vegetation.

Throughout this document, the expression "composition" means various mixtures or combinations of components (A) and (B) (including embodiments defined above), for example, in a single ready-mix form, in a combination spray mixture composed of separate compositions components representing single active ingredients, such as a tank mixture, and in the form of a combined use of single active ingredients when applied in a sequential manner, i.e. one after another in a fairly short period of time, such as a few hours or days. The order in which components (A) and (B) are used is not critical to the implementation of the present invention.

The composition according to the present invention is effective against harmful microorganisms, such as microorganisms that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria.

The composition of the present invention can be used to control plant diseases caused by a wide range of fungal plant pathogens in the classes Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chrytidiomycete, Glomeromycete and/or Mucoromycete.

The composition is effective for controlling a wide range of plant diseases, such as those caused by pathogens affecting the leaves of ornamental, lawn, vegetable, field, grain and fruit crops.

Such pathogens may include oomycetes, including those causing late blights such as diseases caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragapiae, Phytophthora nicotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and ophthora erythroseptica; leading to pythioses, such as diseases caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicola, Pythium irregulare and Pythium ultimum; leading to diseases caused by Peronosporales, such as Peronospora destructor, Peronospora parasitica, Plasmopara viticola, Plasmo

- 58 046405 para halstedii, Pseudoperonospora cubensis, Albugo Candida, Sclerophthora macrospora and Bremia lactucae; and others such as Aphanomyces cochlioides, Labyrinthula zosterae, Peronosclerospora sorghi and Sclerospora graminicola;

ascomycetes, including those leading to varieties of spotting, spotting, blast or blight and/or rot, for example, caused by Pleosporales such as Stemphylium solani, Stagonospora tainanensis, Spilocaea oleaginea, Setosphaeria turcica, Pyrenochaeta lycoperisici, Pleospora herbarum, Phoma destructiva, aeosphaeria herpotrichoides , Phaeocryptocus gaeumannii, Ophiosphaerella graminicola, Ophiobolus graminis, Leptosphaeria maculans, Hendersonia creberrima, Helminthosporium triticirepentis, Setosphaeria turcica, Drechslera glycines, Didymella bryoniae, Cycloconium oleagineum, Corynespora cassiicola, Cochliobolus sativus, aris cactivora, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis , Alternaria alternata, Alternaria brassicicola, Alternaria solani and Alternaria tomatophila, Capnodiales, such as Septoria tritici, Septoria nodorum, Septoria glycines, Cercospora arachidicola, Cercospora sojina, Cercospora zeaemaydis, Cercosporella capsellae and Cercosporella herpotrichoides, Cladosporium carpophil um, Cladosporium effusum, Passalora fulva, Cladosporium oxysporum, Dothistroma septosporum, Isariopsis clavispora, Mycosphaerella fijiensis, Mycosphaerella graminicola, Mycovellosiella koepkeii, Phaeoisariopsis bataticola, Pseudocercospora vitis, Pseudocercosporella herpotrichoides, Ramularia beticola, Ramularia collo-cygni, aporthales, such as Gaeumannomyces graminis, Magnaporthe grisea, Pyricularia oryzae, Diaporthales, such as Anisogramma anomala, Apiognomonia errabunda, Cytospora platani, Diaporthe phaseolorum, Discula destructiva, Gnomonia fructicola, Greeneria uvicola, Melanconium juglandinum, Phomopsis viticola, Sirococcus clavigignenti-juglandacearum, Tubakia dryina, Dicarpella spp., Valsa ceratosperma, and others such as Actinothyrium graminis, Ascochyta pisi, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Asperisporium caricae, Blumeriella jaapii, Candida spp., Capnodium ramosum, Cephaloascus spp., Cephalosporium gramineum, Ceratocystis paradoxa, Chaetomium spp., Hymenoscyphus pseudoalbidus, es spp., Cylindrosporium padi , Diplocarpon malae, Drepanopeziza campestris, Elsinoe ampelina, Epicoccum nigrum, Epidermophyton spp., Eutypa lata, Geotrichum candidum, Gibellina cerealis, Gloeocercospora sorghi, Gloeodes pomigena, Gloeosporium perennans; Gloeotinia temulenta, Griphospaeria corticola, Kabatiella lini, Leptographium microsporum, Leptosphaerulinia crassiasca, Lophodermium seditiosum, Marssonina graminicola, Microdochium nivale, Monilinia fructicola, Monographella albescens, Monosporascus cannonballus, Naemacyclus spp., Ophiostoma novo -ulmi, Paracoccidioides brasiliensis, Penicillium expansum, Pestalotia rhododendri , Petriellidium spp., Pezicula spp., Phialophora gregata, Phyllachora pomigena, Phymatotrichum omnivora, Physalospora abdita, Plectosporium tabacinum, Polyscytalum pustulans, Pseudopeziza medicaginis, Pyrenopeziza brassicae, Ramulispora sorghi, Rhabdocline pseudotsuga e, Rhynchosporium secalis, Sacrocladium oryzae, Scedosporium spp., Schizothyrium pomi, Sclerotinia sclerotiorum, Sclerotinia minor; Sclerotium spp., Typhula ishikariensis, Seimatosporium mariae, Lepteutypa cupressi, Septocyta ruborum, Sphaceloma perseae, Sporonema phacidioides, Stigmina palmivora, Tapesia yallundae, Taphrina bullata, Thielviopsis basicola, Trichoseptoria fructigena, Zygophiala jamaicensis; leading to varieties of powdery mildew, such as diseases caused by Erysiphales, such as Blumeria graminis, Erysiphe polygoni, Uncinula necator, Sphaerotheca fuligena, Podosphaera leucotricha, Podospaera macularis Golovinomyces cichoracearum, Leveillula taurica, Microsphaera diffusa, Oidiopsis gossypii, lactinia guttata and Oidium arachidis; leading to mold species such as those caused by Botryosphaeriales such as Dothiorella aromatica, Diplodia seriata, Guignardia bidwellii, Botrytis cinerea, Botryotinia allii, Botryotinia fabae, Fusicoccum amygdali, Lasiodiplodia theobromae, Macrophoma theicola, Macrophomina phaseolina, Phyllosticta cucurbitace arum; leading to anthracnose diseases, for example those caused by Glommerelales such as Colletotrichum gloeosporioides, Colletotrichum lagenarium, Colletotrichum gossypii, Glomerella cingulata and Colletotrichum graminicola; and leading to varieties of wilt or scorch, such as those caused by Hypocreales such as Acremonium strictum, Claviceps purpurea, Fusarium culmorum, Fusarium graminarum, Fusarium virguliforme, Fusarium oxysporum, Fusarium subglutinans, Fusarium oxysporum f.sp. cubense, Gerlachia nivale, Gibberella fujikuroi, Gibberella zeae, Gliocladium spp., Myrothecium verrucaria, Nectria ramulariae, Trichoderma viride, Trichothecium roseum and Verticillium theobromae;

Basidiomycetes, including leaders of the head, for example, caused by Ustilaginales, such as Ustilaginoidea Virens, Ustilago Nuda, Ustilago Tritici, Ustilago Zeae, leading to rusty varieties, for example, caused by PUCCINIAS Kimi as Cerotelium Fici, Chrysomyxa Arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia hordei, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales, such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and leading to other types of rot and diseases, such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, Itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, solani, Thanetephorus cucurmeris, Entyloma dahliae, Entylomella microspora, Neovossia moliniae and Tilletia caries;

blastocladiomycetes such as Physoderma maydis;

- 59 046405 mucoromycetes, such as Choanephora cucurbitarum.; Mucor spp.; Rhizopus arrhizus; as well as leading to diseases caused by other species and genera that are closely related to those listed above.

In addition to their fungicidal activity, the compositions may also be characterized by activity against bacteria such as Erwinia amylovom, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species, as well as certain protozoa.

The composition according to the present invention is particularly effective against phytopathogenic fungi belonging to the following classes: ascomycetes (eg Venturia, Podosphaera, Erysiphe, Monilinia, Mycosphaerella, Uncinula); basidiomycetes (for example, the genus Hemileia, Rhizoctonia, Phakopsora, Puccinia, Ustilago, Tilletia); imperfect fungi (also known as deuteromycetes; e.g. Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia and Pseudocercosporella); oomycetes (e.g. Phytophthora, Peronospora, Pseudoperonospora, Albugo, Bremia, Pythium, Pseudosclerospora, Plasmopara).

Beneficial plant crops to which the composition of the present invention can be applied include perennial and annual crops such as berry plants, for example, varieties of blackberries, blueberries, cranberries, raspberries and strawberries; grains such as barley, maize (corn), millet, oats, rice, rye, sorghum, triticale and wheat; fibrous plants such as cotton, flax, hemp, jute and sisal; field crops, such as sugar and fodder beets, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea bush and tobacco; fruit trees such as apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; turf grasses, such as Bermuda grass, bluegrass, bentgrass, Eremochloa serpentine, fescue, ryegrass, Augustine grass and Japanese zoysia; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes, such as beans, lentils, peas and varieties; nuts such as almonds, cashews, groundnuts, hazelnuts, peanuts, pecans, pistachios and walnuts; palm trees, such as oil palm; ornamental plants such as flowers, shrubs and trees; other trees such as cocoa tree, coconut tree, olive tree and rubber tree; vegetable crops, e.g. asparagus, eggplant, broccoli, cabbage, carrots, cucumber, garlic, lettuce, zucchini, melon, okra, onions, peppers, potatoes, pumpkin, rhubarb, spinach and tomato, and climbing plants, e.g. grape.

It should be understood that crops also include those crops that occur naturally, are produced by conventional breeding methods, or are produced through genetic engineering. These include crops that contain so-called product attributes (eg improved storage stability, higher nutritional value and improved flavor).

Crop crops also include those crops that have been made tolerant to herbicides such as bromoxynil or to classes of herbicides such as ALS, EPSPS, GS, HPPD and PPO inhibitors. An example of a crop that has been made tolerant to imidazolinones, such as imazamox, through conventional breeding techniques is Clearfield® spring canola. Examples of crops that have been genetically engineered to tolerate herbicides include, for example, glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I®, and LibertyLink®.

Crops should also be understood as crops that are inherently resistant, or crops that have been engineered to be resistant to insect pests. These include plants transformed by the use of recombinant DNA techniques, for example, so that they are capable of synthesizing one or more selective toxins such as those known, for example, from toxin-producing bacteria. Examples of toxins that may be expressed include δ-endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonizing nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.

An example of a crop that has been modified to express a Bacillus thuringiensis toxin is KnockOut® Bt maize (Syngenta Seeds). An example of a crop that contains more than one gene that confers insect resistance, and thus expresses more than one toxin, is VipCot® (Syngenta Seeds). Crops or their seeds can also be resistant to several types of pests (so-called packaged transgenics if produced through genetic modification). For example, a plant may be characterized by the ability to express an insecticidal protein while being tolerant to herbicides, for example, Herculex I® (Dow AgroSciences, Pioneer Hi-Bred International).

- 60 046405

The term beneficial plants should be understood to also include beneficial plants that have been transformed through the use of recombinant DNA techniques such that they are capable of synthesizing one or more selective toxins such as those known, for example, from toxin-producing bacteria, e.g. genus Bacillus.

Examples of such plants are YieldGard® (a maize variety expressing the CryIA(b) toxin); YieldGard Rootworm ® (maize variety expressing CryIIIB(b1) toxin); YieldGard Plus® (maize variety expressing CryIA(b) toxin and CryIIIB(b1) toxin); Starlink® (a maize variety expressing the Cry9(c) toxin); Herculex I® (a maize variety expressing the CryIF(a2) toxin and the enzyme phosphinothricin-Nacetyltransferase (PAT) to provide tolerance to the herbicide glufosinate ammonium); NuCOTN 33B ® (cotton variety expressing CryIA(c) toxin); Bollgard I® (cotton variety expressing CryIA(c) toxin); Bollgard II® (cotton variety expressing CryIA(c) toxin and CryIIA(b) toxin); VIPCOT® (cotton variety expressing VIP toxin); NewLeaf ® (potato variety expressing CryIIIA toxin); NatureGard® Agrisure® GT Advantage (GA21 with glyphosate tolerance trait), Agrisure® CB Advantage (Bt11 with corn borer (CB) trait), Agrisure® RW (with Western corn rootworm resistance trait) and Protecta®.

The term crops should be understood to also include crop plants that have been transformed through the use of recombinant DNA techniques such that they are capable of synthesizing one or more selective toxins such as those known, for example, from toxin-producing bacteria, e.g. genus Bacillus.

Toxins that may be expressed by such transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as 5-endotoxins, for example, Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example, Vip1, Vip2, Vip3 or Vip3A; or insecticidal proteins from bacteria colonizing nematodes, such as Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi such as Streptomycetes toxins, plant lectins such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors such as trypsin inhibitors, serine protease inhibitors, patatin inhibitors, cystatin inhibitors, papain inhibitors; ribosome inactivating proteins (RIPs), such as ricin, maize RIP, abrin, luffin, saporin or bryodin; steroid metabolic enzymes such as 3hydroxysteroid oxidase, ecdysteroid UDP glycosyltransferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA reductase, ion channel blockers such as sodium or calcium channel blockers, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase , dibenzyl synthase, chitinases and glucanases.

In the context of the present invention, 5-endotoxins, for example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1, Vip2, Vip3 or Vip3A, should also be understood explicitly as hybrid toxins , truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by novel combinations of different domains of such proteins (see, for example, WO 02/15701). Truncated toxins are known, for example, truncated Cry1Ab. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. With such amino acid substitutions, sequences recognized by proteases that are not present in the natural toxin are preferably introduced into the toxin, for example, in the case of Cry3A055, a sequence recognized by cathepsin G is introduced into the Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesizing such toxins are disclosed, for example, in EP-A-0374753, WO 93/07278, WO 95/34656, EP-A-0427529, EP-A-451878 and WO 03/052073.

Methods for producing such transgenic plants are generally known to one skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0367474, EP-A-0401979 and WO 90/13651.

The toxin contained in transgenic plants gives the plants tolerance to harmful insects. Such insects can belong to any taxonomic group of insects, but are especially common among beetles (Coleoptera), dipterans (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that encode insect resistance and express one or more toxins are known, and some of them are commercially available. Examples of such plants are YieldGard ® (a maize variety that expresses

- 61 046405 Cry1Ab toxin); YieldGard Rootworm® (a maize variety expressing the Cry3Bb1 toxin); YieldGard Plus ® (maize variety expressing Cry1Ab and Cry3Bb1 toxin); Starlink® (a maize variety expressing the Cry9C toxin); Herculex I® (a maize variety expressing the Cry1Fa2 toxin and the enzyme phosphinothricin N-acetyltransferase (PAT) to provide tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety expressing Cry1Ac toxin); Bollgard I® (cotton variety expressing Cry1Ac toxin); Bollgard II® (cotton variety expressing Cry1Ac and Cry2Ab toxin); VipCot® (cotton variety expressing Vip3A and Cry1Ab toxin); NewLeaf® (potato variety expressing the Cry3A toxin); NatureGard® Agrisure® GT Advantage (GA21 with glyphosate tolerance trait), Agrisure® CB Advantage (Bt11 with corn borer (CB) tolerance trait) and Protecta®.

Additional examples of such transgenic crops are the following.

1. Maize Bt11 from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. A genetically modified Zea mays that has been rendered resistant to corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1Ab toxin. Bt11 maize also transgenically expresses the PAT enzyme to provide tolerance to the herbicide glufosinate ammonium.

2. Maize Bt176 from Syngenta Seeds SAS, Chemin de l'Hoibt 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays that has been rendered resistant to corn borer (Ostrinia nubilalis and Sesamia nonagrioides) through transgenic expression of the Cry1Ab toxin. Bt176 maize also transgenically expresses the PAT enzyme to provide tolerance to the herbicide glufosinate ammonium.

3. Maize MIR604 from Syngenta Seeds Sas, Chemin de l'Hobit 27, F-31 790 Saint-Sauveur, France, registration number C/FR/96/05/10. Maize that has been rendered resistant to insects by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a sequence recognized by the protease cathepsin G. The production of such transgenic maize plants is described in WO 03/018810.

4. Maize MON 863 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses the Cry3Bb1 toxin and is resistant to several insects of the order Coleoptera.

5. Cotton plant IPC 531 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.

6. Maize 1507 from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Maize genetically modified to express the Cry1F protein to provide resistance to certain Lepidoptera insects and the PAT protein to provide tolerance to the herbicide glufosinate ammonium.

7. Maize NK603 x MON 810 from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of hybrid maize varieties obtained through traditional breeding by crossing the genetically modified varieties NK603 and MON 810. NK603 xMON 810 maize transgenically expresses the CP4 EPSPS protein, derived from Agrobacterium sp., strain CP4, which confers tolerance to the herbicide Roundup® (contains glyphosate), as well as the Cry1Ab toxin derived from Bacillus thuringiensis subsp. kurstaki, which provides tolerance to certain members of the order Lepidoptera, including the corn borer.

In addition, to date, no cross-resistance has been observed between the composition containing the mixture of components (A) and (B) and any fungicidal solutions used to provide control of phytopathogenic fungi such as Absidia corymbifera, Alternaria spp., Aphanomyces spp. , Ascochyta spp., Aspergillus spp., including A. flavus, A. fumigatus, A. nidulans, A. niger, A. terrus, Aureobasidium spp., including A. pullulans, Blastomyces dermatitidis, Blumeria graminis, Bremia lactucae, Botryosphaeria spp., including B. dothidea, B. obtusa, Botrytis spp., including B. cinerea, Candida spp., including C. albicans, C. glabrata, C. krusei, C. lusitaniae , C. parapsilosis, C. tropicalis, Cephaloascus fragrans, Ceratocystis spp., Cercospora spp., including C. arachidicola, Cercosporidium personatum, Cladosporium spp., Claviceps purpurea, Coccidioides immitis, Cochliobolus spp., Colletotrichum spp., including including C. musae, Cryptococcus neoformans, Diaporthe spp., Didymella spp., Drechslera spp., Elsinoe spp., Epidermophyton spp., Erwinia amylovora, Erysiphe spp., including E. cichoracearum, Eutypa lata, Fusarium spp., in including F. culmorum, F. graminearum, F. langsethiae, F. moniliforme, F. oxysporum, F. proliferatum, F. subglutinans, F. solani, Gaeumannomyces graminis, Gibberella fujikuroi, Gloeodes pomigena, Gloeosporium musarum, Glomerella cingulate, Guignardia Bidwellii, Gymnosporangium Juniperi-Virginianae, Helminthosporium spp., Hemileia spp., Histoplasma spp., including H. Capsulatum, Laetisaria Fuciformis, LeptogRaphium Indbergi, Livelula Taurica, Lophodermium Seditiosum, Microdochium Nivale, Microsporum spp., Monilinia spp., Mucor spp., Mycosphaerella spp., including M. graminicola, M. pomi, Oncobasidium theobromaeon, Ophiostomapiceae, Paracoccidioides spp., Penicillium spp., including P. digitatum, P. italicum, Petriellidium spp., Per

- 62 046405 onosclerospora spp., including P. maydis, P. philippinensis and P. sorghi, Peronospora spp., Phaeosphaeria nodorum, Phakopsora pachyrhizi, Phellinus igniarus, Phialophora spp., Phoma spp., Phomopsis viticola, Phytophthora spp., including P. infestarts, Plasmopara spp., including P. halstedii, P. viticola, Pleospora spp., Podosphaera spp., including P. leucotricha, Polymyxa graminis, Polymyxa betae, Pseudocercosporella herpotrichoides, Pseudomonas spp., Pseudoperonospora spp., including P. cubensis, P. humuli, Pseudopeziza tracheiphila, Puccinia spp., including P. hordei, P. recondita, P. striiformis, P. triticina, Pyrenopeziza spp., Pyrenophora spp., Pyricularia spp., including P. oryzae, Pythium spp., including P. ultimum, Ramularia spp., Rhizoctonia spp., Rhizomucor pusillus, Rhizopus arrhizus, Rhynchosporium spp., Scedosporium spp., including S. apiospermum and S. prolificons, Schizothyrium pomi, Sclerotinia spp., Sclerotium spp., Septoria spp., including S. nodorum, S. tritici, Sphaerotheca macularis, Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothorix spp., Stagonospora nodorum, Stemphylium spp. , Stereum hirsutum, Thanatephorus cucumeris, Thielaviopsis basicola, Tilletia spp., Trichoderma spp., including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp., Typhula spp., Uncinula necator, Urocystis spp., Ustilago spp. ., Venturia spp., including V. inaequalis, Verticillium spp. and Xanthomonas spp., in particular Zymoseptoria tritici, Puccinia recondita, Puccinia striiformis, Erysiphe graminis, Uncinula necator, Sphaerotheca fuliginea, Leveillula taurica, Phakopsora pachyrhizi, Pyricularia oryzae, Alternaria solani, Alternaria alternata, Mycosphaerella fijiensis, richum lagenarium, Didymella bryoniae, Ascochyta pisii, Verticillium dahliae, Pyrenophora teres, Cercospora beticola, Ramularia collo-cygni, Botrytis cinerea, Sclerotinia sclerotiorum, Monilinia laxa, Monographaella nivalis and Venturia inaequalis.

Indeed, fungicide-resistant strains have been reported in the scientific literature in any of the species listed above, with the strains being resistant to one or more fungicides from at least one of the following classes of fungicides by mechanism of action: External quinone-binding site inhibitors (QoI) , internal quinone-binding site inhibitors (QiI), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation inhibitors (DMI). Such fungicide-resistant strains may contain the following.

A mutation in the mitochondrial cytochrome b gene that confers resistance to Qo inhibitors, where the mutation is G143A, F129L, or G137R. See for example: Gisi et al., Pest Manag Sci 56, 833841 (2000), Lucas, Pestic Outlook 14(6), 268-70 (2003), Fraaije et al., Phytopathol 95(8), 933-41 ( 2005), Sierotzki et al., Pest Manag Sci 63(3), 225-233 (2007), Semar et al., Journal of Plant Diseases and Protection (3), 117-119 (2007); and Pasche et al., Crop Protection 27(3-5), 427-435 (2008).

A mutation in the mitochondrial cytochrome b gene conferring resistance to Qi inhibitors, where the mutation is G37A/C/D/S/V. See for example: Meunier et al., Pest Manag Sci 2019; 75: 21072114.

A mutation in the genes encoding the subunits SdhB,C,D, conferring resistance to SDHI inhibitors, and the mutation is present in the following major pathogens:

Botrytis cinerea: B-P225H/L/T/Y/F, B-N230I, B-H272L/Y/R, C-P80H/L, C-N87S;

Alternaria solani: B-H278R/Y. C-H134R/Q, D-D123E, D-H133R and C-H134R;

Zymoseptoria tritici: sdhB: N225T, N225I, R265P, T268I, T268A. B sdhC: T79N, T79I, W80S, W80A, A84F, N86S, N86A, P127A, R151M/S/T/G, R151S, R151T, H152R/Y, V166M, T168R. B sdhD: I50F, M114V, D129G, T20P+K186R;

Pyrenophora teres: B sdhB: S66P, N235I, H277Y. B sdhC: K49E, R64K, N75S, G79R, H134R, S135R. B sdhD: D124E, H134R, G138V, D145G;

Ramularia collo-cygni: In sdhB: N224T, T267I. B sdhC: N87S, G91R, H146R/L, G171D, H153R; Phakopsora pachyrhizi: C-I86F;

Sclerotinia sclerotiorum: B sdhB: H273Y. B sdhC: G91R, H146R. B sdhD: T108K, H132R, G150R.

The main source of information is www.frac.info, Sierotzki and Scalliet Phytopathology (2013), 103(9): 880-887 and Simoes et al., J Plant Dis Prot (2018), 125: 21-2.

A mutation or combination of mutations in the CYP51 gene conferring resistance to DMI inhibitors, where the mutations are: L50S, D134G, V136A/C, Y137F, S188N, A379G, I381V, deletion 459-460, Y461H/S, N513K, S524T. The main source of information is www.frac.info, Cools et al., Plant Pathol (2013), 62: 36-42 and Schmitz HK et al., Pest Manag Sci (2014), 70: 378-388.

Thus, in a preferred embodiment, compositions according to the present invention containing a mixture of components (A) and (B) are used to provide control of fungal strains that are resistant to one or more fungicides from any of the following MoA fungicide classes: inhibitors external quinone-binding site inhibitors (QoI), internal quinone-binding site inhibitors (QiI), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation inhibitors (DMI).

The compounds of the present invention can be prepared as shown in the following diagrams, in which, unless otherwise indicated, the definition of each variable is as defined above for the compound of formula (I).

The compounds of formula (I) according to the present invention, wherein R ¹ , R ² , R ³ , X and Y are as defined for formula (I), can be prepared by converting the compound of formula

- 63 046405 (II), where R ² , R ³ ', X and Y are as defined for formula (I), using a compound of formula (III), where R ¹ is as defined for formula (I) and R ¹² is a halogen, preferably chlorine, either by thermal heating or by a base. This is shown in Diagram 1 below.

Scheme 1

Compounds of formula (II) wherein R ² , R ³ , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (IV) wherein X and Y are as defined for formula (I ), using a compound of formula (V), wherein R ² and R ³ are as defined for formula (I), and R ¹³ is a halogen, preferably bromine, either by thermal heating or by a base or under conditions Transition metal-catalyzed Buchwald-Hartwig amination. This is shown in Diagram 2 below.

Scheme 2

Compounds of formula (V) wherein R ² and R ³ are as defined for formula (I) and R ¹³ is halogen, preferably bromine, can be prepared by converting a compound of formula (VI) wherein R ² is as defined for formula (I), and R ¹³ is a halogen, preferably bromine, and compounds of formula (VII), where R ³ is as defined for formula (I), either by use of an intermediate acid chloride or directly by means of an agent for formation of a peptide bond. This is shown in diagram 3 below.

Scheme 3

Compounds of formula (VI) wherein R ² is as defined for formula (I) and R ¹³ is halogen, preferably bromine, can be prepared by converting a compound of formula (VIII) wherein R ² is as defined for formula (I), R ¹³ represents halogen, preferably bromine, and R ¹⁴ represents C1-C ₆ -alkyl, and bases. This is shown in Figure 4 below.

Scheme 4

Alternatively, compounds of formula (II) wherein R ² , R ³ , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (IX) wherein R ² , X and Y are as defined as defined for formula (I), using a compound of formula (VII) wherein R ³ is as defined for formula (I), either by using an acid chloride intermediate or directly by using a peptide bond forming agent. This is shown in Figure 5 below.

- 64 046405

Scheme 5

Compounds of formula (IX) wherein R ² , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (X) wherein R ² , X and Y are as defined for formula (I ), and R ¹⁴ represents ^-^-alkyl, using a base. This is shown in Figure 6 below.

Scheme 6

Compounds of formula (X), wherein R ² , X, and Y are as defined for formula (I), and R ¹⁴ is ^-^-alkyl, can be prepared by converting a compound of formula (IV), where X and Y are as defined for formula (I), using a compound of formula (VII), wherein R ² is as defined for formula (I), R ^{B * * * 12} is halogen, preferably bromine, and R ¹³ is is a ^-^-alkyl, either by thermal heating, or by a base, or under the conditions of a transition metal-catalyzed Buchwald-Hartwig amination. This is shown in Figure 7 below.

Scheme 7

Alternatively, compounds of formula (X), where R ² , X and Y are as defined for formula (I), and R ¹⁴ is ^-^-alkyl, can be prepared by converting a compound of formula (XI), where X and Y are as defined for formula (I), and R ¹³ is a halogen, preferably bromine or iodo, using a compound of formula (XII), where R ² is as defined for formula (I), and R ¹⁴ is ^-^-alkyl, under the conditions of transition metal-catalyzed Buchwald-Hartwig amination. This is shown in Figure 8 below.

Scheme 8

Alternatively, compounds of formula (II) wherein R ² , R ³ , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (XI) wherein X and Y are as defined for formula (I), and R ¹³ is a halogen, preferably bromine or iodine, using a compound of formula (XIII), where R ² and R ³ are as defined for formula (I), either by thermal heating or by base, or under transition metal-catalyzed Buchwald-Hartwig amination conditions. This is shown in Figure 9 below.

- 65 046405

Scheme 9

Alternatively, compounds of formula (I) according to the present invention, wherein R ¹ , R ² , R ³ , X and Y are as defined for formula (I), can be prepared by converting a compound of formula (V), where R ² and R ³ are as defined for formula (I), and R ¹³ is a halogen, preferably bromine, using a compound of formula (XIV), where R ¹ , X and Y are as defined for formula (I) , either by thermal heating, by a base, or under transition metal-catalyzed Buchwald-Hartwig amination conditions. This is shown in diagram 10 below.

Scheme 10

Compounds of formula (XIV) wherein R ¹ , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (XV) wherein X and Y are as defined for formula (I) with using a compound of formula (III) wherein R ¹ is as defined for formula (I) and R ¹² is a halogen, preferably chlorine, either by thermal heating or by a base. This is shown in diagram 11 below.

Scheme 11

Alternatively, compounds of formula (I), wherein R ¹ , R ² , R ³ , X and Y are as defined for formula (I), can be prepared by converting a compound of formula (XVI), where R ¹ , R ² , X and Y are as defined for formula (I), using a compound of formula (VII), where R ³ is as defined for formula (I), either by thermal heating or by using a base. This is shown in Figure 12 below.

Scheme 12

Compounds of formula (XVI), wherein R ¹ , R ² , X and Y are as defined for formula (I), can be prepared by converting a compound of formula (IX), where R ² , X and Y are as defined for formula (I), using a compound of formula (III), where R ¹ is as defined for formula (I), and R ¹² represents a halogen, preferably chlorine, either by thermal heating or by using a base. This is shown in diagram 13 below.

- 66 046405

Scheme 13

Alternatively, compounds of formula (XVI) wherein R ¹ , R ² , X and Y are as defined for formula (I) can be prepared by converting a compound of formula (IX) wherein R ² , X and Y are as defined as defined for formula (I), using a compound of formula (XVII), where R ¹ is as defined for formula (I), either by thermal heating or by using a base. This is shown in the diagram below.

Scheme 14

The compositions of the present invention, including all of the embodiments disclosed above and their preferred examples, can be mixed with one or more additional pesticides, including additional fungicides, insecticides, nematicides, bactericides, acaricides, growth regulators, chemosterilants, chemical signal agents , repellents, attractants, pheromones, nutritional stimulants or other biologically active compounds to form a multicomponent pesticide that provides an even wider range of crop protection.

Examples of such agricultural protectants with which the present invention can be formulated are fungicides such as etridiazole, fluazinam, benalaxyl, benalaxyl-M (kyralaxyl), furalaxyl, metalaxyl, metalaxyl-M (mefenoxam), dodicine, M-[ (2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methylformamidine, M-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5dimethylphenyl]-U-ethyl- Y-methylformamidine, M-[[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5yl]oxy]-2,5-dimethylphenyl]-U-ethyl-N-methylformamidine , ethirimol, 3'-chloro-2-methoxy-N-[(3RS)tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (closilacone), cyprodinil, mepanipyrim, pyrimethanil, dithianone, aureofungin , blasticidin-S, biphenyl, chloroneb, dicloran, benzovindiflupyr, pidiflumetofen, hexachlorobenzene, quintozene, tecnazene, (TCNB), tolcofos-methyl, metrafenone, 2,6-dichloro-N(4-trifluoromethylbenzyl)benzamide, fluopicolide (flupicolide), thioximide, flusulfamide, benomyl, carbendazim, carbendazim hydrochloride, chlorphenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, betoxazine, pyriophenone (IKF-309), acibenzolar-Smethyl, pyribencarb (KIF-77 67), butylamine , 3-iodo-2-propynyl-n-butylcarbamate (IPBC), iodocarb (isopropanylbutylcarbamate), isopropanylbutylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N(7-fluoro-1,1, 3,3-tetramethylindan-4-yl)-1-methylpyrazol-4carboxamide diclocymet, N[(5-chloro-2-isopropylphenyl)methyl]-Ncyclopropyl-3-(difluoromethyl)-5fluoro-1-methylpyrazol-4-carboxamide , Ncyclopropyl-3-(difluoromethyl)-5-fluoro-N[(2isopropylphenyl)methyl]-1-methylpyrazole-4-carboxamide, carpropamide, chlorothalonil, flumorph, copper oxine, cymoxanil, fenamacryl, cyazofamide, flutianil, thithiophene, chlozolinate , iprodione, procymidone, vinclozolin, bupirimate, dinoctone, dinopentone, dinobutone, dinocap, meptyldinocap, diphenylamine, phosdiphene, 2,6-dimethyl-[1,4]dithiino[2,3-c:5,6-c']dipyrrole -1,3,5,7(2H,6H)-tetraone, azithiram, etem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc, nabam, propineb, thiram, vapam (sodium metam), zineb , cyram, dithioether, isoprothiolane, ethaboxam, fosetyl, fosetyl-A1 (fosetyl^^, methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramide, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl)glutaronitrile ( bromotalonil), dodine, doguadine, guazatin, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethyrimol, fenhexamide, hymexazole, hydroxyisoxazole, imazalil, imazalil sulfate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone , Bordeaux mixture, calcium polysulfide, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulfate, copper tallate, copper oxide, sulfur, carbaryl, phthalide (phthalide), dingjunezuo (Jun Si Qi), oxathiapiproline, fluorimide, mandipropamide, KSF-1002, benzamorph, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolone, famoxadone, meta- 67 046405 phenylphenol, para -phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6fluorophenyl]propan-2-ol, 2-[2-fluoro-6-[ (8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol, cyflufenamide, ofuras, oxadixil, flutolanil, mepronil, isofetamide, fenpiclonil, fludioxonil, pencicuron, edifenphos, iprobenfos, pyrazophos, phosphoric acids, teclophthalam, captafol, captan, dithalymphos, triforin, fenpropidine, piperaline, osthole, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipine, endothal, ethephon, flumetralin, forchlorfenuron, gibberellic acid, gibberellins, gimexazole, maleic hydrazide, mepiquat, naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-calcium, thidiazuron, tribufos (tributyl phosphorotrithioate), trinexapac, uniconazole, a-naphthaleneacetic acid, polyoxin D (polyoxrim), BLAD, chitosan, phenoxanil, folpet, 3(difluoromethyl)-N-methoxy -1-methyl-N-[1-methyl-2-(2,4,6-trichlorophenyl)ethyl]pyrazole-4-carboxamide, bixafen, fluxapyroxad, furamethpyr, isopyrazam, penflufen, penthiopyrad, sedaxane, fenpyrazamine, diclomesine, pyrifenox , boscalid, fluopyram, diflumetorim, fenarimol, 5-fluoro-2-(ptolylmethoxy)pyrimidin-4-amine, ferimzone, dimethachlon (dimethaclon), pyroquilone, proquinazid, ethoxyquin, quinoxifene, 4,4,5-trifluoro-3,3 -dimethyl-1-(3-quinolyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1 (3-quinolyl)isoquinoline, 5-fluoro-3,3,4,4-tetramethyl-1-(3 -quinolyl)isoquinoline, 9-fluoro-2,2-dimethyl-5-(3 quinolyl)-3H-1,4-benzoxazepine, tebufloquin, oxolinic acid, quinomethionate (hydroxythioquinox, quinoxymethionate), spiroxamine, (E)-N- methyl 2-[2-(2,5-dimethylphenoxymethyl)phenyl]-2-methoxyiminoacetamide, (mandestrobin), azoxystrobin, cumoxystrobin, dimoxystrobin, enestroburin, enoxastrobin, fenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, methaminostrobin, metominostrobin . hydroxymethyl]-2-pyridyl]carbamate, dazomet, isothianil, thiadinil, tifluzamide, benthiazole (TCMTB), silthiophame, zoxamide, anilazine, tricyclazole, (+-)-cis-1-(4-chlorophenyl)-2-(1H- 1,2,4-triazol-1-yl)cycloheptanol (Huanjunzuo), 1-(5-bromo-2pyridyl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1,2, 4-triazol-1-yl)propan-2-ol, 2-(1-tert-butyl)-1-(2chlorophenyl)-3-(1,2,4-triazol-1-yl)propan-2-ol (TCDP) azole, metconazole, myclobutanil , penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, mefentrifluconazole, 2-[[(t^)-5-[(4-fluorophenyl)methyl]-1-hydroxy-2,2 -dimethylcyclopentyl]methyl]-4H1,2,4-triazol-3-thione, 2-[[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-4H- 1,2,4-triazole-3thione, amethoctradine (imidium), iprovalicarb, valifenalate, 2-benzyl-4-chlorophenol (chlorophen), allyl alcohol, azaphenidine, benzalkonium chloride, chloropicrin, cresol, daracid, dichlorophen (dichlorophen), diphenzoquat , dipyrithione, N-(2-p-chlorobenzoylethyl)hexaminium chloride, NNF-0721, octylinone, oxasulfuron, propamidine and propionic acid, insecticides such as abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos -methyl, bifenthrin, biphenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, cromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, , cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, phenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, citrinate, tau-fluvalinate, flufenerim ( UR-50701), flufenoxuron, fonofos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathione, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, oside, nitenpyram, nithiazine, novaluron , noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, fosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pirafluprole, pyrethrin, pyridalyl, pyrifluquinazone, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramate, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultap sodium, tralomethrine, triazamate, trichlorfon and triflu Muron;

bactericides such as streptomycin;

acaricides such as amitraz, quinomethionate, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, phenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridabene and tebufenpyrad, and biologicals such as Bacillus thuringiensis, Bacillus delta-endotoxin thuringiensis, baculovirus and entomopathogenic bacteria, virus and fungi.

Other examples of typical mixture compositions include the following (wherein the term TX represents a compound (as defined in component (A) of the compositions of the present invention) selected from Compound Nos. X.01, X.02, X.03, X.04 , X.05, X.06, X.07, X.08, X.09, X.10, X.11, X.12, X.13, X.14, X.15, X.16, X .17, X.18, X.19, X.20, X.21, X.22, X.23, X.24, X.25, X.26, X.27, X.28, X.29 , X.30, X.31, X.32, X.33, X.34, X.35, X.36 and X.37, as defined in Table X above): connection,

- 68 046405 selected from the group of substances consisting of petroleum oils, + TX, 1,1-bis(4-chlorophenyl)-2ethoxyethanol + TX, 2,4-dichlorophenylbenzenesulfonate + TX, 2-fluoro-N-methyl-N-1 -naphthylacetamide + TX, 4-chlorophenylphenylsulfone + TX, acetoprole + TX, aldoxycarb + TX, amidithione + TX, amidothioate + TX, amitone + TX, amitone hydroxalate + TX, amitraz + TX, aramit + TX, arsenic oxide + TX, azobenzene + TX, nitrogenate + TX, benomyl + TX, benoxaphos + TX, benzyl benzoate + TX, bixaphen + TX, brofenvalerate + TX, bromocyclen + TX, bromophos + TX, bromopropylate + TX, buprofezin + TX, butocarboxim + TX, butoxycarboxim + TX , butylpyridabene + TX, calcium polysulfide + TX, camphechlor + TX, carbanolate + TX, carbophenothione + TX, cimiazole + TX, quinomethionate + TX, chlorobenzide + TX, chlordimeform + TX, chlordimeform hydrochloride + TX, chlorphenetol + TX, chlorphensone + TX , chlorophensulfide + TX, chlorobenzilate + TX, chloromebuform + TX, chloromethiuron + TX, chloropropylate + TX, chlorothiophos + TX, cinerin I + TX, cinerin II + TX, cinerin + TX, closantel + TX, coumaphos + TX, crotamiton + TX , crotoxyphos + TX, kufraneb + TX, cyanoate + TX, DCPM + TX, DDT + TX, demefion + TX, demefion-O + TX, demefion-S + TX, demeton-methyl + TX, demeton-O + TX, demeton -O-methyl + TX, demetonS + TX, demeton^-methyl + TX, demeton^-methylsulfone + TX, dichlofluanid + TX, dichlorvos + TX, diclifos + TX, dienochlor + TX, dimefox + TX, dinex + TX, dinex -diclexin + TX, dinocap-4 + TX, dinocap-6 + TX, dinoctone + TX, dinopentone + TX, dinosulfone + TX, dinoterbone + TX, dioxathion + TX, diphenylsulfone + TX, disulfiram + TX, DNOC + TX, dophenapine + TX, doramectin + TX, endothione + TX, eprinomectin + TX, methyl ethoate + TX, etrimphos + TX, phenazaflor + TX, fenbutatin oxide + TX, phenothiocarb + TX, fenpyrad + TX, fenpyroximate + TX, fenpyrazamine + TX, fenzone + TX, fentrifanil + TX, flubenzimine + TX, flucycloxuron + TX, fluenethyl + TX, fluorbenzide + TX, FMC 1137 + TX, formatenate + TX, formatenate hydrochloride + TX, formparanate + TX, gamma-HCH + TX, glyodine + TX, galfenprox + TX, hexadecylcyclopropanecarboxylate + TX, isocarbophos + TX, jasmoline I + TX, jasmoline II + TX, iodofenphos + TX, lindane + TX, malonoben + TX, mecarbam + TX, mephospholane + TX, mesulfen + TX, metacryphos + TX, methyl bromide + TX, metolcarb + TX, mexacarbate + TX, milbemycin oxime + TX, mipafox + TX, monocrotophos + TX, morphothione + TX, moxidectin + TX, naled + TX, 4-chloro-2-(2-chloro- 2-methylpropyl)-5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one + TX, nifluridide + TX, nikkomycins + TX, nitrilecarb + TX, complex of nitrilecarb and zinc chloride 1:1 + TX, omethoate + TX, oxydeprophos + TX, oxydisulfoton + TX, pp'-DDT + TX, parathion + TX, permethrin + TX, phencaptone + TX, fosalone + TX, phospholane + TX, phosphamidone + TX, polychloroterpenes + TX, polynactins + TX , proclonol + TX, promacil + TX, propoxur + TX, protidation + TX, protoate + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyridafention + TX, pyrimitate + TX, quinalphos + TX, quinthiophos + TX , R-1492 + TX, fosglycine + TX, rotenone + TX, shradan + TX, sebuphos + TX, selamectin + TX, sofamide + TX, SSI-121 + TX, sulfiram + TX, sulfluramide + TX, sulfotep + TX, sulfur + TX, difluvidazine + TX, tau-fluvalinate + TX, TERP + TX, terbam + TX, tetradifon + TX, tetrasul + TX, thiafenox + TX, thiocarboxim + TX, thiophanox + TX, thiometon + TX, thioquinox + TX, thuringiensin + TX, triamiphos + TX, triarathene + TX, triazophos + TX, triazuron + TX, triphenofos + TX, trinactin + TX, vamidothion + TX, vaniliprole + TX, betoxazine + TX, copper dioctanoate + TX, copper sulfate + TX, cibutrin + TX, dichlorophen + TX, dichlorophen + TX, endothal + TX, fentin + TX, slaked lime + TX, nabam + TX, quinoclamine + TX, quinonamide + TX, simazine + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, crufomate + TX, piperazine + TX, thiophanate + TX, chloralose + TX, fenthion + TX, pyridine-4-amine + TX, strychnine + TX, 1-hydroxy-III-pyridine-2-thione + TX, 4-(quinoxaline -2ylamino)benzenesulfonamide + TX, 8-hydroxyquinoline sulfate + TX, bronopol + TX, copper hydroxide + TX, cresol + TX, dipyrithione + TX, dodicine + TX, fenaminosulf + TX, formaldehyde + TX, hydrargafen + TX, kasugamycin + TX , kasugamycin hydrochloride hydrate + TX, nickel bis(dimethyldithiocarbamate) + TX, nitrapyrin + TX, octylinone + TX, oxolinic acid + TX, oxytetracycline + TX, potassium hydroxyquinoline sulfate + TX, probenazole + TX, streptomycin + TX, streptomycin sesquisulfate + TX, teklophthalam + TX, thiomersal + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, Amblyseius spp. + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, Autographa californica NPV + TX, Bacillus sphaericus Neide + TX, Beauveria brongniartii + TX, Chrysoperla carnea + TX , Cryptolaemus montrouzieri + TX, Cydia pomonella GV + TX, Dacnusa sibirica + TX, Diglyphus isaea + TX, Encarsia formosa + TX, Eretmocerus eremicus + TX, Heterorhabditis bacteriophora and H. megidis + TX, Hippodamia convergens + TX, Leptomastix dactylopii + TX , Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, Orius spp. + TX, Paecilomyces fumosoroseus + TX, Phytoseiulus persimilis + TX, Steinernema bibionis + TX, Steinemema carpocapsae + TX, Steinemema feltiae + TX, Steinemema glaseri + TX, Steinemema riobrave + TX, Steinemema riobravis + TX, Steinernema scapterisci + TX, Steinemema spp . + TX, Trichogramma spp. + TX, Typhlodromus occidentalis + TX, Verticillium lecanii + TX, afolate + TX, bisazir + TX, busulfan + TX, dimatif + TX, hemel + TX, hempa + TX, metepa + TX, methiothepa + TX, methylafolate + TX, morzide + TX, penfluron + TX, tepa + TX, thiochempa + TX, thiotepa + TX, tretamine + TX, uredepa + TX, (B)-dec-5-ene-1-yl acetate and (B)-dec-5-ene -1-ol + TX, (E)-tridec-4-en-1yl acetate + TX, (E)-6-methylhept-2-en-4-ol + TX, (E,2)-tetradeca-4,10 -diene-1-yl acetate + TX, (2)-dodec-7

- 69 046405 en-1-yl acetate + TX, (2)-hexadec-11-enal + TX, (2)-hexadec-11-en-1-yl acetate + TX, (2)-hexadec-13-en11-yne -1-yl acetate + TX, (2)-eicos-13-en-10-one + TX, (2)-tetradec-7-en-1-al + TX, (2)-tetradec-9-ene-1 -ol + TX, (2)-tetradec-9-en-1-yl acetate + TX, (7E,92)-dodeca-7,9-dien-1-yl acetate + TX, (92,11E)-tetradeca9,11 -dien-1-ylacetate + TX, (92,11E)-tetradeca-9,12-dien-1-ylacetate + TX, 14-methyloctadec-1-ene + TX, 4-methylnonan-5-ol and 4-methylnonane -5-one + TX, alpha-multistriatin + TX, brevicomin + TX, codelur + TX, codelemon + TX, quelur + TX, disparlur + TX, dodec-8-ene-1-yl acetate + TX, dodec-9-ene -1-yl acetate + TX, dodeca-8 + TX, 10-dien-1-yl acetate + TX, dominicalur + TX, ethyl-4-methyloctanoate + TX, eugenol + TX, frontalin + TX, grandlur + TX, grandlur I + TX, Grandlur II + TX, Grandlur III + TX, Grandlur IV + TX, Hexalur + TX, Ipsdienol + TX, Ipsenol + TX, Japanilur + TX, Lineatin + TX, Litlur + TX, Luplur + TX, Medlur + TX, Megatomoeva acid + TX, methyl eugenol + TX, muscalur + TX, octadeca-2,13-dien1-yl acetate + TX, octadeca-3,13-dien-1-yl acetate + TX, orfralur + TX, oryctalur + TX, ostramon + TX, siglur + TX, sordidin + TX, sulcatol + TX, tetradec-11-ene-1-yl acetate + TX, trimedlur + TX, trimedlur A + TX, trimedlur B ₁ + TX, trimedlur B ₂ + TX, trimedlur C + TX, trunk call + TX, 2(octylthio)ethanol + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, diethyltoluamide + TX, dimethyl carbate + TX, dimethyl phthalate + TX, ethylhexanediol + TX, hexamide + TX, methoquin-butyl + TX, methylneodecanamide + TX, oxamate + TX, picaridin + TX, 1-dichloro-1-nitroethane + TX, 1,1-dichloro-2,2-bis(4-ethylphenyl )ethane + TX, 1,2-dichloropropane with 1,3-dichloropropene + TX, 1-bromo-2-chloroethane + TX, 2,2,2-trichloro-1-(3,4dichlorophenyl)ethyl acetate + TX, 2, 2-dichlorovinyl-2-ethylsulfinylethylmethylphosphate + TX, 2-(1,3dithiolan-2-yl)phenyldimethylcarbamate + TX, 2-(2-butoxyethoxy)ethylthiocyanate + TX, 2-(4,5-dimethyl1,3-dioxolane-2 -yl)phenylmethylcarbamate + TX, 2-(4-chloro-3,5-xylyloxy)ethanol + TX, 2-chlorovinyl diethyl phosphate + TX, 2-imidazolidone + TX, 2-isovalerylindane-1,3-dione + TX, 2-methyl( prop2-ynyl)aminophenylmethylcarbamate + TX, 2-thiocyanatoethyl laurate + TX, 3-bromo-1-chloroprop-1-ene + TX, 3-methyl-1-phenylpyrazol-5-yldimethylcarbamate + TX, 4-methyl(prop-2- inyl)amino-3,5xylylmethylcarbamate + TX, 5,5-dimethyl-3-oxocyclohex-1-enyldimethylcarbamate + TX, acethione + TX, acrylonitrile + TX, aldrin + TX, allosamidine + TX, allixycarb + TX, alpha-ecdysone + TX, aluminum phosphide + TX, aminocarb + TX, anabasine + TX, atidation + TX, azametifos + TX, Bacillus thuringiensis delta-endotoxins + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, bartrin + TX, Bayer 22/190 + TX, Bayer 22408 + TX, beta-cyfluthrin + TX, beta-cypermethrin + TX, bioethanomethrin + TX, biopermethrin + TX, bis(2-chloroethyl)ether + TX, borax + TX, bromfenvinphos + TX, bromine-DDT + TX , bufencarb + TX, butacarb + TX, butathiophos + TX, butonate + TX, calcium arsenate + TX, calcium cyanide + TX, carbon disulfide + TX, carbon tetrachloride + TX, cartap hydrochloride + TX, cevadin + TX, chlorobicyclene + TX, chlordane +TX, chlordecone +TX, chloroform +TX, chloropicrin +TX, chlorphoxime +TX, chlorprazophos +TX, cis-resmethrin +TX, cismethrin +TX, clocitrin +TX, copper acetoarsenite +TX, copper arsenate +TX, copper oleate + TX, cumitoate + TX, cryolite + TX, CS 708 + TX, cyanophenphos + TX, cyanophos + TX, cycletrin + TX, cythioate + TX, d-tetramethrin + TX, DAEP + TX, dazomet + TX, decarbofuran + TX, diamidaphos + TX, dicaptone + TX, dichlorofenthion + TX, dicresyl + TX, dicyclanil + TX, dieldrin + TX, diethyl-5-methylpyrazol-3-ylphosphate + TX, dilor + TX, dimefluthrin + TX, dimethane + TX, dimethrin + TX , dimethylvinphos + TX, dimethylane + TX, dinoprop + TX, dinosam + TX, dinoseb + TX, diophenolan + TX, dioxabenzophos + TX, dithikrofos + TX, DSP + TX, ecdysterone + TX, EI 1642 + TX, EMPC + TX, EPBP + TX, ethaphos + TX, etiophencarb + TX, ethyl formate + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, EXD + TX, fenchlorvos + TX, fenetacarb + TX, fenitrothion + TX, fenoxacrim + TX, phenpyritrin + TX, fensulfothione + TX, fenthion-ethyl + TX, flucofuron + TX, fosmethylane + TX, fospirate + TX, fostiethane + TX, furathiocarb + TX, furethrin + TX, guazatin + TX, guazatin acetates + TX, sodium tetrathiocarbonate + TX , galfenprox + TX, HCH + TX, HEOD + TX, heptachlor + TX, heterophos + TX, HHDN + TX, hydrogen cyanide + TX, hiquincarb + TX, IPSP + TX, isazophos + TX, isobenzan + TX, isodrine + TX, isofenphos + TX, isolan + TX, isoprothiolane + TX, isoxathione + TX, juvenile hormone I + TX, juvenile hormone II + TX, juvenile hormone III + TX, kelevan + TX, kinoprene + TX, lead arsenate + TX, leptophos + TX , lyrimphos + TX, lithidathion + TX, m-cumenylmethylcarbamate + TX, magnesium phosphide + TX, mazidox + TX, mecarfon + TX, menasone + TX, mercuric chloride + TX, mesulfenphos + TX, metam + TX, metam-potassium + TX , metham sodium + TX, methanesulfonyl fluoride + TX, methocrotophos + TX, methoprene + TX, methotrin + TX, methoxychlor + TX, methyl isothiocyanate + TX, methyl chloroform + TX, methylene chloride + TX, methoxadiazone + TX, mirex + TX, naphthalophos + TX , naphthalene + TX, NC-170 + TX, nicotine + TX, nicotine sulfate + TX, nithiazine + TX, nornicotine + TX, O-5-dichloro-4-iodophenyl-O-ethylethylphosphonothioate + TX, O,O-diethyl- O-4-methyl-2-oxo2H-chromen-7-ylphosphorothioate + TX, O,O-diethyl-O-6-methyl-2-propylpyrimidin-4-ylphosphorothioate + TX, O,O,O',O'- tetrapropyldithiopyrophosphate + TX, oleic acid + TX, para-dichlorobenzene + TX, parathion-methyl + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, PH 60-38 + TX, phencapton + TX, phosnichlor + TX, phosphine + TX, phoxim- methyl + TX, pyrimethafos + TX, polychlorodicyclopentadiene isomers + TX, potassium arsenite + TX, potassium thiocyanate + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, profluthrin + TX, promecarb + TX, prothiophos + TX, pyrazophos + TX, pyresmethrin + TX, quassia + TX, quinalphos-methyl + TX, quinothione + TX, rafoxanide + TX, resmethrin

- 70 046405 + TX, rotenone + TX, cadetrin + TX, ryanium + TX, ryanodine + TX, sabadilla) + TX, shradan + TX, sebuphos + TX, SI-0009 + TX, tiapronil + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoride + TX, sodium hexafluorosilicate + TX, sodium pentachlorophenoxide + TX, sodium selenate + TX, sodium thiocyanate + TX, sulcofuron + TX, sulcofuron-sodium + TX, sulfuryl fluoride + TX, sulprophos + TX, tar oils + TX, tazimcarb + TX, TDE + TX, tebupirimphos + TX, temephos + TX, terallethrin + TX, tetrachloroethane + TX, ticrofos + TX, thiocyclam + TX, thiocyclam hydroxalate + TX, thionazine + TX, thiosultap + TX, thiosultap- sodium + TX, tralomethrin + TX, transpermethrin + TX, triazamate + TX, trichlorometaphos-3 + TX, trichloronate + TX, trimetacarb + TX, tolprocarb + TX, trichloropyricarb + TX, triprene + TX, veratridine + TX, veratrine + TX, XMC + TX, zetamethrin + TX, zinc phosphide + TX, zolaprophos + TX and meperfluthrin + TX, tetramethylfluthrin + TX, bis(tributyltin) oxide + TX, bromoacetamide + TX, iron phosphate + TX, niclosamide-olamine + TX , tributyltin oxide + TX, pyrimorph + TX, triphenmorph + TX, 1,2-dibromo-3-chloropropane + TX, 1,3-dichloropropene + TX, 3,4dichlorotetrahydrothiophene-1,1-dioxide + TX, 3-(4 -chlorophenyl)-5-methylrhodanine + TX, 5-methyl-6-thioxo1,3,5-thiadiazinan-3-ylacetic acid + TX, 6-isopentenylaminopurine + TX, anisiflupurine + TX, benclothiase + TX, cytokinins + TX, DCIP + TX, furfural + TX, isamidophos + TX, kinetin + TX, composition based on Myrothecium verrucaria + TX, tetrachlorothiophene + TX, xylenols + TX, zeatin + TX, potassium ethyl xanthate + TX, acibenzolar + TX, acibenzolar^-methyl + TX , Reynoutria sachalinensis extract + TX, alpha-chlorohydrin + TX, antu + TX, barium carbonate + TX, bisthiosemie + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, chlorophacinone + TX, cholecalciferol + TX, coumachlor + TX, coumafuril + TX, coumatetral + TX, crimidine + TX, difenacoum + TX, difethialone + TX, diphacinone + TX, ergocalciferol + TX, flocumafen + TX, fluoroacetamide + TX, flupropadine + TX, flupropadine hydrochloride + TX, norbormide + TX, phosacetim + TX, phosphorus + TX, pindone + TX, pyrinuron + TX, skilliroside + TX, sodium fluoroacetate + TX, thallium sulfate + TX, warfarin + TX, 2-(2butoxyethoxy)ethylpiperonylate + TX, 5-(1,3-benzodioxole) -5-yl)-3-hexylcyclohex-2-enone + TX, farnesol with nerolidol + TX, verbutin + TX, MGK 264 + TX, piperonyl butoxide + TX, piprotal + TX, propylysome + TX, S421 + TX, sesamex + TX , sesasmolin + TX, sulfoxide + TX, anthraquinone + TX, copper naphthenate + TX, copper oxychloride + TX, dicyclopentadiene + TX, thiram + TX, zinc naphthenate + TX, ziram + TX, imanin + TX, ribavirin + TX, chloroinconazide + TX, mercuric oxide + TX, thiophanate-methyl + TX, asaconazole + TX, biterthanol + TX, bromuconazole + TX, cyproconazole + TX, difenoconazole + TX, diniconazole + TX, epoxiconazole + TX, fenbuconazole + TX, fluquinconazole + TX, flusilazole + TX, flutriafol + TX, furamethpir + TX, hexaconazole + TX, imazalil + TX, imibenconazole + TX, ipconazole + TX, metconazole + TX, myclobutanil + TX, paclobutrazol + TX, pefurazoate + TX, penconazole + TX, prothioconazole + TX , pyrifenox + TX, prochloraz + TX, propiconazole + TX, pyrizoxazole + TX, simeconazole + TX, tebuconazole + TX, tetraconazole + TX, triadimefon + TX, triadimenol + TX, triflumizole + TX, triticonazole + TX, ancymidol + TX, fenarimol + TX, nuarimol + TX, bupirimate + TX, dimethylrimol + TX, ethirimol + TX, dodemorph + TX, fenpropidine + TX, fenpropimorph + TX, spiroxamine + TX, tridemorph + TX, cyprodinil + TX, mepanipyrim + TX, pyrimethanil + TX , fenpiclonil + TX, fludioxonil + TX, benalaxyl + TX, furalaxyl + TX, metalaxyl -+ TX, R-metalaxyl + TX, ofuras + TX, oxadixil + TX, carbendazim + TX, debacarb + TX, fuberidazole + TX, thiabendazole + TX, chlozolinate + TX, dichlozolin + TX, myclozolin + TX, procymidone + TX, vinclozolin + TX, boscalid + TX, carboxin + TX, fenfuram + TX, flutolanil + TX, mepronil + TX, oxycarboxin + TX, penthiopyrad + TX, tifluzamide + TX, dodine + TX, iminoctadine + TX, azoxystrobin + TX, dimoxystrobin + TX, enestroburin + TX, phenaminestrobin + TX, flufenoxystrobin + TX, fluoxastrobin + TX, kresoxim-methyl + TX, metominostrobin + TX, trifloxystrobin + TX, orysastrobin + TX, picoxystrobin + TX, pyraclostrobin + TX, pyramethostrobin + TX, pyraoxystrobin + TX, ferbam + TX, mancozeb + TX, maneb + TX, metiram + TX, propineb + TX, zineb + TX, captafol + TX, captan + TX, fluoromide + TX, folpet + TX, tolylfluanid + TX, Bordeaux mixture + TX, copper oxide + TX, mancopper + TX, copper oxine + TX, nitrotal isopropyl + TX, edifenphos + TX, iprobenphos + TX, phosdifene + TX , tolclofos-methyl + TX, anilazine + TX, benthiavalicarb + TX, blasticidin-S + TX, chloroneb + TX, chlorothalonil + TX, cyflufenamide + TX, cymoxanil + TX, cyclobutrifluram + TX, diclocymet + TX, diclomesine + TX, dicloran + TX, diethofencarb + TX, dimethomorph + TX, flumorph + TX, dithianone + TX, ethaboxam + TX, etridiazole + TX, famoxadone + TX, fenamidone + TX, phenoxanil + TX, ferimzone + TX, fluazinam + TX, flumethylsulforim + TX , fluopicolide + TX, fluoxythioconazole + TX, flusulfamide + TX, fluxapyroxad + TX, fenhexamide + TX, fosetyl-aluminum + TX, himexazole + TX, iprovalicarb + TX, cyazofamide + TX, metasulfocarb + TX, metrafenone + TX, pencycuron + TX , phthalide + TX, polyoxins + TX, propamocarb + TX, pyribencarb + TX, proquinazide + TX, pyroquilone + TX, pyriophenone + TX, quinoxifene + TX, quintozene + TX, tiadinyl + TX, triazoxide + TX, tricyclazole + TX, triforin + TX, validamycin + TX, valifenalate + TX, zoxamide + TX, mandipropamide + TX, flubeneteram + TX, isopyrazam + TX, sedaxane + TX, benzovindiflupyr + TX, pidiflumetofen + TX, 3difluoromethyl-1-methyl-III-pyrazole-4 -carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide + TX, isoflucipram + TX, isothianyl + TX, dipimethytrone + TX, 6-ethyl-5,7-dioxopyrrolo [4, 5][1,4]dithiino [1,2-c]isothiazol-3-carbonitrile + TX, 2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl- 71 046405 indan-4-yl] pyridine-3-carboxamide + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine-3carbonitrile + TX, (d)-3-(difluoromethyl)-1-methyl-H-[1,1 ,3-trimethylindan-4-yl]pyrazol-4-carboxamide + TX, 4-(2-bromo-4-fluorophenyl)-H-(2-chloro-6-fluorophenyl)-2,5-dimethylpyrazol-3-amine + TX, 4-(2-bromo-4fluorophenyl)-H-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine + TX, fluindapyr + TX, coumethoxystrobin (jiaxiangjunzhi) + TX, Liubenmisianan + TX, dichlorobenthiazox + TX, mandestrobin + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone + TX, 2-[2-fluoro- 6-[(8-fluoro-2methyl-3-quinolyl)oxy]phenyl]propan-2-ol + TX, oxathiapiproline + TX, tert-butyl-N-[6-[[[(1methyltetrazol-5-yl)phenylmethylene ]amino]oxymethyl]-2-pyridyl]carbamate + TX, pyraziflumide + TX, inpirfluxam + TX, trolprocarb + TX, mefentrifluconazole + TX, ipfentrifluconazole + TX, 2(difluoromethyl)-H-[(3K)-3-ethyl- 1,1-dimethylindan-4-yl]pyridin-3-carboxamide + TX, I-(2,5-dimethyl-4phenoxyphenyl)-N-ethyl-N-methylformamidine + TX, I-[4-(4,5- dichlorothiazol-2-yl)oxy-2,5dimethylphenyl]-N-ethyl-N-methylformamidine + TX, [2-[3-[2-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1yl ]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chlorophenyl]methanesulfonate + TX, but-3-ynyl-N-[6-[[(^) - [(1-methyltetrazol-5-yl)phenylmethylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, methyl-H-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl] -2-methylphenyl]methyl]carbamate + TX, 3-chloro-6methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine + TX, pyridachloromethyl + TX, 3-(difluoromethyl)-1methyl-H- [1,1,3-trimethylindan-4-yl]pyrazol-4-carboxamide + TX, 1-[2-[[1-(4-chlorophenyl)pyrazol-3yl]oxymethyl]-3-methylphenyl]-4-methyltetrazole -5-one + TX, 1-methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5trimethylpyrazol-1-yl)phenoxy]methyl]phenyl]tetrazol-5-one + TX, aminopyrifen + TX, ametoctradine + TX, amisulbrom + TX, penflufen + TX, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino,3-dimethylpent -3-enamide + TX, florylpicoxamide + TX, fenpicoxamide + TX, methylpicoxamide + TX, tebufloquin + TX, ipflufenoquin + TX, quinofumelin + TX, isofetamide + TX, N-[2-[2,4-dichlorophenoxy]phenyl]- 3-(difluoromethyl)-1-methylpyrazole-4-carboxamide + TX, N-[2-[2-chloro-4(trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide + TX , benzothiostrobin + TX, phenamacryl + TX, zinc salt of 5-amino-1,3,4-thiadiazol-2-thiol (2:1) + TX, fluopyram + TX, flufenoxadiasam + TX, flutianil + TX, fluopimomide + TX, pyrapropone + TX, picarbutrazox + TX, 2-(difluoromethyl)-H-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridin-3-carboxamide + TX, 2-(difluoromethyl)-H(( 3R)-1,1,3-trimethylindan-4-yl)pyridin-3-carboxamide + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2hydroxy-3- (1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, methyltetraprole + TX, 2 (difluoromethyl)-N-((3R)-1,1,3-trimethylindan- 4-yl)pyridin-3-carboxamide + TX, a-(1,1-dimethylethyl)-a[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-5-pyrimidinemethanol + TX, fluoxapiproline + TX, enoxast robin + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4-triazol-1-yl )propyl]-3pyridyl]oxy]benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-sulfanyl1,2,4- triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2hydroxy-3-(5-thioxo -4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, trinexapac + TX, cumoxystrobin + TX, zhongshengmitsin + TX, copper thiodiazole + TX, zinc thiazole + TX, amectotractin + TX, iprodione + TX, seboctylamine + TX; N'-[5-bromo-2-methyl-6-[(^)-1-methyl-2-propoxyethoxy|-3pyridyl]-N-ethyl-N-methylformamidine + TX, N'-[5-bromo-2 -methyl-6-[(^)-1-methyl-2-propoxyethoxy|-3pyridyl] -N-ethyl-N-methylformamidine pyridyl] -N-ethyl-N-methylformamidine pyridyl] -N-ethyl-N-methylformamidine

TX, TX, TX,

N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3N' -[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3 pyridyl]-H-isopropyl-N-methylformamidine + TX (these compounds can be prepared using the methods described in WO 2015/ 155075); N'-[5-bromo-2-methyl-6-(2-propoxypropoxy)-3-pyridyl]-Nethyl-N-methylformamidine + TX (this compound can be prepared using the methods described in IPCOM000249876D); N-isopropyl-N'-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1phenylethyl)phenyl]-N-methylformamidine + TX, N'-[4-(1 -cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-5methoxy-2-methylphenyl]-N-isopropyl-N-methylformamidine + TX (these compounds can be prepared using the methods described in WO 2018/228896); N-ethyl-N'-[5-methoxy-2-methyl-4-[(2 trifluoromethyl)oxetan-2-yl]phenyl]-N-methylformamidine + TX, N-ethyl-N'-[5-methoxy- 2-methyl-4-[(2trifluoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methylformamidine + TX (these compounds can be prepared using the methods described in WO 2019/110427); N-[(^)-1-benzyl-3-chloro-1-methylbut-3enyl]-8-fluoroquinoline-3-carboxamide + TX, N-[(^)-1-benzyl-3-chloro-1-methylbut -3-enyl]-8-fluoroquinoline-3-carboxamide + TX, N-[(^)-1-benzyl-3,3,3-trifluoro-1-methylpropyl]-8-fluoroquinoline-3-carboxamide + TX, N- [(^)-1-benzyl-3,3,3-trifluoro-1-methylpropyl]-8-fluoroquinoline-3-carboxamide + TX, N-[(1R)-1benzyl-1,3-dimethylbutyl]-7, 8-difluoroquinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethylbutyl] 7,8-difluoroquinoline-3-carboxamide + TX, 8-fluoro-N-[(1K)- 1-[(33-fluorophenyl)methyl|-1.3dimethylbutyl]quinoline-3-carboxamide + TX, 8-fluoro-H-[(^)-1-[(3-fluorophenyl)methyl]-1,3dimethylbutyl]quinoline- 3-carboxamide + TX, N-[(^)-1-benzyl-1,3-dimethylbutyl]-8-fluoroquinoline-3carboxamide + TX, N-[(^)-1-benzyl-1,3-dimethylbutyl]- 8-fluoroquinoline-3-carboxamide + TX, N-((1R)-1benzyl-3-chloro-1-methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide + TX, N-((^)-1 -benzyl-3-chloro-1methylbut-3-enyl)-8-fluoroquinoline-3-carboxamide + TX (these compounds can be prepared using the methods described in WO 2017/153380); 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro

- 72 046405

3,3-dimethylisoquinoline + TX, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3dimethylisoquinoline + TX, 4,4-difluoro- 3,3-dimethyl-1-(6-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1, 5-a]pyridin-3-yl)isoquinoline + TX, 1-(6-chloro-7methylpyrazolo[1,5-a]pyridin-3-yl)-4,4-difluoro-3,3-dimethylisoquinoline + TX ( these compounds can be obtained using the methods described in WO 2017/025510); 1-(4,5-dimethylbenzimidazol-1-yl)4,4,5-trifluoro-3,3-dimethylisoquinoline + TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3 ,3dimethylisoquinoline + TX, 6-chloro-4,4-di(thoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline + TX, 4,4-difluoro-1-(5-fluoro -4-methyl-benzimidazol-1-yl)-3,3-dimethylisoquinoline + TX, 3-(4,4-difluoro-3,3dimethyl-1-isoquinolyl)-7,8-dihydro-6H-cyclopenta[e] benzimidazole + TX (these compounds can be prepared using the methods described in WO 2016/156085); methyl]cyclopropanecarboxamide + TX, K2-dimethoxy-H

[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide ( trifluoromethyl)-1,2,4-oxadiazol-3-yl] phenyl]methyl]urea (trifluoromethyl)-1,2,4-oxadiazol-3 -yl] phenyl]methyl]urea (trifluoromethyl)-1,2,4 -oxadiazol-3-yl]phenyl]methyl]urea + TX, H-ethyl-2-methyl-H-[[4-[5TX,

TX, TX,

-methoxy-3 -methyl-1-[[4-[51,3-dimethoxy-1-[[4-[53 -ethyl-1-methoxy-1-[[4-[5+ TX, H-[[ 4-[5-(trifluoromethyl)-1.2.4oxadiazol-3-yl](enyl]methyl]propanamide + TX, 4,4-dimethyl-2-[[4-[5-(tri(tormethyl)-1,2 ,4-oxadiazol3-yl](enyl]methyl]isoxazolidin-3-one + TX, 5,5-dimethyl-2-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3yl ](enyl]methyl]isoxazolidin-3-one + TX, ethyl 1-[[4-[5-(tri(tormethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]pyrazole-4-carboxylate + TX, DNdimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl](enyl]methyl]-1,2,4-triazol-3-amine + TX; the compounds in this paragraph can be prepared using the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689 2-[6-(4 chlorophenoxy)-2-(trifluoromethyl)-3- pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol + TX (this compound can be prepared using the methods described in WO 2017/029179); bromophenoxy)-2(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2-ol + TX (this compound can be prepared using the methods described in WO 2017/029179 ); 3-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2hydroxy-propyl]imidazole-4-carbonitrile + TX (this compound can be prepared using the methods described in WO 2016/156290); 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluorophenyl)-2hydroxypropyl]imidazole-4-carbonitrile + TX (this compound can be prepared using the methods described in WO 2016/156290); (4-(enoxy(enyl)methyl-2-amino-6-methylpyridin-3-carboxylate + TX (this compound can be prepared using the methods described in WO 2014/006945); 2,6dimethyl-1H,5H-[1 ,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetron + TX (this compound can be prepared using the methods described in WO 2011/ 138281); ]benzamide + TX; (2,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-H,3-dimethylpent3-enamide + TX (this compound can be prepared with using the methods described in WO 2018/153707); N-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N-methylformamidine + TX; 5-methylphenyl]-N-ethyl-N-methylformamidine + TX (this compound can be prepared using the methods described in WO 2016/202742); ,1-dimethylindan4-yl]pyridin-3-carboxamide + TX (this compound can be obtained using the methods described in WO 2014/095675); (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone + TX, (3-methylisoxazol-5-yl)-[4 -[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone + TX (these compounds can be prepared using the methods described in WO 2017/220485); 2-oxo-N-propyl-2-[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide + TX (this compound can be prepared using the methods described in WO 2018/ 065414); ethyl 1-[[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]2-thienyl]methyl]pyrazole-4-carboxylate + TX (this compound can be prepared using the methods described in WO 2018/158365); 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]acetamide + TX, N[(E)-methoxyiminomethyl]-4-[ 5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]benzamide + TX, N[(2)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] benzamide + TX, N[H-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX (these compounds can be prepared using methods , described in WO 2018/202428).

In typical mixture-based compositions, mixtures of compounds of formula (I) (selected from table X (above)) with the active ingredients described above contain a compound selected from table. X (above), and the active ingredient described above, preferably at a mixture ratio of 100:1 to 1:100, particularly 50:1 to 1:50, more particularly at a mixture ratio of 20:1 to 1:20, even more specifically from 10:1 to 1:10, namely from 5:1 and 1:5, particular preference is given to the ratio from 2:1 to 1:2, and the ratio from 4:1 to 2:1 is also preferred, especially total with a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3: 2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2: 3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4: 75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. These mixture ratios are given by weight.

The mixture-based compositions described above (both in accordance with the present invention and

- 73 046405 and typical mixture-based compositions) can be used in a pest control method that involves applying a composition containing the mixture described above to pests or their environment.

Mixtures containing a compound of formula (I) selected from table. X (above), and one or more of the active ingredients described above, can be used, for example, in a single form of ready-mix, in the form of a combination spray mixture made up of separate compositions of components representing single active ingredients, such as a tank mix, and in the form of combined use of individual active ingredients when used in a sequential manner, i.e. one after another in a fairly short period of time, such as a few hours or days. The order of application of compounds of formula (I) selected from table. X (above) and the active ingredients described above are not essential to the practice of the present invention.

The compositions of the present invention can also be used for crop improvement. In accordance with the present invention, the term crop improvement means improved plant vigor, improved plant quality, improved tolerance to stress factors and/or improved resource utilization.

In accordance with the present invention, the term improvement in plant vigor means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without applying the method of the present invention. Such traits include, but are not limited to, early and/or improved germination, improved germination, ability to use less seed, increased root growth, more developed root system, increased root nodule formation, increased seedling growth rate, increased tillering rate, stronger shoots, more productive shoots, increased or improved plant density, less plant fall (lodging), increased and/or improved plant height, increased plant weight (fresh or dry), larger leaf blades, greener leaf color, increased pigment content, increased photosynthetic activity , earlier flowering, longer panicles, earlier grain maturation, increased seed, fruit or pod size, increased number of pods or ears, increased number of seeds per pod or ear, increased seed weight, increased seed filling, fewer dead lower leaves, retention aging, improved plant viability, increased levels of amino acids in storage tissues and/or lower inputs of required resources (eg, less fertilizer, water and/or labor costs). A plant with improved vigor may be characterized by improvement in any of the above-mentioned traits or any combination of two or more of the above-mentioned traits.

In accordance with the present invention, the term improvement in plant quality means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without applying the method of the present invention. Such attributes include, but are not limited to, improved plant appearance, reduced amount of ethylene (reduced rate of production and/or inhibition of reception), improved quality of harvested material, e.g., seeds, fruits, leaves, vegetables (such improved quality may be manifested as improved appearance of harvested material ), improved carbohydrate content (e.g. increased sugar and/or starch levels, improved sugar-acid ratio, reduced reducing sugars, increased sugar production), improved protein content, improved oil content and composition, improved nutritional value, reduced non-nutritive compounds, improved organoleptic properties (e.g. improved palatability) and/or increased consumer health benefits (e.g. increased levels of vitamins and antioxidants)), improved post-harvest characteristics (e.g. increased shelf life and/or shelf stability, improved processability, facilitated extraction of compounds), more uniform crop development (eg synchronized germination, flowering and/or fruiting of plants) and/or improved seed quality (eg for use in subsequent seasons). An improved quality plant may be characterized by an improvement in any of the above-mentioned traits or any combination of two or more of the above-mentioned traits.

According to the present invention, the term improved tolerance to stress factors means that certain traits are improved qualitatively or quantitatively compared to the same trait in a control plant that was grown under the same conditions without using the method of the present invention. Such traits include, but are not limited to, increased tolerance and/or resistance to abiotic stressors that result in suboptimal growing conditions, such as drought (e.g., any stress that results in insufficient plant water content, insufficient water uptake capacity, or reduced plant water supply ), cold exposure, heat exposure, osmotic stress, UV stress, flooding, increased salinity (e.g. in soil), increased mineral exposure, ozone exposure, exposure

- 74 046405 high intensity lighting and/or limited availability of nutrients (eg nitrogen-containing and/or phosphorus-containing nutrients). A plant with improved stress tolerance may be characterized by an improvement in any of the above-mentioned traits or any combination of two or more of the above-mentioned traits. In the case of stress caused by drought and nutrient deficiencies, such improved tolerance may be due to, for example, more efficient absorption, application or retention of water and nutrients.

In accordance with the present invention, the term improved resource utilization means that plants are able to grow more efficiently using given levels of resources compared to the growth of control plants that are grown under the same conditions without applying the method of the present invention. Specifically, resources include, but are not limited to, fertilizer (eg, nitrogen, phosphorus, potassium, and micronutrients), light, and water. A plant with improved resource utilization may be characterized by improved utilization of any of the above-mentioned resources or any combination of two or more of the above-mentioned resources.

Other improvements to the crops of the present invention include reducing plant height or reducing tillering, which are preferred properties for crops or conditions where less biomass and fewer shoots are desired.

Any or all of the above crop improvements may result in improved yield by improving, for example, plant physiology, plant growth and development, and/or plant architecture. In the context of the present invention, the term yield includes, without limitation, (i) an increase in the rate of biomass production, grain yield, starch content, oil content and/or protein content, which may result from (a) an increase in the amount produced by the plant per se, or (b) improved ability to harvest plant material, (ii) improved composition of harvested material (e.g., improved sugar-acid ratios, improved oil composition, increased nutritional value, reduced non-nutritive compounds, increased consumer health benefits), and/or (iii) increased/lighter ability crop harvesting, improved suitability for crop processing, better storage stability/extended shelf life. Increased crop yield means that when a quantitative measurement can be made, the yield of the corresponding plant product is increased by a measurable amount compared to the yield of the same plant product produced under the same conditions but without the use of the present invention. According to the present invention, it is preferable that the yield is increased by at least 0.5%, more preferably at least 1%, even more preferably at least 2% and even more preferably at least 4%, preferably 5% or even more.

Any or all of the above crop improvements could also lead to better land use, e.g. land that was previously inaccessible or suboptimal for cultivation may become available. For example, plants that exhibit an increased ability to survive drought conditions can be cultivated in areas with suboptimal rainfall, such as those likely bordering a desert or even located in the desert itself.

In one aspect of the present invention, crop improvements are made with virtually no exposure to pests and/or diseases and/or abiotic stress. In a further aspect of the present invention, improvements in plant vigor, stress tolerance, quality and/or yield are achieved with little or no pest and/or disease exposure. For example, pests and/or diseases can be controlled through pesticide treatments that are applied prior to or concurrently with the method of the present invention. In yet another additional aspect of the present invention, improvements in plant vigor, stress tolerance, quality and/or yield are achieved in the absence of pest and/or disease exposure. In a further embodiment, improvements in plant vigor, quality and/or yield are achieved in the absence or virtually no abiotic stress.

The compositions of the present invention can also be used in the field of protecting stored goods from fungal attack. In accordance with the present invention, the term stored goods is understood to mean natural substances of plant and/or animal origin and their processed forms that have been taken from the natural life cycle and for which long-term protection is required. Stored goods of plant origin, such as plants or parts thereof, such as petioles, leaves, tubers, seeds, fruits or grains, may be protected in a freshly harvested state or in a processed form such as pre-dried, moistened, crushed, ground, pressed or roasted . Also falls under the definition of warehouse

- 75 046405 classified timber products, either in the form of unprocessed timber, such as construction timber, power poles and fencing, or in the form of finished products, such as furniture or objects made from wood. Stored goods of animal origin are hides, skins, furs, hair, etc. The composition in accordance with the present invention can provide prevention of adverse effects such as rotting, discoloration or molding. Preferably, the term warehoused goods is understood to mean natural plant substances and/or processed forms thereof, more preferably fruits and their processed forms, such as pome fruits, stone fruits, berries and citrus fruits, as well as processed forms thereof. In another preferred embodiment of the present invention, the term warehoused goods is understood to mean wood.

Therefore, a further aspect of the present invention is a method of protecting stored goods, which includes applying to the stored goods a composition in accordance with the present invention.

The composition of the present invention can also be used in the field of protecting technical materials from fungal attack. In accordance with the present invention, the term technical material includes paper; carpets; structures; cooling and heating systems; facing slabs; ventilation and air conditioning systems, etc.; Preferably, the term technical material is understood to mean cladding boards. The composition in accordance with the present invention can provide prevention of adverse effects such as rotting, discoloration or molding.

The composition in accordance with the present invention is usually formulated by various methods using formulation aids such as carriers, solvents and surfactants. The compositions may be present in various physical forms, for example, sprayable powders, gels, wettable powders, water-dispersible granules, water-dispersible tablets, effervescent pellets, emulsifiable concentrates, microemulsion concentrates, oil-in-water emulsions, oil-based pourable formulations, aqueous dispersions, oil dispersions, suspoemulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water-miscible organic solvent as a carrier), impregnated polymer films or in other forms known, for example, from the Manual on Development and Use of FAO and WHO Specifications for Pesticides, United Nations, First Edition, Second Revision (2010). Such formulations can either be applied directly or diluted before use. Dilutions can be carried out, for example, with water, liquid fertilizers, micronutrients, biological organisms, oil or solvents.

The compositions can be prepared, for example, by mixing the active ingredient with formulation auxiliaries to obtain compositions in the form of fine solids, granules, solutions, dispersions or emulsions. The active ingredients may also be formulated with other excipients, for example, fine solids, mineral oils, vegetable or animal oils, modified vegetable or animal oils, organic solvents, water, surfactants, or combinations thereof.

The active ingredients may also be contained in microcapsules. Microcapsules contain active ingredients in a porous carrier. This allows the active ingredients to be released into the environment in controlled quantities (eg slow release). Microcapsules typically have a diameter ranging from 0.1 to 500 microns. They contain active ingredients in amounts ranging from approximately 25 to 95% by weight of the capsule. The active ingredients may be in the form of a monolithic solid, in the form of fine particles in a solid or liquid dispersion, or in the form of a suitable solution. Encapsulating membranes may contain, for example, natural and synthetic rubbers, cellulose, styrene-butadiene copolymers, polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyurethane or chemically modified polymers and starch xanthates or other polymers that are known to one skilled in the art. Alternatively, very fine microcapsules can be prepared in which the active ingredient is contained as fine particles in a solid matrix of the base material, but the microcapsules are not themselves encapsulated.

Formulation aids which are suitable for preparing the compositions according to the present invention are known per se. Liquid carriers that can be used are water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylene carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl esters of acetic acid , diacetone alcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N.N-dimethylformamide. dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol

- 76 046405 col, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha-pinene, d-limonene, ethyl lactate, ethylene glycol, butyl ether ethylene glycol, ethylene glycol methyl ether, gamma-butyrolactone, glycerin, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate, lactic acid, laurylamine, oxide, methoxypropanol, methyl isoamyl ketone, methyl isobutyl ketone , methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, nhexane, n-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, oxylene, phenol, polyethylene glycol, propionic acid, propyl lactate, propylene carbonate, propylene glycol, methyl ether propylene glycol, p -xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene, perchlorethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol and high molecular weight alcohols such such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerin, N-methyl-2-pyrrolidone, etc.

Suitable solid carriers are, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, diatomaceous earth, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed hulls, wheat flour, soya flour, pumice, wood flour, ground shells walnuts, lignin and similar substances.

A large number of surfactants can be used successfully in both solid and liquid formulations, especially in those formulations that can be diluted with a vehicle before use. Surfactants may be anionic, cationic, nonionic, or polymeric, and may be used as emulsifiers, wetting agents or suspending agents, or for other purposes. Typical surfactants include, for example, alkyl sulfate salts such as diethanolammonium lauryl sulfate, alkyl aryl sulfonate salts such as calcium dodecylbenzenesulfonate, alkylphenol/alkylene oxide adducts such as nonylphenol ethoxylate, alcohol/alkylene oxide adducts such as tridecyl alcohol ethoxylate, soaps such such as sodium stearate, alkyl naphthalene sulfonate salts such as sodium dibutyl naphthalene sulfonate, dialkyl ester sulfosuccinate salts such as sodium di(2ethylhexyl) sulfosuccinate, sorbitol esters such as sorbitoleate, quaternary amines such as lauryl trimethyl ammonium chloride, polyethylene glycol fatty acid esters such as such as polyethylene glycol stearate, ethylene oxide-propylene oxide block copolymers and mono- and dialkyl phosphate ester salts, as well as additional substances described, for example, in McCutcheon's Detergents and Emulsifiers Annual, MC Publishing Corp., Ridgewood New Jersey (1981).

Additional adjuvants that may be used in pesticide formulations include crystallization inhibitors, viscosity modifiers, suspending agents, colorants, antioxidants, foaming agents, light absorbing agents, mixing aids, defoamers, complexing agents, neutralizing or pH-modifying agents, and buffers, corrosion inhibitors, fragrances, wetting agents, absorption enhancers, micronutrients, plasticizers, glidants, lubricants, dispersants, thickeners, antifreeze, microbicides, and liquid and solid fertilizers.

The compositions of the present invention may include an additive containing a vegetable or animal oil, mineral oil, alkyl esters of such oils, or mixtures of such oils and oil derivatives. The amount of oil additive in the composition in accordance with the present invention is usually from 0.01 to 10%, based on the amount of the mixture to be used. For example, the oil additive can be added to the sprayer reservoir at the required concentration after the spray mixture is prepared. Preferred oil additives contain mineral or vegetable oils, such as canola oil, olive oil or sunflower oil, emulsified vegetable oil, alkyl esters of vegetable oils, such as methyl derivatives, or an animal oil, such as fish oil or beef tallow. Preferred oil additives contain alkyl esters of C8-C22 fatty acids, in particular methyl derivatives of _C12 - _C18 fatty acids, for example, methyl esters of lauric acid, palmitic acid and oleic acid (methyl laurate, methyl palmitate and methyl oleate, respectively). Many oil derivatives are known from Compendium of Herbicide Adjuvants, ^10th Edition, Southern Illinois University, 2010.

The compositions typically contain from 0.1 to 99% by weight, in particular from 0.1 to 95% by weight of the compounds of component (A) and component (B) and from 1 to 99.9% by weight of a formulation aid, which preferably contains from 0 to 25% by weight of surfactant. Since commercial products may preferably be formulated as concentrates, the end user will typically use diluted formulations.

Application rates vary widely and depend on the properties of the soil, the method of application

- 77 046405 crop, pest to be controlled, prevailing climatic conditions and other factors determined by the method of application, time of application and the target crop. As a general guideline, the compounds can be applied at rates from 1 to 2000 l/ha, in particular from 10 to 1000 l/ha.

Certain mixture compositions containing the compound of formula (I) described above may exhibit a synergistic effect. It is observed whenever the effectiveness of a combination of active ingredients is greater than the sum of the effectiveness values of the individual components. The expected potency E for a given combination of active ingredients obeys the so-called Colby formula and can be calculated as follows (COLBY, S.R. Calc synulatingergistic and antagonistic responses of herbicide combination. Weeds, Vol. 15, pages 20-22; 1967):

ppm = milligrams of active ingredient (= a.i.) per liter of spray mixture,

X = % potency of active ingredient (A) using p ppm of active ingredient, Y = % potency of active ingredient (B) using q ppm of active ingredient.

According to the Colby formula, the expected (additive) effectiveness of the active ingredients (A) + (B) in the case of using p + q ppm of the active ingredient is:

E=x+y-2LZ

100

If the actual observed efficiency (O) is greater than the expected efficiency (E), then the efficiency of the combination is superadditive, i.e. there is a synergistic effect. In mathematical terms, synergy corresponds to a positive difference (O-E). In the case of only complementary addition of activity indicators (expected activity), the specified difference (OE) is equal to zero. A negative value of the indicated difference (O-E) indicates a loss of activity compared to expected activity.

However, in addition to the actual synergistic effect with respect to fungicidal activity, the composition in accordance with the present invention may also be characterized by additional unexpected advantageous properties. Examples of such advantageous properties that may be mentioned are more efficient degradability; improved toxicological and/or ecotoxicological properties; improved beneficial plant characteristics including germination, crop yield, more developed root system, increased tillering rate, increased plant height, larger leaf blade, fewer dead lower leaves, stronger shoots, greener leaf color, less fertilizer requirement, less seed requirement, more productive shoots, earlier flowering, earlier grain maturation, less plant drop (lodging), increased seedling growth rate, improved plant vigor and earlier germination.

The composition in accordance with the present invention can be used in relation to phytopathogenic microorganisms, beneficial plants, their place of growth, their propagation material, stored goods or technical materials that are at risk of being damaged by microorganisms.

The composition in accordance with the present invention can be applied before or after microorganism contamination of useful plants, their propagation material, stored goods or technical materials.

The amount in which the composition according to the present invention will be used will depend on various factors such as the compounds used; the object of treatment, such as, for example, plants, soil or seeds; type of treatment, such as, for example, spraying, pollination or seed treatment; the purpose of the processing, such as, for example, prophylactic or therapeutic; type of fungus to be controlled or time of application.

When applied to useful plants, component (A) is generally applied at a rate of 5 to 2000 g ai/ha, in particular 10 to 1000 g ai/ha, for example 50, 75, 100 or 200 g a.i./ha, usually together with from 1 to 5000 g a.i./ha, in particular from 2 to 2000 g a.i./ha, for example 100, 250, 500, 800 , 1000, 1500 g a.i./ha component (B).

In agricultural practice, application rates of the composition according to the present invention depend on the type of effect desired, and are typically in the range of 20 to 4000 g of total composition per hectare.

If the composition according to the present invention is used for treating seeds, rates of 0.001 to 50 g of the compound as component (A) per kg of seed, preferably 0.01 to 10 g per kg of seed and 0.001 to 50 g of the compound are usually sufficient. as component (B) per kg of seed, preferably from 0.01 to 10 g per kg of seed.

To avoid doubt of interpretation, when a literary citation, patent application, or patent is cited in the text of this application, the full text of said citation is incorporated herein by reference.

- 78 046405

Examples

The following examples serve to illustrate the present invention. The compounds (and compositions) of the present invention can be distinguished from the known compounds (and compositions) by their higher potency at low rates of application, which can be verified by one skilled in the art using the experimental procedures set forth in the Examples section, using, if necessary, lower application rates, for example, 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm or 0.2 ppm of active ingredient(s).

Throughout this description, temperatures are given in degrees Celsius (°C) and m.p. means melting point. LC/MS means liquid chromatography-mass spectrometry, and the description of the device and methods is as follows:

Method A: ACQUITY UPLC from Waters, Waters UPLC HSS T3, 1.8 µm particle size, 30 x 2.1 mm column, 0.85 ml/min, 60°C, H ₂ O/MeOH 95:5 + 0, 05% HCOOH (90%)/CH ₃ CN + 0.05% HCOOH (10%) - 1.2 min - CH ₃ CN + 0.05% HCOOH (100%) - 0.30 min, ACQUITY mass spectrometer Waters SQD, Ionization Method: Electrospray (ESI), Polarity: Positive Ion, Capillary Voltage (kV) 3.00, Cone Voltage (V) 30.00, Extractor Voltage (V) 2.00, Initial Temperature ( °C) 150, desolvation temperature (°C) 350, gas flow in the cone (l/h) 0, desolvation gas flow (l/h) 650).

Method B: ACQUITY UPLC from Waters, Waters UPLC HSS T3, 1.8 µm particle size, 30 x 2.1 mm column, 0.85 ml/min, 60°C, H ₂ O/MeOH 95:5 + 0, 05% HCOOH (90%)/CH ₃ CN + 0.05% HCOOH (10%) - 2.7 min - CH3CN + 0.05% HCOOH (100%) - 0.30 min, ACQUITY SQD mass spectrometer from Waters, ionization method: electrospray (ESI), polarity: positive ion, capillary voltage (kV) 3.00, cone voltage (V) 30.00, extractor voltage (V) 2.00, initial temperature (°C ) 150, desolvation temperature (°C) 350, gas flow in the cone (l/h) 0, desolvation gas flow (l/h) 650)).

Method C: MS: Waters ZQ mass spectrometer (single quadrupole mass spectrometer);

Device parameters: ionization method: electrospray, polarity: positive (negative) ions, capillary voltage (kV) 3.00, cone voltage (V) 30.00, extractor voltage (V) 2.00, gas temperature (° C) 350, drying gas flow (ml/min) 9.8, nebulizer pressure 45 psi. in., mass range: 90 to 1000 Da.

HPLC: Agilent HP 1100 HPLC: Solvent degasser, ZCQ pump, ZDQ pump, heated column space, and diode array detector. Column: porpshell 120 C18, particle size 2.7 µm, 120 angstroms, 4.6 x 50 mm, temperature: 30°C, DAD wavelength range (nm): 190 to 400, solvent gradient: A = water + 0.1% HCOOH. B = Acetonitrile + 0.08% HCOOH.

Mobile phase: _______________________________________________

Time (min) A% IN% Flow (ml/min) 0 85 15 0.6 4 5 95 0.6 10 5 95 0.6

Method D: mass spectrometer as in method C.

HPLC: Shimadzu LC-20A. Column: Dikma, Diamonsil C18(Z) (5 µm, 150*4.6 mm).

Mobile phase A: H2O (with 0.1% TFA added); mobile phase B: ACN (with the addition of 0.l% TFA). Flow rate: 1.0 ml/min.

Detection: UV at 254 nm. Oven temperature: 40°C.

Mobile phase: _____________________________________

Time (min) A% IN% 0 90 10 15 0 100 25 0 100 27 90 10 35 90 10

- 79 046405

Examples of compositions Wettable powders A) b) With) active ingredients [components (A) and (B)] 25% 50% 75% sodium lignosulfonate 5% 5% - sodium lauryl sulfate 3% - 5% sodium diisobutylnaphthalene sulfonate - 6% 10% polyethylene glycol phenolic ether - 2% - (7-8 mol ethylene oxide) highly dispersed silicic acid 5% 10% 10% kaolin 62% 27% -

The active ingredient is thoroughly mixed with the excipients and the mixture is thoroughly ground in a suitable mill to obtain wettable powders that can be reconstituted

water to obtain suspensions with the required concentration. Powders for dry seed treatment A) b) With) active ingredients [components (A) and (B)] 25% 50% 75% light mineral oil 5% 5% 5% highly dispersed silicic acid 5% 5% - kaolin 65% 40% - talc - - 20%

The active ingredient is thoroughly mixed with the excipients and the mixture is thoroughly ground in a suitable mill to obtain powders which can be directly used for seed treatment.

Emulsifiable concentrate active ingredients [components (A) and (B)] 10% polyethylene glycol octylphenol ether 3% (4-5 mol ethylene oxide) calcium dodecylbenzenesulfonate 3% castor oil polyglycol ether 4% (3-5 mol ethylene oxide)

cyclohexanone thirty% xylene mixture 50% From this concentrate, by diluting with water, emulsions of any required degree of dilution can be obtained, which can be used for plant protection. Dust-like preparations a) b) c) active ingredients [components (A) and (B)] 5% 6% 4% talc 95% - - kaolin - 94% - mineral filler - - 96%

Ready-to-use powdered preparations are prepared by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry seed dressing.

Extruded granules active ingredients [components (A) 15% and (B)] sodium lignosulfonate 2% carboxymethylcellulose 1% kaolin 82%

The active ingredient is mixed and crushed with the excipients and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

- 80 046405

Coated granules active ingredients [components (A) 8%

And (B)] polyethylene glycol (molecular weight 3% 200) kaolin 89%

The finely ground active ingredient is evenly applied to the kaolin moistened with polyethylene glycol in a mixing device. In this way, dust-free, coated granules are obtained.

Suspension concentrate active ingredients [components (A) and (B)] 40% propylene glycol 10% polyethylene glycol nonylphenol ether (15 mol 6% ethylene oxide) sodium lignosulfonate 10% carboxymethylcellulose 1% silicone oil (as a 75% emulsion in water) 1% water 32%

The finely divided active ingredient is thoroughly mixed with the excipients to obtain a suspension concentrate from which suspensions of any desired degree of dilution can be prepared by dilution with water. Using such diluted solutions, living plants, as well as plant propagation material, can be treated and protected from contamination by microorganisms by spraying, watering or dipping.

Flowable seed treatment concentrate active ingredients [components (A) and (B)] 40% propylene glycol 5% butanol-PO/EO copolymer 2% tristyrene phenol with 10-20 moles EO 2%

1,2-Benzisothiazolin-3-one (as a 20% solution in water) 0.5% calcium salt of monoazopigment 5% silicone oil (as a 75% emulsion in water) 0.2% water 45.3%

The finely divided active ingredient is thoroughly mixed with the excipients to obtain a suspension concentrate from which suspensions of any desired degree of dilution can be prepared by dilution with water. Using such diluted solutions, living plants, as well as plant propagation material, can be treated and protected from contamination by microorganisms by spraying, watering or dipping.

Slow-release capsule suspension.

Mix 28 parts of the combination of active ingredients [components (A) and (B)] with 2 parts of an aromatic solvent and 7 parts of a mixture of toluene diisocyanate/polymethylene polyphenyl isocyanate (8:1). This mixture is emulsified in a mixture of 1.2 parts polyvinyl alcohol, 0.05 parts antifoam and 51.6 parts water to obtain the desired particle size. To this emulsion is added a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts water. The mixture is stirred until the polymerization reaction is completed. The resulting capsule suspension is stabilized by adding 0.25 parts thickener and 3 parts dispersant. The composition of the capsule suspension contains 28% active ingredients. The average diameter of capsules is 8-15 microns. The resulting composition is applied to the seeds in the form of an aqueous suspension in a device suitable for the purpose.

List of abbreviations: °C = degrees Celsius, CDCl ₃ = chloroform-d, d = doublet, Pd ₂ (dBa) ₃ = tris(dibenzylideneacetone)dipalladium(0), DIPEA = ^^-diisopropylethylamine, DMF = dimethylformamide, HATU = hexafluorophosphate E^i^dimethylamino^ethylenefSHPDD-triazolo^^-^pyridinium 3oxide, m = multiplet, MHz = megahertz, mp = melting point, N = normal, ppm = parts per million, q = quartet, s = singlet, t = triplet , THF = tetrahydrofuran, Xantphos = 4,5bis(diphenylphosphino)-9,9-dimethylxanthene.

- 81 046405

Examples of receiving.

Using the synthetic procedures described above and below, compounds of formula (I) can be prepared accordingly.

a) Preparation of methyl 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4-carboxylate

Under argon, to a degassed, stirred mixture of methyl 2-bromo-5-methylthiazol-4-carboxylate (4.6 g, 18.5 mmol, 1 eq.) and 2,6-difluoropyridin-4-amine (1 eq.) in Xantphos (0.2 eq), Pd ₂ (dba)3 (0.1 eq) and cesium carbonate (2 eq) were added to 1,4-dioxane (660 ml). The reaction mixture was heated to reflux temperature and stirred for 4 hours, after which the temperature was allowed to drop to room temperature. The mixture was diluted with ethyl acetate and filtered through celite, and the resulting filtrate was concentrated using a rotary evaporator. Purification by silica gel column chromatography (cyclohexane/ethyl acetate eluting mixture) provided the desired methyl 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4carboxylate (1.8 g, 6 .31 mmol).

¹ H NMR (400 MHz, CDCl ₃ ): δ = 2.73 (s, 3H), 3.94 (s, 3H), 6.75 (s, 1H).

b) Preparation of 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4-carboxylic acid

Add lithium hydroxide monohydrate (4 eq.) to a solution of 2-[(2,6-difluoro-4-pyridyl)amino]-5methylthiazole-4-carboxylic acid (1.8 g, 6.31 mmol) in a mixture of tetrahydrofuran (35 ml) and water (12 ml). The reaction mixture was stirred for 16 h at room temperature, then the solvents were removed in vacuo. The precipitate was diluted with ethyl acetate and water, then 2 N was added slowly. hydrochloric acid until pH reaches 3-4. The resulting precipitate was isolated by filtration and washed twice with water to give the desired product as 2-[(2,6-difluoro-4pyridyl)amino]-5-methylthiazole-4-carboxylic acid (1.55 g, 5.71 mmol) .

1H NMR (400 MHz, (CD ₃ ) ₂ SO): δ = 2.69 (s, 3H), 7.30 (s, 2H), 11.35 (bs, 1H), 12.90 (bs, 1H ).

c) Preparation of 2-[(2,6-difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5-methylthiazol-4-carboxamide

To a solution of 2-[(2,6-difluoro-4-pyridyl)amino]-5-methylthiazole-4-carboxylic acid (250 mg, 0.92 mmol, 1 eq.) in DMF (9.2 ml) was added successively (2,2-dimethylcyclobutyl)ammonium chloride (1.1 eq.), HATU (1.1 eq.) and DIP{EA (2.6 eq.). The resulting solution was stirred at room temperature for 1 hour until the starting material was completely consumed (monitored by LCMS). Then a saturated NaHCO ₃ solution was added to the mixture and the solution was extracted three times with ethyl acetate. The organic phases were combined, dried over sodium sulfate and volatiles were removed using a rotary evaporator. Purification by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate mixtures) gave the desired product, which was 2-[(2,6-difluoro4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5-methylthiazole -4-carboxamide (280 mg, 86% yield).

1H NMR (400 MHz, CDCl3): δ = 1.17 (s, 3H), 1.20 (s, 3H), 1.50 - 1.75 (m, 2H), 1.86 - 1.92 ( m, 1H), 2.29 2.36 (m, 1H), 2.79 (s, 3H), 4.25 - 4.31 (m, 1H), 6.87 (s, 2H), 7, 32 (d, 1H), 7.67 (s, 1H).

- 82 046405

d) 2-[Acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.36)

Mixture of 2-[(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (1.9 g, 5.4 mmol) in acetyl chloride (20 ml) stirred under reflux for 3 days. The reaction mixture was then allowed to cool to room temperature and volatiles were removed using a rotary evaporator. Purification of the crude material by silica gel column chromatography (eluent: cyclohexane/ethyl acetate) gave the desired product as 2-[acetyl-(2,6-difluoro-4pyridyl)amino]-N-(2, 2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide (1.57 g, 3.98 mmol, 74% yield).

^1H NMR (400 MHz, CDCL3): δ = 0.92 (s, 3H), 1.12 (s, 3H), 1.48 - 1.75 (m, 3H), 2.10-2.30 (m, 1H), 2.17 (s, 3H), 2.79 (s, 3H), 4.25 -4.31 (m, 1H), 6.87 (s, 2H), 7.32 ( d, 1H).

2-[(2,6-Difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.38) can be prepared in a similar manner.

^1H NMR (400 MHz, CDCl3) δ ppm 0.92 (s, 3H), 1.12 (s, 3H), 1.18 - 1.26 (m, 6H), 1.47 - 1.63 ( m, 2H), 1.63 - 1.76 (m, 1H), 2.25 (m, 1H), 2.55 - 2.71 (m, 1H), 2.80 (s, 3H), 4 .20 (m, 1H), 6.90 (s, 2H), 7.00 (br d, 1H).

Methyl ^)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate can be prepared as follows:

Under argon, a 1 M solution of zinc chloride in THF (2.54 mmol) was added to a 2 M solution of cyclopentylmagnesium bromide in THF (2.54 mmol) and the pale yellow suspension was stirred at room temperature for 10 minutes, at which time a slight exothermic effect was observed. A solution of methyl ^)-2-(5-bromo-2-methylphenoxy)-3-methoxyprop-2-enoate (0.153 g, 0.51 mmol) in tetrahydrofuran (2.5 ml) and PdCl ₂ (dppf) was then added (0.19 g, 0.025 mmol) and the pale yellow suspension was heated at 50°C for 3 hours. Then the reaction mixture was ensured to reach room temperature, it was quenched with a saturated aqueous solution of NH4Cl and extracted with tert-butyl methyl ether. The total combined organic fraction was then washed with water and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography (cyclohexane:EtOAc gradient) to obtain 0.106 mg of the title compound as a white solid (mp 80-83°C).

^1H NMR (400 MHz, CDCl3) δ ppm: 7.35 (s, 1H), 7.09 (d, 1H), 6.82 (d, 1H), 6.60 (s, 1H), 3. 90 (s, 3H), 3.72 (s, 3H), 2.91 (m, 1H), 2.32 (s, 3H), 2.10 - 1.97 (m, 2H), 1.85 - 1.75 (m, 2H), 1.74 - 1.65 (m, 2H), 1.60 - 1.45 (m, 2H).

One skilled in the art will appreciate that methyl ^)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate can be synthesized using an equivalent method by replacing cyclopentyl magnesium bromide with cyclohexyl magnesium bromide.

Methyl ^)-2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate can be prepared as follows:

Under argon, add a solution of [3-[^]-2-methoxy-1-methoxycarbonylvinyloxy]-4methylphenyl]boronic acid (1 g, 3.76 mmol, 1.00 eq.) and 2,4-dibromothiazole (1.37 g, 5.64 mmol, 1.50 eq.) in 1,4-dioxane (15 ml) and water (3 ml) was added sodium carbonate (1.19 g, 11.28 mmol, 3 eq.) and Pd(dppf )Cl ₂ -DCM (0.157 g, 0.188 mmol, 0.05 eq). The reaction mixture was heated to 90°C and stirred at this temperature for 2 hours. The resulting dark brown solution was cooled to room temperature, diluted with EtOAc and washed with aq. saturated NaHCO ₃ solution. The organic layer was washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EtOAc) to give methyl ^)2-[5-(4-bromothiazol-2-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate as an orange solid va.

^1H NMR (400 MHz, CDCl3) δ ppm= 7.43-7.47 (dd, 1H), 7.32-7.34 (d, 1H), 7.28-7.30 (s, 1H) , 7.21-7.25 (m, 1H), 7.18 (s, 1H), 3.93 (s, 3H), 3.74 (s, 3H), 2.41 (s, 3H).

Methyl-^)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate can be prepared as follows: to a solution of methyl-^)- 3-methoxy-2-[2-methyl-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)phenoxy]prop-2-enoate (5.00 g, 14.4 mmol), sodium periodate (9.31 g, 43.1 mmol, 3.00 eq) was added to tetrahydrofuran:water (4:1, v/v, 72 mL), followed by

- 83 046405 aqueous solution of HCl (2.0 M, 1.79 ml, 3.59 mmol, 0.25 equiv). The resulting white suspension was stirred at room temperature for 4 hours, then EtOAc and water were added. The layers were separated and the aqueous phase was extracted with EtOAc. The total combined organic layer was washed with brine, dried with Na ₂ SO ₄ , filtered and concentrated in vacuo to give [3[^)-2-methoxy-1-methoxycarbonylvinyloxy]-4-methylphenyl]boronic acid as a white solid.

^1H NMR (400 MHz, DMSO) δ ppm 7.96 (brs, 2H), 7.54 (s, 1H), 7.33 (d, 1H), 7.12 (m, 2H), 3.85 (s, 3H), 3.64 (s, 3H), 2.23 (s, 3H).

Then: to a solution of [3-[^)-2-methoxy-1-methoxycarbonylvinyloxy]-4methylphenyl]boronic acid (5.0 g, 19 mmol) and 2-bromo-5-(trifluoromethyl)thiazole (1.2) degassed with argon eq.) in 1,4dioxane (38 ml) and water (3.8 ml), X-Phos Pd G2 (0.032 eq.) was added, followed by cesium carbonate (2.0 eq.). The reaction mixture was stirred at 90°C for 2 hours. The dark brown solution was allowed to return to room temperature, diluted with EtOAc and washed with aq. NaHCO ₃ solution and saline solution. The organic layer was dried with MgSO ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (cyclohexane:EtOAc) to give methyl (N)-3-methoxy-2-[2-methyl-5-[5-(trifluoromethyl)thiazol-2yl]phenoxy]prop-2-enoate.

One skilled in the art will appreciate that methyl ^)-2-[5-(4-cyclohexylthiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate and methyl ^)-2-[5- [4-(ethoxymethyl)thiazol-2-yl]-2methylphenoxy]-3-methoxyprop-2-enoate can be synthesized using an equivalent method by replacing 2-bromo-5-(trifluoromethyl)thiazole with a suitable thiazole group.

Table T1

Melting point (m.p.) and/or retention time ( _Rt ) data for compounds

X.01-X.38 in accordance with formula (I)

Structure

Connection name

[2-1(2,6-difluoro-4-pyridyl)-[5methyl-4 -(spiro 13.41 octan-3 ylcarbamoyl)thiazol-2yl amino I -1 -methyl-2 oxoethyl] methyl carbonate methyl-4 -(spiro 13.4 ] octan-3 yl amino I -1 -methyl-2 oxoethyl] acetate mass/charge = 469 (M+1) mass/charge = 509 (M+1) mass/charge = 493 (M+1)

R, = 15.33 minutes (D);

R. = 5.10 minutes (C);

R, = 5.18 minutes (C);

[2 - [ [4 -(cyclobutylcarbamoyl) 5-methylthiazol-2-yl I -(2,6methyl-2oxoethyl] ethyl carbonate

[2 -[(2,6-difluoro-4-pyridyl) - [5 ylcarbamoyl)thiazol-2difluoro-4-pyridyl)amino] -1 - 84 046405

[2-[(2,6-difluoro-4-pyridyl)-[42-[(2,6-difluoro-4-pyridyl)-(2hydroxypropanoyl)amino I -5 revenge-V-c p iro 13.4]octane- 3 ylthiazo l-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)-(2phenylacetyl)amino]-A-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide

[2-[(2,6-difluoro-4-pyridyl)-[5methyl-4 -(spiro 13.41 octan-3 ylcarbamoyl)thiazol-2yl amino I -1 -methyl-2 oxoethyl] ethyl carbonate mass/charge = 471 (M +1) mass/charge = 437 (M+1) mass/charge = 523 (M+1) mass/charge = 451 (M+1) mass/charge = 497 (M+1) mass/charge = 411 (M +1) mass/charge = 453 (M+1)

R. = 1.23 minutes (A);

R, = 5.10 minutes (C);

R, = 5.41 minutes (C);

R, = 5.15 minutes (C);

R, = 13.80 minutes (D);

R, = 1.10 minutes (A);

R. = 1.06 minutes (A);

\-cyclobutyl-2-1 (2.6-difluoro4-pyridyl)-(2methoxypropanoyl)amino J -5 methylthiazol-4-carboxamide dimethylcyclobutyl)carbamoyl -5-methylthiazol-2-yl amino 2-oxoethyl I acetate

2-Gacetyl-(2,6-difluoro-4pyridyl)amino]-5-methoxy-Aspiro 13.4]octan-3-ylthiazo l-4 carboxamide

2-[2-benzyloxypropanoyl(2,6-difluoro-4pyridyl)amino]-Ncyclobutyl-5-methylthiazol-4carboxamide

- 85 046405

X.12

X.13

X.14

X.15

- [(2-benzyloxyacetyl)-(2,6difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-5methyl-M-s and iro [3.4]octane-3 ylthiazo l-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)-(2ethoxyacetyl)amino]-jV-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide \'-cyclobutyl-2-|(2.6-difluoro4-pyridyl) -(2methoxyacetyl)amino]-5methylthiazole-4-carboxamide

2-[acetyl-(2,6-difluoro-4pyridyl)amino]-Ncyclobutyl-5-methylthiazol-4carboxamide

_H3C

R, = 15.94 minutes (D); MS: mass/charge = 451 (M+1)

R, = 13.64 minutes (D);

MS: mass/charge = 398 (M+1)

R, = 13.92 minutes (D);

MS: mass/charge = 367 (M+1)

R, = 1.22 minutes (A);

MS: mass/charge = 501 (M+1)

R _t = 1.14 minutes (A);

MS: mass/charge = 439 (M+1)

- 86 046405

X.16

X.17

X.18

X.19

X.20

X.21

- [diethylcarbamoi l-(2,6 difluoro-4-pyridyl)amino]-V(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)(furan-2-carboxyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

2-[(2-chloroacetyl)-(2,6-difluoro4-pyridyl)amino] +V-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide methyl-5-[(2,6-difluoro-4pyridyl) - [4 - [(2,2 dimethylcyclobutyl)carbamoyl] -5 -methylthiazol-2-yl] amino] 5 -oxopentanoate methyl-3 -[(2,6-difluoro-4pyridyl) - [4 - [(2, 2 dimethylcyclobutyl)carbamoyl] -5 -methylthiazol-2-yl] amino] 3 -oxo pro panoate

2-[(2,6-difluoro-4-pyridyl)(3,3,3trifluoropropanoyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

minutes (A);

MS: mass/charge = 429/431 (M+1)

R _t =l.19 minutes (A); MS: mass/charge = 452 (M+1)

R _t = 1.09 minutes (A);

MS: mass/charge = 453 (M+1)

R _t =l.12 minutes (A);

MS: mass/charge = 481 (M+1), 15 minutes (A); MS: mass/charge = 447 (M+1), 15 minutes (A); MS: mass/charge = 463 (M+1)

- 87 046405

X.22

X.23

X.24

X.25

X.26

X.27

2-[cyclopropanecarbonyl-(2,6difluoro-4-pyridyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)-(2fluoroacetyl)amino]-N-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide

5-isopropyl-M-(2.6-difluoro-4pyridyl)-C-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2 yl]carbamothioate prop-2-ynyl-M-(2.6-difluoro- 4pyridyl)-K-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate fsnyl-M-(2.6-difluoro-4pyridyl)-K-[4-[(2,2dimethylcyclobutyl)carbamoy l] -5 -methylthiazol-2 yl] carbamate methyl-4-[(2,6-difluoro-4pyridyl)-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5 -methylthiazol-2-yl] amino] 4 -oxobutanoate

dn ₃

155 - 158

160 - 163

165 - 170

129-131

138-140

158-162

R _t = 1.28 minutes (A);

MS: mass/charge = 455 (M+1)

R _t =l,ll minutes (A);

MS: mass/charge = 467 (M+1)

R _t = 1.16 minutes (A);

MS: mass/charge = 421 (M+1)

R _t =l.14 minutes (A);

MS: mass/charge = 435 (M+1)

R _t = 1.23 minutes (A);

MS: mass/charge = 473 (M+1)

R, = 1.09 minutes (A);

MS: mass/charge = 413 (M+1)

- 88 046405

X.28

2-methoxyethyl-M-(2,6-difluoro4-pyridyl)-N-[4 - [(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate

X.29

2-[(2,6-difluoro-4-pyridyl)-(2methoxyacetyl)amino]-N-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide

X.30 ethyl-N-(2,6-difluoro-4pyridyl)-K-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate

2-[(2,6-difluoro-4-pyridyl)(thiophene-2-carbonyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

X.32 methyl-N-(2,6-difluoro-4pyridyl)-K-[4-[(2,2dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate

H.ZZ

2-[(2,6-difluoro-4pyridyl)formylamino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide

СНз

102 - 108

178-185

132-135

R _t = 1.14 minutes (A);

MS: mass/charge = 455 (M+1)

R _t = 1.08 minutes (A);

MS: mass/charge = 425 (M+1)

R _t = 1.16 minutes (A);

MS: mass/charge = 425 (M+1)

R _t = 1.19 minutes (A);

MS: mass/charge = 463 (M+1)

R _t = 1.14 minutes (A);

MS: mass/charge = 411 (M+1)

R, = 1.09 minutes (A);

MS: mass/charge = 381 (M+1)

- 89 046405

X.34

X.35

X.36

X.37

X.38

2-[benzoyl-(2,6-difluoro-4pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide

2-[acetyl-(2,6-difluoro-4pyridyl)amino]-N-(2,2dimethylcyclobutyl)-5 methylthiazol-4-carboxamide

2-[(2,6-difluoro-4-pyridyl)-(2methylpropanoyl)amino]-N(2,2-dimethylcyclobutyl)-5methylthiazol-4-carboxamide ethyl-2-[(2,6-difluoro-4pyridyl) - [4-[(2,2 dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2-yl]amino]2-oxoacetate

2-[acetyl-(2,6-difluoro-4pyridyl)amino]-5-methyl-Nspiro[3,4]octan-3-ylthiazol-4carboxamide

159-161

142-151

141 - 145

123 - 126

СНз

R _t =l.17 minutes (A);

MS: mass/charge = 453 (M+1)

R _t =l.19 minutes (A); MS: mass/charge = 457 (M+1)

R _t = 1.09 minutes (A);

MS: mass/charge = 395 (M+1)

R _t =l.15 minutes (A); MS: mass/charge = 421 (M+1)

R _t =l.19 minutes (C);

MS: mass/charge = 423 (M+1)

Biological examples

Example A1. Alternaria solani / tomato / leaf disc (Alternaria blight).

Baby tomato leaf disks were placed on agar in multi-well plates (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated with a suspension of fungal spores 2 days after application. The inoculated leaf disks were incubated at 23°C/21°C (day/night) and 80% relative humidity under a 12/12 h (light/dark) light cycle in a climate chamber and the activity of the compound was assessed as a percentage of disease control. compared to untreated material when the corresponding degree of disease damage was demonstrated on untreated leaf discs representing control discs (5-7 days after application). The following compounds provided at least 80% control of Alternaria solani at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.04, X.08, X.09, X.14, X.15, X.17, X.18, X.21, X.23, X.25, X.27, X.29, X33, X.34, X.35, X.36, X.38.

Example A2. Treatment of liquid culture of Botryotinia fuckeliana (Botrytis cinerea) / (grey rot).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (Vogel broth). After the solution (DMSO) of the test compound is added to a microtiter plate (96-well format), a nutrient broth containing fungal spores is added. The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application. The following compounds provided at least 70% control of Botryotinia fuckeliana at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.14, X.15, X.29, X.33, X.34, X.35, X.36, X.38.

Example A3. Treatment of liquid culture of Glomerella lagenarium (Colletotrichum lagenarium) / (anthracnose).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding a solution (DMSO) of the test compound

- 90 046405 a nutrient broth containing fungal spores is added to a microtiter plate (96-well format). Test plates are incubated at 24°C and growth inhibition is measured photometrically 3-4 days after application. The following compounds provided at least 80% control of Glomerella lagenarium at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.01, X.03, X.04, X.05, X.08, X.09, X.11, X.14, X.15, X.16, X.17, X.18, X.21, X.23, X.27, X.29, X.33, X. 34, X.35, X.36, X.38.

Example A4. Treatment to prevent leaf disc infection / wheat / Blumeria graminis f. sp. tritici (Erysiphe graminis f. sp. tritici) / (powdery mildew of wheat).

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated by shaking powdery mildew-infected plants over test plates 1 day after application. The inoculated leaf disks were incubated at 20°C and 60% relative humidity under a light regime of 24 hours dark followed by 12 hours light/12 hours dark in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (6-8 days after application). The following compounds provided at least 80% control of Blumeria graminis f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.07, X.08, X. 09, X.10, X.11, X.12, X.13, X.14, X.15, X.16, X.17, X.18, X.19, X.21, X.23, X.24, X.25, X.26, X.27, X.28, X.29, X.30, X.31, X.32, X.33, X.34, X.35, X. 36, X.37, X.38.

Example A5. Treatment to prevent infection of leaf discs / wheat / Phaeosphaeria nodorum (Septoria nodorum) / (septoria glume blight).

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs were inoculated with a suspension of fungal spores 2 days after application. The inoculated test leaf discs were incubated at 20°C and 75% relative humidity under a 12-hour light/12-hour dark cycle in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material when exhibiting the appropriate degree of damage. due to disease on untreated control leaf disks (5-7 days after application). The following compounds provided at least 80% control of Phaeosphaeria nodorum at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.02, X.17, X.18, X.27.

Example A6. Treatment of liquid culture of Monographella nivalis (Microdochium nivale) / (root rot of cereals).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After the solution (DMSO) of the test compound is added to a microtiter plate (96-well format), a nutrient broth containing fungal spores is added. The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Monographella nivalis at 20 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.03, X.04, X.05, X.08, X.09, X.11, X.12, X.14, X.15, X.16, X.17, X.18, X.21, X.23, X.26, X.27, X. 28, X.29, X.31, X.33, X.34, X.35, X.36, X.38.

Example A7. Treatment of liquid culture of Mycosphaerella arachidis (Cercospora arachidicola) / (early cercospora leaf blight).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After the solution (DMSO) of the test compound is added to a microtiter plate (96-well format), a nutrient broth containing fungal spores is added. The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Mycosphaerella arachidis at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.04, X.08, X.17, X.18, X.21, X.27, X.29, X.33, X.34.

Example A8. Treatment to prevent infestation / soybean / Phakopsora pachyrhizi / (soybean rust).

Soybean leaf disks were placed on aqueous agar solution in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. One day after application, leaf discs were inoculated by spraying a spore suspension onto the lower surface of the leaf. After an incubation period of 24-36 hours in a climate chamber in the dark at 20°C and 75% relative humidity, the leaf disk was kept at 20°C at 12

- 91 046405 hours of light/day and 75% relative humidity. Compound activity was assessed as a percentage of disease control compared to untreated material when the corresponding degree of disease damage was observed on untreated control leaf discs (12-14 days after application). The following compounds provided at least 80% control of Phakopsora pachyrhizi at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.07, X.08, X.14, X.15, X.17, X.27, X.29, X.33, X.34, X.35, X.38.

Example A9. Treatment for the treatment of leaf disc infection / wheat / Puccinia recondita f. sp. tritici / (brown rust).

Segments of wheat leaves of the Kanzler variety are placed on agar in multi-well plates (24-well format). Leaf segments are inoculated with a suspension of fungal spores. The plates are stored in the dark at 19°C and 75% relative humidity. The formulated test compound, diluted in water, is administered 1 day after inoculation. Leaf segments are incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark cycle in a climate chamber and compound activity is assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of disease damage. on untreated control leaf segments (6-8 days after application). The following compounds provided at least 80% control of Puccinia recondita f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.08, X.14, X.15, X.17, X.18, X.21, X.23, X. 27 X.28, X.29, X.33, X.34, X.38.

Example A10. Treatment to prevent leaf disc infection / wheat / Puccinia reconditaf. sp. tritici (brown rust).

Leaf segments of the Kanzler wheat variety are placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. Leaf discs are inoculated with a suspension of fungal spores 1 day after application. Inoculated leaf segments are incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark environment in a climate chamber and compound activity is assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of damage due to diseases on untreated control leaf segments (7-9 days after application). The following compounds provided at least 80% control of Puccinia recondita f. sp. tritici at 200 ppm compared to the untreated control, which under the same conditions showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.07, X.08, X. 09, X.11, X.12, X.13, X.14, X.15, X.17, X.18, X.19, X.21, X.23, X.27, X.28, X.29, X.33, X.34, X.35, X.36, X.38.

Example A11. Treatment to prevent infection of leaf disk / rice / Magnaporthe grisea (Pyricularia oryzae) / (rice blast).

Ballila rice leaf segments were placed on agar in a multi-well plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf segments were inoculated with a suspension of fungal spores 2 days after application. The inoculated leaf segments were incubated at 22°C and 80% relative humidity under a light regime of 24 hours dark followed by 12 hours light/12 hours dark in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (5-7 days after application). The following compounds provided at least 80% control of Magnaporthe grisea at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.01, X.02, X.03, X.04, X.05, X.07, X.08, X.09, X.10, X.11, X.12, X.13, X.14, X.15, X.16, X.17, X.18, X. 19, X.21, X.23, X.25, X.26, X.27, X.28, X.29, X.31, X.32, X.33, X.34, X.35, X.36, X.37, X.38.

Example A12. Treatment to prevent infection of leaf disc / barley / Pyrenophora teres / (net spot).

Hasso barley leaf segments were placed on agar in a multi-well plate (24-well format) and sprayed with the formulated test compound diluted in water. Leaf segments were inoculated with a suspension of fungal spores 2 days after application. Inoculated leaf segments were incubated at 20°C and 65% relative humidity under a 12-hour light/12-hour dark cycle in a climate chamber and compound activity was assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of damage due to diseases on untreated control leaf segments (5-7 days after application).

The following compounds provided at least 80% control of Pyrenophora teres at 200 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.01, X.03, X.04, X.08, X.10, X.11, X.12, X.14, X.15, X.17, X.18, X.23, X.25, X.27, X.29, X.33, X.34, X. 35, X.36, X.37, X.38.

- 92 046405

Example A13. Treatment of liquid culture of Sclerotinia sclerotiorum / (white rot).

Mycelium fragments from a newly grown fungal culture in liquid medium were directly mixed with nutrient broth (potato dextrose broth, PDB). After adding the solution (DMSO) of the test compound, nutrient broth containing the fungal material was added to the microtiter plate (96-well format). The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application.

The following compounds provided at least 80% control of Sclerotinia sclerotiorum at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.18, X.34.

Example A14. Treatment of liquid culture of Mycosphaerella graminicola (Septoria tritici) / (septoria).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). After the solution (DMSO) of the test compound is added to a microtiter plate (96-well format), a nutrient broth containing fungal spores is added. The test compound plates were incubated at 24°C and growth inhibition was determined photometrically 4-5 days after application. The following compounds provided at least 80% control of Mycosphaerella graminicola at 20 ppm compared to the untreated control, which showed extensive disease development under the same conditions: X.01, X.03, X.04, X.05, X.08, X.09, X.14, X.15, X.17, X.18, X.21, X.27, X.29, X.33, X.34, X.36.

Additional examples of biological tests related to fungicidal compositions containing a mixture of components (A) and (B) as active ingredients.

Example B1. Activity against Zymoseptoria tritici (leaf spot).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6 X.29 Mefentrifluconazole 3.3:1 2:0.6

- 93 046405

X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Pid if lu metof her 10:1 20:2 X.29 Pid if lu metof her 100:1 20:0.2 X.29 Pid iflu metof her 1:1 2:2 X.29 Pid iflu metof her 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 100:1 20:0.2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Phenpicoxamide 3.3:1 2:0.6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Chlorothalonil 3.33:1 2:0.6

- 94 046405

X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mankozeb 1:10 2:20 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Fluazinam 10:1 20:2 X.29 Fluazinam 100:1 20:0.2 X.29 Fluazinam 1:1 2:2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2 X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Folpet 1:3 2:6 X.29 Folpet 1:1 2:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Tricyclic azole 1:1 20:20 X.29 Tricyclic azole 3:1 20:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 X-(1-benzyl-1,3- 10:1 20:2

- 95 046405

dimethyl butyl) - 8 fluoroquinoline-3 carboxamide X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- dimethylisoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2

- 96 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20

- 97 046405

X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pidiflumetofen 10:1 60:6 X.36 Pidiflumetofen 100:1 60:0.6 X.36 Pidiflumetofen 3.3:1 20:6 X.36 Pidiflumetofen 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metharylpicoxamide 10:1 60:6 X.36 Metharylpicoxamide 100:1 60:0.6 X.36 Metharylpicoxamide 3.3:1 20:6 X.36 Metharylpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6

- 98 046405

X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Fluazinam 10:1 60:6 X.36 Fluazinam 100:1 60:0.6 X.36 Fluazinam 3.3:1 20:6 X.36 Fluazinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 - 10:1 60:6

- 99 046405

carboxamide X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 33.3:1 20:0.6

- 100 046405

dimethylisoquinoline X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazole- 1 - 33.3:1 20:0.6

- 101 046405

yl)-4,4-difluoro-3,3 dimethylisoquinoline X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclic azole 3:1 60:20 X.36 Tricyclic azole 10:1 60:6 X.36 Tricyclic azole 1:1 20:20 X.36 Tricyclic azole 3.3:1 20:6 X.36 Pirokv ILON 3:1 60:20 X.36 Pirokv ILON 10:1 60:6 X.36 Pirokv ILON 1:1 20:20 X.36 Pirokv ILON 3.3:1 20:6

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6

- 102 046405

X.38 T reef loxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Pr otioconazole 10:1 60:6 X.38 Pr otioconazole 100:1 60:0.6 X.38 Pr otioconazole 3.3:1 20:6 X.38 Pr otioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Mefentrifluconazole 33.3:1 20:0.6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6

- 103 046405

X.38 Benzovindiflupyr 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid if lu metof her 10:1 60:6 X.38 Pid if lu metof her 100:1 60:0.6 X.38 Pid iflu metof her 3.3:1 20:6 X.38 Pid iflu metof her 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar ilpicoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mankozeb 1:1 20:20 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 3.3:1 20:6

- 104 046405

X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 10:1 60:6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6

- 105 046405

Example B2. Activity against Botrytis cinerea (grey mold).

Fungal conidia from cryostorage were directly mixed with nutrient broth (Minimal Vogel Media) containing 200 μmol SHAM. A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 2:0.6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Propiconazole 1:3 2:6 X.29 Propiconazole 3.3:1 2:0.6

- 106 046405

X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6 X.29 Mefentrifluconazole 3.3:1 2:0.6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Fenpropidine 1:10 2:20 X.29 Fenpropidine 1:1 2:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Phenpropimorph 1:1 2:2 X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluxapyroxad 1:1 2:2 X.29 Fluxapyroxad 10:1 2:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Fluopyram 1:1 2:2 X.29 Fluopyram 10:1 2:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Isopyrase 10:1 2:0.2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2 X.29 Sedaksan 1:1 2:2 X.29 Sedaksan 10:1 2:0.2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid if lu metof her 10:1 20:2 X.29 Pid if lu metof her 100:1 20:0.2

- 107 046405

X.29 Pidiflumetofen 1:1 2:2 X.29 Pid if lu metof her 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isoflucipram 10:1 2:0.2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 100:1 20:0.2 X.29 Isofetamide 1:1 2:2 X.29 Isofetamide 10:1 2:0.2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Fluindapir 1:1 2:2 X.29 Fluindapir 10:1 2:0.2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Phenpicoxamide 3.3:1 2:0.6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Chlorothalonil 3.33:1 2:0.6 X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mankozeb 1:10 2:20 X.29 Mankozeb 1:3 2:6 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Mandipropamide 1:10 2:20 X.29 Mandipropamide 1:3 2:6

- 108 046405

X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Oxathiapiproline 1:10 2:20 X.29 Oxathiapiproline 1:3 2:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Flu Azinam 10:1 2:0.2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Fludioxonil 3.3:1 2:0.6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Metalaxyl-M 1:10 2:20 X.29 Metalaxyl-M 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2 X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Folpet 1:3 2:6 X.29 Folpet 1:1 2:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2 X.29 Ipflufenoquin 10:1 2:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 Tricyclazole 1:1 20:20 X.29 Tricyclazole 3:1 20:6 X.29 Tricyclazole 1:10 2:20

- 109 046405

X.29 Tricyclazole 1:3 2:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 Pyroquilon 1:10 2:20 X.29 Pyroquilon 1:3 2:6 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 20:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 100:1 20:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 2:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 2:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 100:1 20:0.2

- 110 046405

dimethylisoquinoline X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 2:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 2:2 X.29 1-(4,5d imethylbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 2:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 2:0.2

- 111 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6

- 112 046405

X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid if lu metof her 10:1 60:6 X.36 Pid if lu metof her 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar il picoxamide 10:1 60:6

- 113 046405

X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2

- 114 046405

X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6

- 115 046405

X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(4.5- 100:1 60:0.6

- 116 046405

d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Tricyclazole 1:1 20:20 X.36 Tricyclazole 3.3:1 20:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6 X.36 Pyroquilon 1:1 20:20 X.36 Pyroquilon 3.3:1 20:6

- 117 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Mefentrifluconazole 33.3:1 20:0.6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6

- 118 046405

X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid if lu metof en 10:1 60:6 X.38 Pid if lu metof en 100:1 60:0.6 X.38 Pid iflu metof en 3.3:1 20:6 X.38 Pid iflu metof en 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar il picoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mankozeb 1:1 20:20 X.38 Mankozeb 3.3:1 20:6

- 119 046405

X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Mandipropamide 1:1 20:20 X.38 Mandipropamide 3.3:1 20:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Oxathiapiproline 1:1 20:20 X.38 Oxathiapiproline 3.3:1 20:6 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 100:1 60:0.6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6 X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Metalaxyl-M 1:1 20:20 X.38 Metalaxyl-M 3.3:1 20:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8 fluoroquinoline-3 carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 X-(1-benzyl-1,3- 3.3:1 20:6

- 120 046405

dimethylbutyl)-8fluoroquinoline-3 carboxamide X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6

- 121 046405

X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6

- 122 046405

X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Sedaksan 33.3:1 20:0.6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6 X.38 Tricyclazole 3:1 60:20 X.38 Tricyclazole 10:1 60:6 X.38 Tricyclazole 1:1 20:20 X.38 Tricyclazole 3.3:1 20:6 X.38 Pyroquilon 3:1 60:20 X.38 Pyroquilon 10:1 60:6 X.38 Pyroquilon 1:1 20:20 X.38 Pyroquilon 3.3:1 20:6

Example B3. Activity against Glomerella lagenarium syn. Colletotrichum lagenarium (cucurbit anthracnose)

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 123 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Propiconazole 1:3 2:6 X.29 Propiconazole 3.3:1 2:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Fenpropidine 1:10 2:20 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Phenpropimorph 1:1 2:2

- 124 046405

X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Fluopyram 1:1 2:2 X.29 Fluopyram 10:1 2:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2 X.29 Sedaksan 1:1 2:2 X.29 Sedaksan 10:1 2:0.2 X.29 Benzovindiflupyr 10:1 20:2 X.29 Benzovindiflupyr 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid if lu metof her 10:1 20:2 X.29 Pid if lu metof en 100:1 20:0.2 X.29 Pid iflu metof en 1:1 2:2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 100:1 20:0.2 X.29 Isofetamide 1:1 2:2 X.29 Isofetamide 10:1 2:0.2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Fluindapir 1:1 2:2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Phenpicoxamide 3.3:1 2:0.6 X.29 Florylpicoxamide 10:1 20:2

- 125 046405

X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Chlorothalonil 3.33:1 2:0.6 X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mankozeb 1:10 2:20 X.29 Mankozeb 1:3 2:6 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Mandipropamide 1:10 2:20 X.29 Mandipropamide 1:3 2:6 X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Oxathiapiproline 1:10 2:20 X.29 Oxathiapiproline 1:3 2:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Flu Azinam 10:1 2:0.2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Fludioxonil 3.3:1 2:0.6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Metalaxyl-M 1:10 2:20 X.29 Metalaxyl-M 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2

- 126 046405

X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Folpet 1:3 2:6 X.29 Folpet 1:1 2:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2 X.29 Ipflufenoquin 10:1 2:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 Tricyclazole 1:1 20:20 X.29 Tricyclazole 3:1 20:6 X.29 Tricyclazole 1:10 2:20 X.29 Tricyclazole 1:3 2:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 Pyroquilon 1:10 2:20 X.29 Pyroquilon 1:3 2:6 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 20:2 X.29 PM-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 2:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)- 100:1 20:0.2

- 127 046405

8-fluoroquinoline-3 carboxamide X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 2:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 2:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4.5- 10:1 20:2

- 128 046405

dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline X.29 1-(4.5- dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4.5- dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3dimethylisoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 2:0.2

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6

- 129 046405

X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid if lu metof her 10:1 60:6 X.36 Pid if lu metof her 100:1 60:0.6

- 130 046405

X.36 Pid if lu metof her 3.3:1 20:6 X.36 Pid if lu metof her 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metharylpicoxamide 10:1 60:6 X.36 Metharylpicoxamide 100:1 60:0.6 X.36 Metharylpicoxamide 3.3:1 20:6 X.36 Metharylpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mand ipre opamide 3:1 60:20 X.36 Mand ipre opamide 10:1 60:6 X.36 Mand ipre opamide 1:1 20:20 X.36 Mand ipre opamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6

- 131 046405

X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(l-benzyl-3,3,3-trifluoro1-methylpropyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-3,3,3-trifluoro1-methylpropyl)-8fluoroquinoline-3 - 100:1 60:0.6

- 132 046405

carboxamide X.36 N-(1-benzyl-3,3,3-trifluoro1-methylpropyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(1-benzyl-3,3,3-trifluoro1-methylpropyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3-yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3-yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3-yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3-yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazole- 1 - 100:1 60:0.6

- 133 046405

yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Tricyclazole 1:1 20:20 X.36 Tricyclazole 3.3:1 20:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6 X.36 Pyroquilon 1:1 20:20 X.36 Pyroquilon 3.3:1 20:6

- 134 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6

- 135 046405

X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid if lu metof en 10:1 60:6 X.38 Pid if lu metof en 100:1 60:0.6 X.38 Pid iflu metof en 3.3:1 20:6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar il picoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6

- 136 046405

X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mankozeb 1:1 20:20 X.38 Mankozeb 3.3:1 20:6 X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Mandipropamide 1:1 20:20 X.38 Mandipropamide 3.3:1 20:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Oxathiapiproline 1:1 20:20 X.38 Fluazinam 10:1 60:6 X.38 Fluazinam 100:1 60:0.6 X.38 Fluazinam 3.3:1 20:6 X.38 Fluazinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6 X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 - 100:1 60:0.6

- 137 046405

carboxamide X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o [1,5- 10:1 60:6

- 138 046405

a] pyridin-3yl)isoquinoline X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6

- 139 046405

X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6 X.38 Tricyclazole 3:1 60:20 X.38 Tricyclazole 10:1 60:6 X.38 Tricyclazole 1:1 20:20 X.38 Tricyclazole 3.3:1 20:6 X.38 Pyroquilon 3:1 60:20 X.38 Pyroquilon 10:1 60:6 X.38 Pyroquilon 1:1 20:20 X.38 Pyroquilon 3.3:1 20:6

Example B4. Activity against Mycosphaerella arachidis syn. Cercospora arachidicola (peanut brown leaf spot).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates containing test compounds were incubated at 24°C and growth inhibition was determined photometrically after approximately 5-6 days at 620 nm. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 140 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 2:0.6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Propiconazole 1:3 2:6 X.29 Propiconazole 3.3:1 2:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6 X.29 Mefentrifluconazole 3.3:1 2:0.6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 1:10 2:20 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20

- 141 046405

X.29 Phenpropimorph 1:1 2:2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 1:1 2:2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Isopyrase 10:1 2:0.2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupyr 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid iflu metof en 10:1 20:2 X.29 Pid iflu metof en 100:1 20:0.2 X.29 Pid iflu metof en 1:1 2:2 X.29 Pid iflu metof en 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isoflucipram 10:1 2:0.2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 1:1 2:2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 1:1 2:2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Mankozeb 1:1 20:20 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 1:1 2:2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2

- 142 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6

- 143 046405

X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid if lu metof her 10:1 60:6 X.36 Pid if lu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6

- 144 046405

X.36 Metharylpicoxamide 10:1 60:6 X.36 Metharylpicoxamide 100:1 60:0.6 X.36 Metharylpicoxamide 3.3:1 20:6 X.36 Metharylpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Fluazinam 10:1 60:6 X.36 Fluazinam 100:1 60:0.6 X.36 Fluazinam 3.3:1 20:6 X.36 Fluazinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6

- 145 046405

X.36 T4-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3- 100:1 60:0.6

- 146 046405

dimethylisoquinoline | | X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6

- 147 046405

X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Mefentrifluconazole 33.3:1 20:0.6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid if lu metof her 10:1 60:6 X.38 Pid if lu metof en 100:1 60:0.6 X.38 Pid iflu metof en 3.3:1 20:6 X.38 Pid iflu metof en 33.3:1 20:0.6

- 148 046405

X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar il picoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 100:1 60:0.6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Sedaksan 33.3:1 20:0.6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6

- 149 046405

Example B5. Activity against Pyricularia oryzae (rice blast).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 hours. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6

- 150 046405

X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 2:0.6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Propiconazole 1:3 2:6 X.29 Propiconazole 3.3:1 2:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6 X.29 Mefentrifluconazole 3.3:1 2:0.6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Fenpropidine 1:10 2:20 X.29 Fenpropidine 1:1 2:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Phenpropimorph 1:1 2:2 X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluxapyroxad 1:1 2:2 X.29 Fluxapyroxad 10:1 2:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Fluopyram 1:1 2:2 X.29 Fluopyram 10:1 2:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Isopyrase 10:1 2:0.2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2

- 151 046405

X.29 Sedaksan 1:1 2:2 X.29 Sedaksan 10:1 2:0.2 X.29 Benzovindiflupyr 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid iflu metof her 10:1 20:2 X.29 Pid iflu metof her 100:1 20:0.2 X.29 Pid iflu metof her 1:1 2:2 X.29 Pidiflumetofen 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isoflucipram 10:1 2:0.2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 100:1 20:0.2 X.29 Isofetamide 1:1 2:2 X.29 Isofetamide 10:1 2:0.2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Fluindapir 1:1 2:2 X.29 Fluindapir 10:1 2:0.2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Phenpicoxamide 3.3:1 2:0.6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Chlorothalonil 3.33:1 2:0.6

- 152 046405

X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mankozeb 1:10 2:20 X.29 Mankozeb 1:3 2:6 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Mandipropamide 1:10 2:20 X.29 Mandipropamide 1:3 2:6 X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Oxathiapiproline 1:10 2:20 X.29 Oxathiapiproline 1:3 2:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Flu Azinam 10:1 2:0.2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Fludioxonil 3.3:1 2:0.6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Metalaxyl-M 1:10 2:20 X.29 Metalaxyl-M 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2 X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Folpet 1:3 2:6 X.29 Folpet 1:1 2:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2

- 153 046405

X.29 Ipflufenoquin 10:1 2:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 Tricyclazole 1:1 20:20 X.29 Tricyclazole 3:1 20:6 X.29 Tricyclazole 1:10 2:20 X.29 Tricyclazole 1:3 2:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 Pyroquilon 1:10 2:20 X.29 Pyroquilon 1:3 2:6 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 20:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 2:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 2:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 - 10:1 2:0.2

- 154 046405

carboxamide X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 2:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2 X.29 1-(4.5- d methylbenzimide azol-1 - 1:1 2:2

- 155 046405

yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 2:0.2

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6

- 156 046405

X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid if lu metof en 10:1 60:6 X.36 Pid if lu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6

- 157 046405

X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar ilpicoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6

- 158 046405

X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8 fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6

- 159 046405

X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3- 3.3:1 20:6

- 160 046405

dimethylisoquinoline X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Tricyclazole 1:1 20:20 X.36 Tricyclazole 3.3:1 20:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6 X.36 Pyroquilon 1:1 20:20 X.36 Pyroquilon 3.3:1 20:6

- 161 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Mefentrifluconazole 33.3:1 20:0.6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6

- 162 046405

X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid iflu metof en 10:1 60:6 X.38 Pid iflu metof en 100:1 60:0.6 X.38 Pidiflumetofen 3.3:1 20:6 X.38 Pid iflu metof en 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar ilpicoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6

- 163 046405

X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mankozeb 1:1 20:20 X.38 Mankozeb 3.3:1 20:6 X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Mandipropamide 1:1 20:20 X.38 Mandipropamide 3.3:1 20:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Oxathiapiproline 1:1 20:20 X.38 Oxathiapiproline 3.3:1 20:6 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 100:1 60:0.6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6 X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Metalaxyl-M 1:1 20:20 X.38 Metalaxyl-M 3.3:1 20:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6

- 164 046405

X.38 Aminopyrifene 33.3:1 20:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 3.3:1 20:6

- 165 046405

dimethylisoquinoline X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- 3.3:1 20:6

- 166 046405

d imetilbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Sedaksan 33.3:1 20:0.6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6 X.38 Tricyclazole 3:1 60:20 X.38 Tricyclazole 10:1 60:6 X.38 Tricyclazole 1:1 20:20 X.38 Tricyclazole 3.3:1 20:6 X.38 Pyroquilon 3:1 60:20 X.38 Pyroquilon 10:1 60:6 X.38 Pyroquilon 1:1 20:20 X.38 Pyroquilon 3.3:1 20:6

Example B6. Activity against Monographaella nivalis syn. Microdochium nivale (snow mold, root rot of cereals).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test.

- 167 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 2:0.6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Propiconazole 1:3 2:6 X.29 Propiconazole 3.3:1 2:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6 X.29 Mefentrifluconazole 1:3 2:6

- 168 046405

X.29 Mefentrifluconazole 3.3:1 2:0.6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Fenpropidine 1:10 2:20 X.29 Fenpropidine 1:1 2:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Phenpropimorph 1:1 2:2 X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluxapyroxad 1:1 2:2 X.29 Fluxapyroxad 10:1 2:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Fluopyram 1:1 2:2 X.29 Fluopyram 10:1 2:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Isopyrase 10:1 2:0.2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2 X.29 Sedaksan 1:1 2:2 X.29 Sedaksan 10:1 2:0.2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid if lu metof her 10:1 20:2 X.29 Pid if lu metof her 100:1 20:0.2 X.29 Pid iflu metof her 1:1 2:2 X.29 Pid iflu metof her 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isoflucipram 10:1 2:0.2 X.29 Isofetamide 10:1 20:2

- 169 046405

X.29 Isofetamide 100:1 20:0.2 X.29 Isofetamide 1:1 2:2 X.29 Isofetamide 10:1 2:0.2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Fluindapir 1:1 2:2 X.29 Fluindapir 10:1 2:0.2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Phenpicoxamide 3.3:1 2:0.6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Chlorothalonil 1:3 2:6 X.29 Chlorothalonil 3.33:1 2:0.6 X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mankozeb 1:10 2:20 X.29 Mankozeb 1:3 2:6 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Mandipropamide 1:10 2:20 X.29 Mandipropamide 1:3 2:6 X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Oxathiapiproline 1:10 2:20 X.29 Oxathiapiproline 1:3 2:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Flu Azinam 10:1 2:0.2

- 170 046405

X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Fludioxonil 3.3:1 2:0.6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Metalaxyl-M 1:10 2:20 X.29 Metalaxyl-M 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2 X.29 Aminopyrifene 1:1 2:2 X.29 Aminopyrifene 10:1 2:0.2 X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Folpet 1:3 2:6 X.29 Folpet 1:1 2:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2 X.29 Ipflufenoquin 10:1 2:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 Tricyclazole 1:1 20:20 X.29 Tricyclazole 3:1 20:6 X.29 Tricyclazole 1:10 2:20 X.29 Tricyclazole 1:3 2:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 Pyroquilon 1:10 2:20 X.29 Pyroquilon 1:3 2:6 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinol in-3 - 10:1 20:2

- 171 046405

carboxamide X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 2:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 2:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3- 10:1 2:0.2

- 172 046405

dimethylisoquinoline X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazole- 1 - 10:1 2:0.2 yl)-4,4-difluoro-3,3dimethylisoquinoline

- 173 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20

- 174 046405

X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid iflu metof her 10:1 60:6 X.36 Pid iflu metof her 100:1 60:0.6 X.36 Pid iflu metof her 3.3:1 20:6 X.36 Pid iflu metof her 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar il picoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20

- 175 046405

X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3- 100:1 60:0.6

- 176 046405

dimethylbutyl)-8fluoroquinoline-3 carboxamide X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6

- 177 046405

X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6

- 178 046405

X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Tricyclazole 1:1 20:20 X.36 Tricyclazole 3.3:1 20:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6 X.36 Pyroquilon 1:1 20:20 X.36 Pyroquilon 3.3:1 20:6

Component A (Connection) Component B A:B ratio Conc, (rrsh) (A: B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6

- 179 046405

X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid iflu metof en 10:1 60:6 X.38 Pid iflu metof en 100:1 60:0.6 X.38 Pid iflu metof en 3.3:1 20:6

- 180 046405

X.38 Pid iflu metof en 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar ilpicoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mankozeb 1:1 20:20 X.38 Mankozeb 3.3:1 20:6 X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Mandipropamide 1:1 20:20 X.38 Mandipropamide 3.3:1 20:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Oxathiapiproline 1:1 20:20 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 100:1 60:0.6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6

- 181 046405

X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6 X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6.7- d-methylpyrazolo[1,5- 10:1 60:6

- 182 046405

a] pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazole- 1 - 33.3:1 20:0.6

- 183 046405

yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Sedaksan 33.3:1 20:0.6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6 X.38 Tricyclazole 3:1 60:20 X.38 Tricyclazole 10:1 60:6 X.38 Tricyclazole 1:1 20:20 X.38 Tricyclazole 3.3:1 20:6 X.38 Pyroquilon 3:1 60:20 X.38 Pyroquilon 10:1 60:6

Example B7. Activity against Cercospora beticola (leaf spot).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 3-4 days at 620 nm. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 184 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 1:1 2:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 1:3 2:6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Florylpicoxamide 10:1 2:0.2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 1:3 2:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 1:1 2:2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 1:3 2:6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 1:1 2:2 X.29 Folpet 3.3:1 20:6 X.29 Folpet 1:3 2:6 X.29 Ipflufenoquin 10:1 20:2

- 185 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Trifloxystrobin 10:1 60:6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Hexaconazole 10:1 60:6 X.36 Hexaconazole 100:1 60:0.6 X.36 Hexaconazole 3.3:1 20:6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6

- 186 046405

X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Pid iflu metof en 10:1 60:6 X.36 Pid iflu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Fluindapir 10:1 60:6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar il picoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Mankozeb 3:1 60:20 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6

- 187 046405

X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6

- 188 046405

X.36 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4.5- d imethylbenzimidazol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4.5- d imethylbenzimidazol-1 yl)-4,4-d iforo-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 3.3:1 20:6 X.38 Hexaconazole 10:1 60:6 X.38 Hexaconazole 3.3:1 20:6 X.38 Hexaconazole 33.3:1 20:0.6

- 189 046405

X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Pid iflu metof en 10:1 60:6 X.38 Pid iflu metof en 3.3:1 20:6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar ilpicoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6

- 190 046405

X.38 Cyprodinil 3.3:1 20:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6

Example B8. Activity against Pyrenophora teres (net spot).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates with test compounds were incubated at 24°C and growth inhibition was determined photometrically after 72 h at 620 nm. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 191 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Difenoconazole 3.3:1 2:0.6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 1:3 2:6 X.29 Propiconazole 3.3:1 20:6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Prothioconazole 3.3:1 2:0.6 X.29 Phenpropimorph 1:1 20:20

- 192 046405

X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Sedaksan 10:1 20:2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Pidiflumetofen 10:1 20:2 X.29 Pid iflu metof her 100:1 20:0.2 X.29 Pid iflu metof her 1:1 2:2 X.29 Pid iflu metof her 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isofetamide 10:1 20:2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2 X.29 Fluindapir 10:1 20:2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 1:3 2:6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 1:1 2:2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Flu Azinam 10:1 2:0.2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6

- 193 046405

X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinol in-3 carboxamide 10:1 20:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinol in-3 carboxamide 1:1 2:2 X.29 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3- dimethylisoquinoline 10:1 20:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3- dimethylisoquinoline 100:1 20:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3- dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5trifluoro-3,3- dimethylisoquinoline 10:1 2:0.2

- 194 046405

X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 2:2 X.29 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 2:0.2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 2:0.2

- 195 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6

- 196 046405

X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid iflu metof en 10:1 60:6 X.36 Pid iflu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metharylpicoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20

- 197 046405

X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6 X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 - 100:1 60:0.6

- 198 046405

carboxamide X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o [1,5- 10:1 60:6

- 199 046405

a] pyridin-3yl)isoquinoline X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 Isopyrase 10:1 60:6

- 200 046405

X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Tricyclazole 1:1 20:20 X.36 Tricyclazole 3.3:1 20:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6 X.36 Pyroquilon 1:1 20:20 X.36 Pyroquilon 3.3:1 20:6 Component A ,, „ „ , ,, Conc, (ppm) , Component B Ratio A:B .. ' (Connection) (A:B) X.38 Azoxystrobin 10:1 60:6 X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6

- 201 046405

X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6 X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid iflu metof her 10:1 60:6 X.38 Pid iflu metof her 100:1 60:0.6

- 202 046405

X.38 Pid iflu metof her 3.3:1 20:6 X.38 Pid iflu metof her 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar il picoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6 X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Fluazinam 10:1 60:6 X.38 Fluazinam 100:1 60:0.6 X.38 Fluazinam 3.3:1 20:6 X.38 Fluazinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6

- 203 046405

X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(l-benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5- 10:1 60:6

- 204 046405

trifluoro-3,3dimethylisoquinoline X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 - 33.3:1 20:0.6

- 205 046405

dimethylisoquinoline X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6 X.38 Tricyclazole 3:1 60:20 X.38 Tricyclazole 10:1 60:6 X.38 Pyroquilon 3:1 60:20 X.38 Pyroquilon 10:1 60:6

Example B9. Activity against Alternaria solani (Alternaria blight of tomatoes/potatoes).

Fungal conidia from cryogenic storage were directly mixed with nutrient broth (potato dextrose broth, PDB). A solution of test compounds in DMSO was added to a microtiter plate (96-well format) and nutrient broth containing fungal spores was added. Plates of test compounds were incubated at 24°C and growth inhibition was determined photometrically after 48 hours. The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test.

- 206 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 10:1 20:2 X.29 Azoxystrobin 100:1 20:0.2 X.29 Azoxystrobin 1:1 2:2 X.29 Azoxystrobin 10:1 2:0.2 X.29 Trifloxystrobin 10:1 20:2 X.29 Trifloxystrobin 100:1 20:0.2 X.29 Trifloxystrobin 1:1 2:2 X.29 Trifloxystrobin 10:1 2:0.2 X.29 Methyltetraprole 10:1 20:2 X.29 Methyltetraprole 100:1 20:0.2 X.29 Methyltetraprole 1:1 2:2 X.29 Methyltetraprole 10:1 2:0.2 X.29 Difenoconazole 3.3:1 20:6 X.29 Difenoconazole 33.3:1 20:0.6 X.29 Difenoconazole 1:3 2:6 X.29 Hexaconazole 3.3:1 20:6 X.29 Hexaconazole 33.3:1 20:0.6 X.29 Hexaconazole 1:3 2:6 X.29 Propiconazole 3.3:1 20:6 X.29 Propiconazole 33.3:1 20:0.6 X.29 Prothioconazole 3.3:1 20:6 X.29 Prothioconazole 33.3:1 20:0.6 X.29 Prothioconazole 1:3 2:6 X.29 Mefentrifluconazole 3.3:1 20:6 X.29 Mefentrifluconazole 33.3:1 20:0.6

- 207 046405

X.29 Mefentrifluconazole 1:3 2:6 X.29 Fenpropidine 1:1 20:20 X.29 Fenpropidine 10:1 20:2 X.29 Phenpropimorph 1:1 20:20 X.29 Phenpropimorph 10:1 20:2 X.29 Phenpropimorph 1:10 2:20 X.29 Fluxapyroxad 10:1 20:2 X.29 Fluxapyroxad 100:1 20:0.2 X.29 Fluopyram 10:1 20:2 X.29 Fluopyram 100:1 20:0.2 X.29 Fluopyram 1:1 2:2 X.29 Fluopyram 10:1 2:0.2 X.29 Isopyrase 10:1 20:2 X.29 Isopyrase 100:1 20:0.2 X.29 Isopyrase 1:1 2:2 X.29 Isopyrase 10:1 2:0.2 X.29 Sedaksan 10:1 20:2 X.29 Sedaksan 100:1 20:0.2 X.29 Sedaksan 1:1 2:2 X.29 Benzovindiflupir 10:1 20:2 X.29 Benzovindiflupir 100:1 20:0.2 X.29 Benzovindiflupir 1:1 2:2 X.29 Benzovindiflupir 10:1 2:0.2 X.29 Pid iflu metof en 10:1 20:2 X.29 Pid iflu metof en 100:1 20:0.2 X.29 Pid iflu metof en 1:1 2:2 X.29 Pid iflu metof en 10:1 2:0.2 X.29 Isoflucipram 10:1 20:2 X.29 Isoflucipram 100:1 20:0.2 X.29 Isoflucipram 1:1 2:2 X.29 Isoflucipram 10:1 2:0.2 X.29 Isofetamide 10:1 20:2 X.29 Isofetamide 100:1 20:0.2 X.29 Isofetamide 1:1 2:2 X.29 Pyrapropone 10:1 20:2 X.29 Pyrapropone 100:1 20:0.2 X.29 Pyrapropone 1:1 2:2

- 208 046405

X.29 Pyrapropone 10:1 2:0.2 X.29 Fluindapir 10:1 20:2 X.29 Fluindapir 100:1 20:0.2 X.29 Fluindapir 1:1 2:2 X.29 Phenpicoxamide 3.3:1 20:6 X.29 Phenpicoxamide 33.3:1 20:0.6 X.29 Phenpicoxamide 1:3 2:6 X.29 Florylpicoxamide 10:1 20:2 X.29 Florylpicoxamide 100:1 20:0.2 X.29 Florylpicoxamide 1:1 2:2 X.29 Chlorothalonil 3.3:1 20:6 X.29 Chlorothalonil 33.3:1 20:0.6 X.29 Mankozeb 1:1 20:20 X.29 Mankozeb 3.3:1 20:6 X.29 Mandipropamide 1:1 20:20 X.29 Mandipropamide 3.3:1 20:6 X.29 Oxathiapiproline 1:1 20:20 X.29 Oxathiapiproline 3.3:1 20:6 X.29 Flu Azinam 10:1 20:2 X.29 Flu Azinam 100:1 20:0.2 X.29 Flu Azinam 1:1 2:2 X.29 Fludioxonil 3.3:1 20:6 X.29 Fludioxonil 33.3:1 20:0.6 X.29 Fludioxonil 1:3 2:6 X.29 Fludioxonil 3.3:1 2:0.6 X.29 Cyprodinil 3.3:1 20:6 X.29 Cyprodinil 33.3:1 20:0.6 X.29 Cyprodinil 1:3 2:6 X.29 Cyprodinil 3.3:1 2:0.6 X.29 Metalaxyl-M 1:1 20:20 X.29 Metalaxyl-M 3.3:1 20:6 X.29 Metalaxyl-M 1:10 2:20 X.29 Metalaxyl-M 1:3 2:6 X.29 Aminopyrifene 10:1 20:2 X.29 Aminopyrifene 100:1 20:0.2

- 209 046405

X.29 Folpet 3.3:1 20:6 X.29 Folpet 10:1 20:2 X.29 Ipflufenoquin 10:1 20:2 X.29 Ipflufenoquin 100:1 20:0.2 X.29 Ipflufenoquin 1:1 2:2 X.29 Ipflufenoquin 10:1 2:0.2 X.29 Quinofumelin 10:1 20:2 X.29 Quinofumelin 100:1 20:0.2 X.29 Quinofumelin 1:1 2:2 X.29 Quinofumelin 10:1 2:0.2 X.29 Tricyclazole 1:1 20:20 X.29 Tricyclazole 3:1 20:6 X.29 Pyroquilon 1:1 20:20 X.29 Pyroquilon 3:1 20:6 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 20:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 2:2 X.29 X-(1-benzyl-1,3dimethylbutyl)-8 fluoroquinoline-3 carboxamide 10:1 2:0.2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 20:2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 20:0.2 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 2:2 X.29 N-(l-benzyl-3,3,3- 10:1 2:0.2

- 210 046405

trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(6,7dimethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 2:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 20:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 20:0.2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 2:2 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 20:0.2

- 211 046405

X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 2:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 20:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 20:0.2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 2:2 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 2:0.2

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6

- 212 046405

X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Prothioconazole 10:1 60:6 X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid iflu metof en 10:1 60:6 X.36 Pid iflu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6

- 213 046405

X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6 X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar ilpicoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Fluazinam 10:1 60:6 X.36 Fluazinam 100:1 60:0.6 X.36 Fluazinam 3.3:1 20:6 X.36 Fluazinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6

- 214 046405

X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(l-benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(1-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.36 1-(6.7- d-methylpyrazolo[1,5- 100:1 60:0.6

- 215 046405

a] pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazole- 1 - 10:1 60:6

- 216 046405

yl)-4,4-difluoro-3,3dimethylisoquinoline X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6 X.36 Tricyclazole 3:1 60:20 X.36 Tricyclazole 10:1 60:6 X.36 Pyroquilon 3:1 60:20 X.36 Pyroquilon 10:1 60:6

Example B10. Treatment of liquid culture of Sclerotinia sclerotiorum / (white rot).

Mycelial fragments of a newly grown fungal culture in liquid medium were directly mixed with nutrient broth (Minimal Vogel Media) containing 200 μmol of SHAM. After adding the solution (DMSO) of the test compounds, nutrient broth containing fungal material was added to a microtiter plate (96-well format). Plates containing test compounds were incubated at 24°C and growth inhibition was determined photometrically 3-4 days after application. The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

- 217 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 10:1 60:6 X.36 Azoxystrobin 100:1 60:0.6 X.36 Azoxystrobin 3.3:1 20:6 X.36 Azoxystrobin 33.3:1 20:0.6 X.36 Trifloxystrobin 10:1 60:6 X.36 Trifloxystrobin 100:1 60:0.6 X.36 Trifloxystrobin 3.3:1 20:6 X.36 Trifloxystrobin 33.3:1 20:0.6 X.36 Methyltetraprole 10:1 60:6 X.36 Methyltetraprole 100:1 60:0.6 X.36 Methyltetraprole 3.3:1 20:6 X.36 Methyltetraprole 33.3:1 20:0.6 X.36 Difenoconazole 10:1 60:6 X.36 Difenoconazole 100:1 60:0.6 X.36 Difenoconazole 3.3:1 20:6 X.36 Difenoconazole 33.3:1 20:0.6 X.36 Hexaconazole 10:1 60:6 X.36 Hexaconazole 100:1 60:0.6 X.36 Hexaconazole 3.3:1 20:6 X.36 Hexaconazole 33.3:1 20:0.6 X.36 Propiconazole 10:1 60:6 X.36 Propiconazole 100:1 60:0.6 X.36 Propiconazole 3.3:1 20:6 X.36 Propiconazole 33.3:1 20:0.6 X.36 Prothioconazole 10:1 60:6

- 218 046405

X.36 Prothioconazole 100:1 60:0.6 X.36 Prothioconazole 3.3:1 20:6 X.36 Prothioconazole 33.3:1 20:0.6 X.36 Mefentrifluconazole 10:1 60:6 X.36 Mefentrifluconazole 100:1 60:0.6 X.36 Mefentrifluconazole 3.3:1 20:6 X.36 Mefentrifluconazole 33.3:1 20:0.6 X.36 Fenpropidine 3:1 60:20 X.36 Fenpropidine 10:1 60:6 X.36 Fenpropidine 1:1 20:20 X.36 Fenpropidine 3.3:1 20:6 X.36 Phenpropimorph 3:1 60:20 X.36 Phenpropimorph 10:1 60:6 X.36 Phenpropimorph 1:1 20:20 X.36 Phenpropimorph 3.3:1 20:6 X.36 Fluxapyroxad 10:1 60:6 X.36 Fluxapyroxad 100:1 60:0.6 X.36 Fluxapyroxad 3.3:1 20:6 X.36 Fluxapyroxad 33.3:1 20:0.6 X.36 Fluopyram 10:1 60:6 X.36 Fluopyram 100:1 60:0.6 X.36 Fluopyram 3.3:1 20:6 X.36 Fluopyram 33.3:1 20:0.6 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 100:1 60:0.6 X.36 Benzovindiflupir 3.3:1 20:6 X.36 Benzovindiflupir 33.3:1 20:0.6 X.36 Pid iflu metof en 10:1 60:6 X.36 Pid iflu metof en 100:1 60:0.6 X.36 Pid iflu metof en 3.3:1 20:6 X.36 Pid iflu metof en 33.3:1 20:0.6 X.36 Isoflucipram 10:1 60:6 X.36 Isoflucipram 100:1 60:0.6 X.36 Isoflucipram 3.3:1 20:6 X.36 Isoflucipram 33.3:1 20:0.6 X.36 Fluindapir 10:1 60:6 X.36 Fluindapir 100:1 60:0.6 X.36 Fluindapir 3.3:1 20:6 X.36 Fluindapir 33.3:1 20:0.6

- 219 046405

X.36 Florylpicoxamide 10:1 60:6 X.36 Florylpicoxamide 100:1 60:0.6 X.36 Florylpicoxamide 3.3:1 20:6 X.36 Florylpicoxamide 33.3:1 20:0.6 X.36 Metar il picoxamide 10:1 60:6 X.36 Metar ilpicoxamide 100:1 60:0.6 X.36 Metar ilpicoxamide 3.3:1 20:6 X.36 Metar ilpicoxamide 33.3:1 20:0.6 X.36 Chlorothalonil 10:1 60:6 X.36 Chlorothalonil 100:1 60:0.6 X.36 Chlorothalonil 3.3:1 20:6 X.36 Chlorothalonil 33.3:1 20:0.6 X.36 Mankozeb 3:1 60:20 X.36 Mankozeb 10:1 60:6 X.36 Mankozeb 1:1 20:20 X.36 Mankozeb 3.3:1 20:6 X.36 Mandipropamide 3:1 60:20 X.36 Mandipropamide 10:1 60:6 X.36 Mandipropamide 1:1 20:20 X.36 Mandipropamide 3.3:1 20:6 X.36 Oxathiapiproline 3:1 60:20 X.36 Oxathiapiproline 10:1 60:6 X.36 Oxathiapiproline 1:1 20:20 X.36 Oxathiapiproline 3.3:1 20:6 X.36 Flu Azinam 10:1 60:6 X.36 Flu Azinam 100:1 60:0.6 X.36 Flu Azinam 3.3:1 20:6 X.36 Flu Azinam 33.3:1 20:0.6 X.36 Fludioxonil 10:1 60:6 X.36 Fludioxonil 100:1 60:0.6 X.36 Fludioxonil 3.3:1 20:6 X.36 Fludioxonil 33.3:1 20:0.6 X.36 Cyprodinil 10:1 60:6 X.36 Cyprodinil 100:1 60:0.6 X.36 Cyprodinil 3.3:1 20:6 X.36 Cyprodinil 33.3:1 20:0.6 X.36 Metalaxyl-M 3:1 60:20 X.36 Metalaxyl-M 10:1 60:6

- 220 046405

X.36 Metalaxyl-M 1:1 20:20 X.36 Metalaxyl-M 3.3:1 20:6 X.36 Folpet 10:1 60:6 X.36 Folpet 30:1 60:2 X.36 Folpet 3.3:1 20:6 X.36 Folpet 10:1 20:2 X.36 Aminopyrifene 10:1 60:6 X.36 Aminopyrifene 100:1 60:0.6 X.36 Aminopyrifene 3.3:1 20:6 X.36 Aminopyrifene 33.3:1 20:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.36 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.36 1-(6.7- d-methylpyrazolo[1,5- 10:1 60:6

- 221 046405

a] pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 10:1 60:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.36 1-(4,5dimethylbenzimidazole- 1 - 33.3:1 20:0.6

- 222 046405

yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1-(4.5- X.36 d methylbenzimide azol-1 - 10:1 60:6 yl)-4,4-difluoro-3,3- dimethylisoquinoline 1-(4.5- X.36 d methylbenzimide azol-1 - 100:1 60:0.6 yl)-4,4-difluoro-3,3- dimethylisoquinoline 1-(4.5- X.36 d methylbenzimide azol-1 - 3.3:1 20:6 yl)-4,4-difluoro-3,3- dimethylisoquinoline 1-(4.5- X.36 d methylbenzimide azol-1 - 33.3:1 20:0.6 yl)-4,4-difluoro-3,3- dimethylisoquinoline X.36 Isopyrase 10:1 60:6 X.36 Isopyrase 100:1 60:0.6 X.36 Isopyrase 3.3:1 20:6 X.36 Isopyrase 33.3:1 20:0.6 X.36 Sedaksan 10:1 60:6 X.36 Sedaksan 100:1 60:0.6 X.36 Sedaksan 3.3:1 20:6 X.36 Sedaksan 33.3:1 20:0.6 X.36 Isofetamide 10:1 60:6 X.36 Isofetamide 100:1 60:0.6 X.36 Isofetamide 3.3:1 20:6 X.36 Isofetamide 33.3:1 20:0.6 X.36 Ipflufenoquin 10:1 60:6 X.36 Ipflufenoquin 100:1 60:0.6 X.36 Ipflufenoquin 3.3:1 20:6 X.36 Ipflufenoquin 33.3:1 20:0.6 X.36 Quinofumelin 10:1 60:6 X.36 Quinofumelin 100:1 60:0.6 X.36 Quinofumelin 3.3:1 20:6 X.36 Quinofumelin 33.3:1 20:0.6

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 10:1 60:6

- 223 046405

X.38 Azoxystrobin 100:1 60:0.6 X.38 Azoxystrobin 3.3:1 20:6 X.38 Azoxystrobin 33.3:1 20:0.6 X.38 Trifloxystrobin 10:1 60:6 X.38 Trifloxystrobin 100:1 60:0.6 X.38 Trifloxystrobin 3.3:1 20:6 X.38 Trifloxystrobin 33.3:1 20:0.6 X.38 Methyltetraprole 10:1 60:6 X.38 Methyltetraprole 100:1 60:0.6 X.38 Methyltetraprole 3.3:1 20:6 X.38 Methyltetraprole 33.3:1 20:0.6 X.38 Difenoconazole 10:1 60:6 X.38 Difenoconazole 100:1 60:0.6 X.38 Difenoconazole 3.3:1 20:6 X.38 Difenoconazole 33.3:1 20:0.6 X.38 Hexaconazole 10:1 60:6 X.38 Hexaconazole 100:1 60:0.6 X.38 Hexaconazole 3.3:1 20:6 X.38 Hexaconazole 33.3:1 20:0.6 X.38 Propiconazole 10:1 60:6 X.38 Propiconazole 100:1 60:0.6 X.38 Propiconazole 3.3:1 20:6 X.38 Propiconazole 33.3:1 20:0.6 X.38 Prothioconazole 10:1 60:6 X.38 Prothioconazole 100:1 60:0.6 X.38 Prothioconazole 3.3:1 20:6 X.38 Prothioconazole 33.3:1 20:0.6 X.38 Mefentrifluconazole 10:1 60:6 X.38 Mefentrifluconazole 100:1 60:0.6 X.38 Mefentrifluconazole 3.3:1 20:6 X.38 Mefentrifluconazole 33.3:1 20:0.6 X.38 Fenpropidine 3:1 60:20 X.38 Fenpropidine 10:1 60:6 X.38 Fenpropidine 1:1 20:20 X.38 Fenpropidine 3.3:1 20:6 X.38 Phenpropimorph 3:1 60:20 X.38 Phenpropimorph 10:1 60:6 X.38 Phenpropimorph 1:1 20:20 X.38 Phenpropimorph 3.3:1 20:6

- 224 046405

X.38 Fluxapyroxad 10:1 60:6 X.38 Fluxapyroxad 100:1 60:0.6 X.38 Fluxapyroxad 3.3:1 20:6 X.38 Fluxapyroxad 33.3:1 20:0.6 X.38 Fluopyram 10:1 60:6 X.38 Fluopyram 100:1 60:0.6 X.38 Fluopyram 3.3:1 20:6 X.38 Fluopyram 33.3:1 20:0.6 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 100:1 60:0.6 X.38 Benzovindiflupir 3.3:1 20:6 X.38 Benzovindiflupir 33.3:1 20:0.6 X.38 Pid if lu metof her 10:1 60:6 X.38 Pid if lu metof her 100:1 60:0.6 X.38 Pid iflu metof her 3.3:1 20:6 X.38 Pid iflu metof her 33.3:1 20:0.6 X.38 Isoflucipram 10:1 60:6 X.38 Isoflucipram 100:1 60:0.6 X.38 Isoflucipram 3.3:1 20:6 X.38 Isoflucipram 33.3:1 20:0.6 X.38 Fluindapir 10:1 60:6 X.38 Fluindapir 100:1 60:0.6 X.38 Fluindapir 3.3:1 20:6 X.38 Fluindapir 33.3:1 20:0.6 X.38 Florylpicoxamide 10:1 60:6 X.38 Florylpicoxamide 100:1 60:0.6 X.38 Florylpicoxamide 3.3:1 20:6 X.38 Florylpicoxamide 33.3:1 20:0.6 X.38 Metar il picoxamide 10:1 60:6 X.38 Metar ilpicoxamide 100:1 60:0.6 X.38 Metar ilpicoxamide 3.3:1 20:6 X.38 Metar ilpicoxamide 33.3:1 20:0.6 X.38 Chlorothalonil 10:1 60:6 X.38 Chlorothalonil 100:1 60:0.6 X.38 Chlorothalonil 3.3:1 20:6 X.38 Chlorothalonil 33.3:1 20:0.6 X.38 Mankozeb 3:1 60:20 X.38 Mankozeb 10:1 60:6

- 225 046405

X.38 Mankozeb 1:1 20:20 X.38 Mankozeb 3.3:1 20:6 X.38 Mandipropamide 3:1 60:20 X.38 Mandipropamide 10:1 60:6 X.38 Mandipropamide 1:1 20:20 X.38 Mandipropamide 3.3:1 20:6 X.38 Oxathiapiproline 3:1 60:20 X.38 Oxathiapiproline 10:1 60:6 X.38 Oxathiapiproline 1:1 20:20 X.38 Oxathiapiproline 3.3:1 20:6 X.38 Flu Azinam 10:1 60:6 X.38 Flu Azinam 100:1 60:0.6 X.38 Flu Azinam 3.3:1 20:6 X.38 Flu Azinam 33.3:1 20:0.6 X.38 Fludioxonil 10:1 60:6 X.38 Fludioxonil 100:1 60:0.6 X.38 Fludioxonil 3.3:1 20:6 X.38 Fludioxonil 33.3:1 20:0.6 X.38 Cyprodinil 10:1 60:6 X.38 Cyprodinil 100:1 60:0.6 X.38 Cyprodinil 3.3:1 20:6 X.38 Cyprodinil 33.3:1 20:0.6 X.38 Metalaxyl-M 3:1 60:20 X.38 Metalaxyl-M 10:1 60:6 X.38 Metalaxyl-M 1:1 20:20 X.38 Metalaxyl-M 3.3:1 20:6 X.38 Folpet 10:1 60:6 X.38 Folpet 30:1 60:2 X.38 Folpet 3.3:1 20:6 X.38 Folpet 10:1 20:2 X.38 Aminopyrifene 10:1 60:6 X.38 Aminopyrifene 100:1 60:0.6 X.38 Aminopyrifene 3.3:1 20:6 X.38 Aminopyrifene 33.3:1 20:0.6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 10:1 60:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8- 100:1 60:0.6

- 226 046405

fluoroquinoline-3 carboxamide X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 10:1 60:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 100:1 60:0.6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 20:6 X.38 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 33.3:1 20:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 33.3:1 20:0.6 X.38 4,4-difluoro-3,3-dimethyl-1 - 10:1 60:6

- 227 046405

(7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline X.38 4,4-difluoro-3, 3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 100:1 60:0.6 X.38 4,4-difluoro-3, 3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 20:6 X.38 4,4-difluoro-3, 3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imethylbenzimidazol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 20:6 X.38 1-(4.5- d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 33.3:1 20:0.6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 10:1 60:6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 100:1 60:0.6 X.38 1-(4.5- d imethylbenzimide azol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 20:6 X.38 1-(4.5- d imethylbenzimidazol-1 yl)-4,4-difluoro-3,3dimethylisoquinoline 33.3:1 20:0.6

- 228 046405

X.38 Isopyrase 10:1 60:6 X.38 Isopyrase 100:1 60:0.6 X.38 Isopyrase 3.3:1 20:6 X.38 Isopyrase 33.3:1 20:0.6 X.38 Sedaksan 10:1 60:6 X.38 Sedaksan 100:1 60:0.6 X.38 Sedaksan 3.3:1 20:6 X.38 Sedaksan 33.3:1 20:0.6 X.38 Isofetamide 10:1 60:6 X.38 Isofetamide 100:1 60:0.6 X.38 Isofetamide 3.3:1 20:6 X.38 Isofetamide 33.3:1 20:0.6 X.38 Ipflufenoquin 10:1 60:6 X.38 Ipflufenoquin 100:1 60:0.6 X.38 Ipflufenoquin 3.3:1 20:6 X.38 Ipflufenoquin 33.3:1 20:0.6 X.38 Quinofumelin 10:1 60:6 X.38 Quinofumelin 100:1 60:0.6 X.38 Quinofumelin 3.3:1 20:6 X.38 Quinofumelin 33.3:1 20:0.6

Example B11. Treatment to prevent leaf disc infection / wheat / Blumeria graminis f. sp. tritici (Erysiphe graminis f sp. tritici) / (powdery mildew of wheat).

Leaf segments of the wheat variety Kanzler were placed on agar in a multiwell plate (24-well format) and sprayed with the formulated test compounds diluted in water. Leaf discs were inoculated by shaking powdery mildew-infected plants over test plates 1 day after application. The inoculated leaf disks were incubated at 20°C and 60% relative humidity under a light regime of 24 hours dark followed by 12 hours light/12 hours dark in a climate chamber and the activity of the compound was assessed as a percentage of disease control compared to untreated material at manifestation of the corresponding degree of damage due to the disease on untreated control leaf segments (6-8 days after application). The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

- 229 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 1.6:1 100:60 X.29 Azoxystrobin 5:1 100:20 X.29 Azoxystrobin 1:2 30:60 X.29 Azoxystrobin 3:2 30:20 X.29 Trifloxystrobin 1.6:1 100:60 X.29 Trifloxystrobin 5:1 100:20 X.29 Trifloxystrobin 1:2 30:60 X.29 Trifloxystrobin 3:2 30:20 X.29 Methyltetraprole 1.6:1 100:60 X.29 Methyltetraprole 5:1 100:20 X.29 Methyltetraprole 1:2 30:60 X.29 Methyltetraprole 3:2 30:20 X.29 Difenoconazole 1.6:1 100:60 X.29 Difenoconazole 5:1 100:20 X.29 Difenoconazole 1:2 30:60 X.29 Difenoconazole 3:2 30:20 X.29 Hexaconazole 1.6:1 100:60 X.29 Hexaconazole 5:1 100:20 X.29 Hexaconazole 1:2 30:60 X.29 Hexaconazole 3:2 30:20 X.29 Propiconazole 1.6:1 100:60 X.29 Propiconazole 5:1 100:20 X.29 Propiconazole 1:2 30:60 X.29 Propiconazole 3:2 30:20 X.29 Prothioconazole 1.6:1 100:60 X.29 Prothioconazole 5:1 100:20 X.29 Prothioconazole 1:2 30:60 X.29 Prothioconazole 3:2 30:20 X.29 Mefentrifluconazole 1.6:1 100:60 X.29 Mefentrifluconazole 5:1 100:20 X.29 Mefentrifluconazole 1:2 30:60 X.29 Mefentrifluconazole 3:2 30:20 X.29 Fenpropidine 1:1 100:100 X.29 Fenpropidine 3.3:1 100:30 X.29 Fenpropidine 1:3.3 30:100 X.29 Fenpropidine 1:1 30:30

- 230 046405

X.29 Phenpropimorph 1.6:1 100:60 X.29 Phenpropimorph 5:1 100:20 X.29 Phenpropimorph 1:2 30:60 X.29 Phenpropimorph 3:2 30:20 X.29 Fluxapyroxad 1.6:1 100:60 X.29 Fluxapyroxad 5:1 100:20 X.29 Fluxapyroxad 1:2 30:60 X.29 Fluxapyroxad 3:2 30:20 X.29 Fluopyram 1:1 100:100 X.29 Fluopyram 3.3:1 100:30 X.29 Fluopyram 1:3.3 30:100 X.29 Fluopyram 1:1 30:30 X.29 Benzovindiflupir 1.6:1 100:60 X.29 Benzovindiflupir 5:1 100:20 X.29 Benzovindiflupir 1:2 30:60 X.29 Benzovindiflupir 3:2 30:20 X.29 Pid iflu metof en 1.6:1 100:60 X.29 Pid iflu metof en 5:1 100:20 X.29 Pid iflu metof en 1:2 30:60 X.29 Pid iflu metof en 3:2 30:20 X.29 Isoflucipram 1.6:1 100:60 X.29 Isoflucipram 5:1 100:20 X.29 Isoflucipram 1:2 30:60 X.29 Isoflucipram 3:2 30:20 X.29 Florylpicoxamide 1.6:1 100:60 X.29 Florylpicoxamide 5:1 100:20 X.29 Florylpicoxamide 1:2 30:60 X.29 Florylpicoxamide 3:2 30:20 X.29 Metharylpicoxamide 1:1 100:100 X.29 Metharylpicoxamide 3.3:1 100:30 X.29 Metharylpicoxamide 1:3.3 30:100 X.29 Metharylpicoxamide 1:1 30:30 X.29 Fosetyl aluminum 1:1 100:100 X.29 Fosetyl aluminum 3.3:1 100:30 X.29 Fosetyl aluminum 1:3.3 30:100 X.29 Fosetyl aluminum 1:1 30:30 X.29 Chlorothalonil 1:1 100:100 X.29 Chlorothalonil 3.3:1 100:30

- 231 046405

X.29 Chlorothalonil 1:3.3 30:100 X.29 Chlorothalonil 1:1 30:30 X.29 Mankozeb 1:1 100:100 X.29 Mankozeb 3.3:1 100:30 X.29 Mankozeb 1:3.3 30:100 X.29 Mankozeb 1:1 30:30 X.29 Mandipropamide 1:1 100:100 X.29 Mandipropamide 3.3:1 100:30 X.29 Mandipropamide 1:3.3 30:100 X.29 Mandipropamide 1:1 30:30 X.29 Oxathiapiproline 1:1 100:100 X.29 Oxathiapiproline 3.3:1 100:30 X.29 Oxathiapiproline 1:3.3 30:100 X.29 Oxathiapiproline 1:1 30:30 X.29 Flu Azinam 1:1 100:100 X.29 Flu Azinam 3.3:1 100:30 X.29 Flu Azinam 1:3.3 30:100 X.29 Flu Azinam 1:1 30:30 X.29 Fludioxonil 1:1 100:100 X.29 Fludioxonil 3.3:1 100:30 X.29 Fludioxonil 1:3.3 30:100 X.29 Fludioxonil 1:1 30:30 X.29 Cyprodinil 1:1 100:100 X.29 Cyprodinil 3.3:1 100:30 X.29 Cyprodinil 1:3.3 30:100 X.29 Cyprodinil 1:1 30:30 X.29 Metalaxyl-M 1:1 100:100 X.29 Metalaxyl-M 3.3:1 100:30 X.29 Metalaxyl-M 1:3.3 30:100 X.29 Metalaxyl-M 1:1 30:30 X.29 Folpet 1:1 100:100 X.29 Folpet 3.3:1 100:30 X.29 Folpet 1:3.3 30:100 X.29 Folpet 1:1 30:30 X.29 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-M-ethyl-Mmethylformamidine 1:1 100:100 X.29 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)- 3.3:1 100:30

- 232 046405

3-pyridyl]-X-ethyl-Xmethylformamidine X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:3.3 30:100 X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 30:30 X.29 N-H3onponHn-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:1 100:100 X.29 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 3.3:1 100:30 X.29 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:3.3 30:100 X.29 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:1 30:30 X.29 TAEGRO® 1:1 100:100 X.29 TAEGRO® 3.3:1 100:30 X.29 TAEGRO® 1:3.3 30:100 X.29 TAEGRO® 1:1 30:30 X.29 Timorex GoldTM 1:1 100:100 X.29 Timorex GoldTM 3.3:1 100:30 X.29 Timorex GoldTM 1:3.3 30:100 X.29 Timorex GoldTM 1:1 30:30 X.29 Isofetamide 1.6:1 100:60 X.29 Isofetamide 5:1 100:20 X.29 Isofetamide 1:2 30:60 X.29 Isofetamide 3:2 30:20 X.29 Acibenzolar-C-methyl 1:1 100:100 X.29 Acibenzolar-C-methyl 3.3:1 100:30

- 233 046405

X.29 Acibenzolar-C-methyl 1:3.3 30:100 X.29 Acibenzolar-C-methyl 1:1 30:30 X.29 Aminopyrifene 1:1 100:100 X.29 Aminopyrifene 3.3:1 100:30 X.29 Aminopyrifene 1:3.3 30:100 X.29 Aminopyrifene 1:1 30:30 X.29 Cyflufenamide 5:1 100:20 X.29 Cyflufenamide 50:1 100:2 X.29 Cyflufenamide 3:2 30:20 X.29 Cyflufenamide 15:1 30:2 X.29 Metraphenone 5:1 100:20 X.29 Metraphenone 50:1 100:2 X.29 Metraphenone 3:2 30:20 X.29 Metraphenone 15:1 30:2 X.29 M-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 100:100 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 100:30 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 30:100 X.29 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 30:30 X.29 N-(l -benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3.3 30:100 X.29 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)- 1:1 30:30

- 234 046405

8-fluoroquinoline-3 carboxamide X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.29 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 100:100 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 100:30 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.29 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 100:100 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30 X.29 1-(4.5- 1:3.3 30:100

- 235 046405

d imetilbenzimide azol-1 yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 1:1 100:100 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 3.3:1 100:30 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 1:3.3 30:100 X.29 1-(4,5dimethylbenzimidazol-1yl)-4,4-d iforo-3,3 dimethylisoquinoline 1:1 30:30

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 1.6:1 100:60 X.36 Azoxystrobin 5:1 100:20 X.36 Azoxystrobin 1:2 30:60 X.36 Azoxystrobin 3:2 30:20 X.36 Trifloxystrobin 1.6:1 100:60 X.36 Trifloxystrobin 5:1 100:20 X.36 Trifloxystrobin 1:2 30:60 X.36 Trifloxystrobin 3:2 30:20 X.36 Methyltetraprole 1.6:1 100:60 X.36 Methyltetraprole 5:1 100:20 X.36 Methyltetraprole 1:2 30:60 X.36 Methyltetraprole 3:2 30:20 X.36 Difenoconazole 1.6:1 100:60 X.36 Difenoconazole 5:1 100:20 X.36 Difenoconazole 1:2 30:60 X.36 Difenoconazole 3:2 30:20 X.36 Hexaconazole 1.6:1 100:60 X.36 Hexaconazole 5:1 100:20

- 236 046405

X.36 Hexaconazole D.2 30:60 X.36 Hexaconazole 3:2 30:20 X.36 Propiconazole 1.6:1 100:60 X.36 Propiconazole 5:1 100:20 X.36 Propiconazole 1:2 30:60 X.36 Propiconazole 3:2 30:20 X.36 Pr otioconazole 1.6:1 100:60 X.36 Pr otioconazole 5:1 100:20 X.36 Pr otioconazole 1:2 30:60 X.36 Pr otioconazole 3:2 30:20 X.36 Mefentrifluconazole 1.6:1 100:60 X.36 Mefentrifluconazole 5:1 100:20 X.36 Mefentrifluconazole 1:2 30:60 X.36 Mefentrifluconazole 3:2 30:20 X.36 Fenpropidine 1:1 100:100 X.36 Fenpropidine 3.3:1 100:30 X.36 Fenpropidine 1:3.3 30:100 X.36 Fenpropidine 1:1 30:30 X.36 Phenpropimorph 1.6:1 100:60 X.36 Phenpropimorph 5:1 100:20 X.36 Phenpropimorph 1:2 30:60 X.36 Phenpropimorph 3:2 30:20 X.36 Fluxapyroxad 1.6:1 100:60 X.36 Fluxapyroxad 5:1 100:20 X.36 Fluxapyroxad 1:2 30:60 X.36 Fluxapyroxad 3:2 30:20 X.36 Fluopyram 1:1 100:100 X.36 Fluopyram 3.3:1 100:30 X.36 Fluopyram 1:3.3 30:100 X.36 Fluopyram 1:1 30:30 X.36 Benzovindiflupir 1.6:1 100:60 X.36 Benzovindiflupir 5:1 100:20 X.36 Benzovindiflupir 1:2 30:60 X.36 Benzovindiflupir 3:2 30:20 X.36 Pid iflu metof her 1.6:1 100:60 X.36 Pidiflumetofen 5:1 100:20 X.36 Pid iflu metof her 1:2 30:60 X.36 Pid iflu metof her 3:2 30:20

- 237 046405

X.36 Isoflucipram 1.6:1 100:60 X.36 Isoflucipram 5:1 100:20 X.36 Isoflucipram 1:2 30:60 X.36 Isoflucipram 3:2 30:20 X.36 Florylpicoxamide 1.6:1 100:60 X.36 Florylpicoxamide 5:1 100:20 X.36 Florylpicoxamide 1:2 30:60 X.36 Florylpicoxamide 3:2 30:20 X.36 Metharylpicoxamide 1:1 100:100 X.36 Metharylpicoxamide 3.3:1 100:30 X.36 Metharylpicoxamide 1:3.3 30:100 X.36 Metharylpicoxamide 1:1 30:30 X.36 Fosetyl aluminum 1:1 100:100 X.36 Fosetyl aluminum 3.3:1 100:30 X.36 Fosetyl aluminum 1:3.3 30:100 X.36 Fosetyl aluminum 1:1 30:30 X.36 Chlorothalonil 1:1 100:100 X.36 Chlorothalonil 3.3:1 100:30 X.36 Chlorothalonil 1:3.3 30:100 X.36 Chlorothalonil 1:1 30:30 X.36 Mankozeb 1:1 100:100 X.36 Mankozeb 3.3:1 100:30 X.36 Mankozeb 1:3.3 30:100 X.36 Mankozeb 1:1 30:30 X.36 Mandipropamide 1:1 100:100 X.36 Mandipropamide 3.3:1 100:30 X.36 Mandipropamide 1:3.3 30:100 X.36 Mandipropamide 1:1 30:30 X.36 Oxathiapiproline 1:1 100:100 X.36 Oxathiapiproline 3.3:1 100:30 X.36 Oxathiapiproline 1:3.3 30:100 X.36 Oxathiapiproline 1:1 30:30 X.36 Flu Azinam 1:1 100:100 X.36 Flu Azinam 3.3:1 100:30 X.36 Flu Azinam 1:3.3 30:100 X.36 Flu Azinam 1:1 30:30 X.36 Fludioxonil 1:1 100:100 X.36 Fludioxonil 3.3:1 100:30 X.36 Fludioxonil 1:3.3 30:100

- 238 046405

X.36 Fludioxonil 1:1 30:30 X.36 Cyprodinil 1:1 100:100 X.36 Cyprodinil 3.3:1 100:30 X.36 Cyprodinil 1:3.3 30:100 X.36 Cyprodinil 1:1 30:30 X.36 Metalaxyl-M 1:1 100:100 X.36 Metalaxyl-M 3.3:1 100:30 X.36 Metalaxyl-M 1:3.3 30:100 X.36 Metalaxyl-M 1:1 30:30 X.36 Folpet 1:1 100:100 X.36 Folpet 3.3:1 100:30 X.36 Folpet 1:3.3 30:100 X.36 Folpet 1:1 30:30 X.36 T\G-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-T4methylformamidine 1:1 100:100 X.36 T\G-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-T4methylformamidine 3.3:1 100:30 X.36 T\G-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-T4methylformamidine 1:3.3 30:100 X.36 T\G-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-T4-ethyl-T4methylformamidine 1:1 30:30 X.36 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:1 100:100 X.36 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 3.3:1 100:30 X.36 N-H3onponmi-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:3.3 30:100

- 239 046405

X.36 N-H3onponiui-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Imethylformamidine 1:1 30:30 X.36 TAEGRO® 1:1 100:100 X.36 TAEGRO® 3.3:1 100:30 X.36 TAEGRO® 1:3.3 30:100 X.36 TAEGRO® 1:1 30:30 X.36 Timorex GoldTM 1:1 100:100 X.36 Timorex GoldTM 3.3:1 100:30 X.36 Timorex GoldTM 1:3.3 30:100 X.36 Timorex GoldTM 1:1 30:30 X.36 Isofetamide 1.6:1 100:60 X.36 Isofetamide 5:1 100:20 X.36 Isofetamide 1:2 30:60 X.36 Isofetamide 3:2 30:20 X.36 Acibenzolar-C-methyl 1:1 100:100 X.36 Acibenzolar-C-methyl 3.3:1 100:30 X.36 Acibenzolar-C-methyl 1:3.3 30:100 X.36 Acibenzolar-C-methyl 1:1 30:30 X.36 Aminopyrifene 1:1 100:100 X.36 Aminopyrifene 3.3:1 100:30 X.36 Aminopyrifene 1:3.3 30:100 X.36 Aminopyrifene 1:1 30:30 X.36 Cyflufenamide 5:1 100:20 X.36 Cyflufenamide 50:1 100:2 X.36 Cyflufenamide 3:2 30:20 X.36 Cyflufenamide 15:1 30:2 X.36 Metraphenone 5:1 100:20 X.36 Metraphenone 50:1 100:2 X.36 Metraphenone 3:2 30:20 X.36 Metraphenone 15:1 30:2 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 100:100 X.36 T4-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 100:30

- 240 046405

X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 30:100 X.36 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 30:30 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3.3 30:100 X.36 N-(1-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 30:30 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.36 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.36 4,4-difluoro-3, 3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridine-3- 1:1 100:100

- 241 046405

yl)isoquinoline X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 3.3:1 100:30 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.36 4,4-difluoro-3,3-dimethyl-1 (7-methylpyrazolo[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 100:100 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:3.3 30:100 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 100:100 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.36 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 30:30

- 242 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 1.6:1 100:60 X.38 Azoxystrobin 5:1 100:20 X.38 Azoxystrobin 1:2 30:60 X.38 Azoxystrobin 3:2 30:20 X.38 Trifloxystrobin 1.6:1 100:60 X.38 Trifloxystrobin 5:1 100:20 X.38 Trifloxystrobin 1:2 30:60 X.38 Trifloxystrobin 3:2 30:20 X.38 Methyltetraprole 1.6:1 100:60 X.38 Methyltetraprole 5:1 100:20 X.38 Methyltetraprole 1:2 30:60 X.38 Methyltetraprole 3:2 30:20 X.38 Difenoconazole 1.6:1 100:60 X.38 Difenoconazole 5:1 100:20 X.38 Difenoconazole 1:2 30:60 X.38 Difenoconazole 3:2 30:20 X.38 Hexaconazole 1.6:1 100:60 X.38 Hexaconazole 5:1 100:20 X.38 Hexaconazole 1:2 30:60 X.38 Hexaconazole 3:2 30:20 X.38 Propiconazole 1.6:1 100:60 X.38 Propiconazole 5:1 100:20 X.38 Propiconazole 1:2 30:60 X.38 Propiconazole 3:2 30:20 X.38 Prothioconazole 1.6:1 100:60 X.38 Prothioconazole 5:1 100:20 X.38 Prothioconazole 1:2 30:60 X.38 Prothioconazole 3:2 30:20 X.38 Mefentrifluconazole 1.6:1 100:60 X.38 Mefentrifluconazole 5:1 100:20 X.38 Mefentrifluconazole 1:2 30:60 X.38 Mefentrifluconazole 3:2 30:20 X.38 Fenpropidine 1:1 100:100 X.38 Fenpropidine 3.3:1 100:30 X.38 Fenpropidine 1:3.3 30:100 X.38 Fenpropidine 1:1 30:30 X.38 Phenpropimorph 1.6:1 100:60

- 243 046405

X.38 Phenpropimorph 5:1 100:20 X.38 Phenpropimorph 1:2 30:60 X.38 Phenpropimorph 3:2 30:20 X.38 Fluxapyroxad 1.6:1 100:60 X.38 Fluxapyroxad 5:1 100:20 X.38 Fluxapyroxad 1:2 30:60 X.38 Fluxapyroxad 3:2 30:20 X.38 Fluopyram 1:1 100:100 X.38 Fluopyram 3.3:1 100:30 X.38 Fluopyram 1:3.3 30:100 X.38 Fluopyram 1:1 30:30 X.38 Benzovindiflupir 1.6:1 100:60 X.38 Benzovindiflupir 5:1 100:20 X.38 Benzovindiflupir 1:2 30:60 X.38 Benzovindiflupir 3:2 30:20 X.38 Pid iflu metof her 1.6:1 100:60 X.38 Pid iflu metof her 5:1 100:20 X.38 Pid iflu metof her 1:2 30:60 X.38 Pid iflu metof her 3:2 30:20 X.38 Isoflucipram 1.6:1 100:60 X.38 Isoflucipram 5:1 100:20 X.38 Isoflucipram 1:2 30:60 X.38 Isoflucipram 3:2 30:20 X.38 Florylpicoxamide 1.6:1 100:60 X.38 Florylpicoxamide 5:1 100:20 X.38 Florylpicoxamide 1:2 30:60 X.38 Florylpicoxamide 3:2 30:20 X.38 Metar ilpicoxamide 1:1 100:100 X.38 Metar ilpicoxamide 3.3:1 100:30 X.38 Metar ilpicoxamide 1:3.3 30:100 X.38 Metar ilpicoxamide 1:1 30:30 X.38 Fosetyl aluminum 1:1 100:100 X.38 Fosetyl aluminum 3.3:1 100:30 X.38 Fosetyl aluminum 1:3.3 30:100 X.38 Fosetyl aluminum 1:1 30:30 X.38 Chlorothalonil 1:1 100:100 X.38 Chlorothalonil 3.3:1 100:30 X.38 Chlorothalonil 1:3.3 30:100 X.38 Chlorothalonil 1:1 30:30

- 244 046405

X.38 Mankozeb 1:1 100:100 X.38 Mankozeb 3.3:1 100:30 X.38 Mankozeb 1:3.3 30:100 X.38 Mankozeb 1:1 30:30 X.38 Mandipropamide 1:1 100:100 X.38 Mandipropamide 3.3:1 100:30 X.38 Mandipropamide 1:3.3 30:100 X.38 Mandipropamide 1:1 30:30 X.38 Oxathiapiproline 1:1 100:100 X.38 Oxathiapiproline 3.3:1 100:30 X.38 Oxathiapiproline 1:3.3 30:100 X.38 Oxathiapiproline 1:1 30:30 X.38 Flu Azinam 1:1 100:100 X.38 Flu Azinam 3.3:1 100:30 X.38 Flu Azinam 1:3.3 30:100 X.38 Flu Azinam 1:1 30:30 X.38 Fludioxonil 1:1 100:100 X.38 Fludioxonil 3.3:1 100:30 X.38 Fludioxonil 1:3.3 30:100 X.38 Fludioxonil 1:1 30:30 X.38 Cyprodinil 1:1 100:100 X.38 Cyprodinil 3.3:1 100:30 X.38 Cyprodinil 1:3.3 30:100 X.38 Cyprodinil 1:1 30:30 X.38 Metalaxyl-M 1:1 100:100 X.38 Metalaxyl-M 3.3:1 100:30 X.38 Metalaxyl-M 1:3.3 30:100 X.38 Metalaxyl-M 1:1 30:30 X.38 Folpet 1:1 100:100 X.38 Folpet 3.3:1 100:30 X.38 Folpet 1:3.3 30:100 X.38 Folpet 1:1 30:30 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 100:100 X.38 Ν' -[5-bromo-2-methyl-6-(1 methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3.3:1 100:30

- 245 046405

X.38 T\G-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:3.3 30:100 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:1 30:30 X.38 Ν-Η3θπροπιιπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Xmethylformamidine 1:1 100:100 X.38 Ν-Η3θπροπππ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Xmethylformamidine 3.3:1 100:30 X.38 N-H3onponmi-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Xmethylformamidine 1:3.3 30:100 X.38 N-H3onponmi-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Xmethylformamidine 1:1 30:30 X.38 TAEGRO® 1:1 100:100 X.38 TAEGRO® 3.3:1 100:30 X.38 TAEGRO® 1:3.3 30:100 X.38 TAEGRO® 1:1 30:30 X.38 Timorex GoldTM 1:1 100:100 X.38 Timorex GoldTM 3.3:1 100:30 X.38 Timorex GoldTM 1:3.3 30:100 X.38 Timorex GoldTM 1:1 30:30 X.38 Isofetamide 1.6:1 100:60 X.38 Isofetamide 5:1 100:20 X.38 Isofetamide 1:2 30:60 X.38 Isofetamide 3:2 30:20 X.38 Acibenzolar-C-methyl 1:1 100:100 X.38 Acibenzolar-C-methyl 3.3:1 100:30 X.38 Acibenzolar-C-methyl 1:3.3 30:100 X.38 Acibenzolar-C-methyl 1:1 30:30

- 246 046405

X.38 Aminopyrifene 1:1 100:100 X.38 Aminopyrifene 3.3:1 100:30 X.38 Aminopyrifene 1:3.3 30:100 X.38 Aminopyrifene 1:1 30:30 X.38 Cyflufenamide 5:1 100:20 X.38 Cyflufenamide 50:1 100:2 X.38 Cyflufenamide 3:2 30:20 X.38 Cyflufenamide 15:1 30:2 X.38 Metraphenone 5:1 100:20 X.38 Metraphenone 50:1 100:2 X.38 Metraphenone 3:2 30:20 X.38 Metraphenone 15:1 30:2 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 100:100 X.38 N-(l-benzyl-1,3 dimethylbutyl)-8fluoroquinoline-3 carboxamide 3.3:1 100:30 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:3.3 30:100 X.38 X-(1-benzyl-1,3dimethylbutyl)-8fluoroquinoline-3 carboxamide 1:1 30:30 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 100:100 X.38 N-(l-benzyl-3,3,3 trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 3.3:1 100:30 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:3.3 30:100 X.38 N-(l-benzyl-3,3,3trifluoro-1-methylpropyl)8-fluoroquinoline-3 carboxamide 1:1 30:30

- 247 046405

X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 100:100 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.38 1-(6,7d imethylpyrazolo[1,5a]pyridin-3-yl)-4,4,5 trifluoro-3,3dimethylisoquinoline 1:1 30:30 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 100:100 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 3.3:1 100:30 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:3.3 30:100 X.38 4,4-difluoro-3,3-dimethyl-1 (7-methyl pyrazole o[1,5a]pyridin-3yl)isoquinoline 1:1 30:30 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 100:100 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 3.3:1 100:30 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3- 1:3.3 30:100

- 248 046405

dimethylisoquinoline X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4,5-trifluoro-3,3 dimethylisoquinoline 1:1 30:30 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 100:100 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 3.3:1 100:30 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:3.3 30:100 X.38 1-(4,5dimethylbenzimidazol-1yl)-4,4-difluoro-3,3dimethylisoquinoline 1:1 30:30

Example B12. Treatment to prevent leaf disc infection / wheat / Puccinia recondita f sp. tritici (brown rust).

Leaf segments of the Kanzler wheat variety are placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compounds diluted in water. Leaf discs are inoculated with a suspension of fungal spores 1 day after application. Inoculated leaf segments are incubated at 19°C and 75% relative humidity under a 12-hour light/12-hour dark environment in a climate chamber and compound activity is assessed as a percentage of disease control compared to untreated material exhibiting the appropriate degree of damage due to diseases on untreated control leaf segments (7-9 days after application). The following mixture-based formulations (A:B) at the indicated concentration (in ppm) provided at least 80% disease control in this test compared to the untreated control, which showed extensive disease development under the same conditions.

- 249 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.29 Azoxystrobin 1.6:1 100:60 X.29 Azoxystrobin 5:1 100:20 X.29 Azoxystrobin 1:2 30:60 X.29 Azoxystrobin 3:2 30:20 X.29 Trifloxystrobin 1.6:1 100:60 X.29 Trifloxystrobin 5:1 100:20 X.29 Trifloxystrobin 1:2 30:60 X.29 Trifloxystrobin 3:2 30:20 X.29 Methyltetraprole 1.6:1 100:60 X.29 Methyltetraprole 5:1 100:20 X.29 Methyltetraprole 1:2 30:60 X.29 Methyltetraprole 3:2 30:20 X.29 Ciproconazole 1.6:1 100:60 X.29 Ciproconazole 5:1 100:20 X.29 Ciproconazole 1:2 30:60 X.29 Cyproconazole 3:2 30:20 X.29 Difenoconazole 1:1 100:100 X.29 Difenoconazole 3.3:1 100:30 X.29 Difenoconazole 1:3.3 30:100 X.29 Difenoconazole 1:1 30:30 X.29 Hexaconazole 1:1 100:100 X.29 Hexaconazole 3.3:1 100:30 X.29 Hexaconazole 1:3.3 30:100 X.29 Hexaconazole 1:1 30:30 X.29 Propiconazole 1:1 100:100 X.29 Propiconazole 3.3:1 100:30 X.29 Propiconazole 1:3.3 30:100 X.29 Propiconazole 1:1 30:30 X.29 Prothioconazole 1:1 100:100 X.29 Prothioconazole 3.3:1 100:30 X.29 Prothioconazole 1:3.3 30:100 X.29 Prothioconazole 1:1 30:30 X.29 Mefentrifluconazole 1.6:1 100:60 X.29 Mefentrifluconazole 5:1 100:20 X.29 Mefentrifluconazole 1:2 30:60 X.29 Mefentrifluconazole 3:2 30:20 X.29 Fenpropidine 1:1 100:100 X.29 Fenpropidine 3.3:1 100:30 X.29 Fenpropidine 1:3.3 30:100 X.29 Fenpropidine 1:1 30:30

- 250 046405

X.29 Phenpropimorph 1:1 100:100 X.29 Phenpropimorph 3.3:1 100:30 X.29 Phenpropimorph 1:3.3 30:100 X.29 Phenpropimorph 1:1 30:30 X.29 Bixafen 1:1 100:60 X.29 Bixafen 3.3:1 100:20 X.29 Bixafen 1:2 30:60 X.29 Bixafen 3:2 30:20 X.29 Fluxapyroxad 1.6:1 100:60 X.29 Fluxapyroxad 5:1 100:20 X.29 Fluxapyroxad 1:2 30:60 X.29 Fluxapyroxad 3:2 30:20 X.29 Fluopyram 1:1 100:100 X.29 Fluopyram 3.3:1 100:30 X.29 Fluopyram 1:3.3 30:100 X.29 Fluopyram 1:1 30:30 X.29 Benzovindiflupir 1.6:1 100:60 X.29 Benzovindiflupir 5:1 100:20 X.29 Benzovindiflupir 1:2 30:60 X.29 Benzovindiflupir 3:2 30:20 X.29 Pid iflu metof en 1:1 100:100 X.29 Pid iflu metof en 3.3:1 100:30 X.29 Pid iflu metof en 1:3.3 30:100 X.29 Pid iflu metof en 1:1 30:30 X.29 Isoflucipram 1.6:1 100:60 X.29 Isoflucipram 5:1 100:20 X.29 Isoflucipram 1:2 30:60 X.29 Isoflucipram 3:2 30:20 X.29 Fluindapir 1.6:1 100:60 X.29 Fluindapir 5:1 100:20 X.29 Fluindapir 1:2 30:60 X.29 Fluindapir 3:2 30:20 X.29 Florylpicoxamide 1:1 100:100 X.29 Florylpicoxamide 3.3:1 100:30 X.29 Florylpicoxamide 1:3.3 30:100 X.29 Florylpicoxamide 1:1 30:30 X.29 Metharylpicoxamide 1.6:1 100:60 X.29 Metharylpicoxamide 5:1 100:20 X.29 Metharylpicoxamide 1:2 30:60

- 251 046405

X.29 Metharylpicoxamide 3:2 30:20 X.29 Fosetyl aluminum 1:1 100:100 X.29 Fosetyl aluminum 3.3:1 100:30 X.29 Fosetyl aluminum 1:3.3 30:100 X.29 Fosetyl aluminum 1:1 30:30 X.29 Chlorothalonil 1:1 100:100 X.29 Chlorothalonil 3.3:1 100:30 X.29 Chlorothalonil 1:3.3 30:100 X.29 Chlorothalonil 1:1 30:30 X.29 Mankozeb 1:1 100:100 X.29 Mankozeb 3.3:1 100:30 X.29 Mankozeb 1:3.3 30:100 X.29 Mankozeb 1:1 30:30 X.29 Mandipropamide 1:1 100:100 X.29 Mandipropamide 3.3:1 100:30 X.29 Mandipropamide 1:3.3 30:100 X.29 Mandipropamide 1:1 30:30 X.29 Oxathiapiproline 1:1 100:100 X.29 Oxathiapiproline 3.3:1 100:30 X.29 Oxathiapiproline 1:3.3 30:100 X.29 Oxathiapiproline 1:1 30:30 X.29 Fluazinam 1:1 100:100 X.29 Fluazinam 3.3:1 100:30 X.29 Fluazinam 1:3.3 30:100 X.29 Fluazinam 1:1 30:30 X.29 Fludioxonil 1:1 100:100 X.29 Fludioxonil 3.3:1 100:30 X.29 Fludioxonil 1:3.3 30:100 X.29 Fludioxonil 1:1 30:30 X.29 Cyprodinil 1:1 100:100 X.29 Cyprodinil 3.3:1 100:30 X.29 Cyprodinil 1:3.3 30:100 X.29 Cyprodinil 1:1 30:30 X.29 Metalaxyl-M 1:1 100:100 X.29 Metalaxyl-M 3.3:1 100:30 X.29 Metalaxyl-M 1:3.3 30:100 X.29 Metalaxyl-M 1:1 30:30 X.29 Folpet eleven 100:100

- 252 046405

X.29 Folpet 3.3:1 100:30 X.29 Folpet 1:3.3 30:100 X.29 Folpet 1:1 30:30 X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1.6:1 100:60 X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 5:1 100:20 X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:2 30:60 X.29 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3:2 30:20 X.29 N-H3onponna-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1.6:1 100:60 X.29 Ν-π3θπροπηπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 5:1 100:20 X.29 Ν-π3θπροπηπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:2 30:60 X.29 Ν-π3θπροπηπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 3:2 30:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20

- 253 046405

X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1:2 30:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 3:2 30:20 X.29 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.29 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.29 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.29 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.29 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.29 methyl-(2)-2-(5cyclopentyl-2methylphenoxy)-3 - 5:1 100:20

- 254 046405

methoxyprop-2-enoate X.29 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.29 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.29 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.29 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.29 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1:2 30:60 X.29 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 5:1 100:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 3:2 30:20 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[4- 5:1 100:20 (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:2 30:60 X.29 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

- 255 046405

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.36 Azoxystrobin 1.6:1 100:60 X.36 Azoxystrobin 5:1 100:20 X.36 Azoxystrobin 1:2 30:60 X.36 Azoxystrobin 3:2 30:20 X.36 Trifloxystrobin 1.6:1 100:60 X.36 Trifloxystrobin 5:1 100:20 X.36 Trifloxystrobin 1:2 30:60 X.36 Trifloxystrobin 3:2 30:20 X.36 Methyltetraprole 1.6:1 100:60 X.36 Methyltetraprole 5:1 100:20 X.36 Methyltetraprole 1:2 30:60 X.36 Methyltetraprole 3:2 30:20 X.36 Cyproconazole 1.6:1 100:60 X.36 Ciproconazole 5:1 100:20 X.36 Ciproconazole 1:2 30:60 X.36 Ciproconazole 3:2 30:20 X.36 Difenoconazole 1:1 100:100 X.36 Difenoconazole 3.3:1 100:30 X.36 Difenoconazole 1:3.3 30:100 X.36 Difenoconazole 1:1 30:30 X.36 Hexaconazole 1:1 100:100 X.36 Hexaconazole 3.3:1 100:30 X.36 Hexaconazole 1:3.3 30:100 X.36 Hexaconazole 1:1 30:30 X.36 Propiconazole 1:1 100:100 X.36 Propiconazole 3.3:1 100:30 X.36 Propiconazole 1:3.3 30:100 X.36 Propiconazole 1:1 30:30

- 256 046405

X.36 Prothioconazole 1:1 100:100 X.36 Prothioconazole 3.3:1 100:30 X.36 Pr otioconazole 1:3.3 30:100 X.36 Pr otioconazole 1:1 30:30 X.36 Mefentrifluconazole 1.6:1 100:60 X.36 Mefentrifluconazole 5:1 100:20 X.36 Mefentrifluconazole 1:2 30:60 X.36 Mefentrifluconazole 3:2 30:20 X.36 Fenpropidine 1:1 100:100 X.36 Fenpropidine 3.3:1 100:30 X.36 Fenpropidine 1:3.3 30:100 X.36 Fenpropidine 1:1 30:30 X.36 Phenpropimorph 1:1 100:100 X.36 Phenpropimorph 3.3:1 100:30 X.36 Phenpropimorph 1:3.3 30:100 X.36 Phenpropimorph 1:1 30:30 X.36 Bixafen 1:1 100:60 X.36 Bixafen 3.3:1 100:20 X.36 Bixafen 1:2 30:60 X.36 Bixafen 3:2 30:20 X.36 Fluxapyroxad 1.6:1 100:60 X.36 Fluxapyroxad 5:1 100:20 X.36 Fluxapyroxad 1:2 30:60 X.36 Fluxapyroxad 3:2 30:20 X.36 Fluopyram 1:1 100:100 X.36 Fluopyram 3.3:1 100:30 X.36 Fluopyram 1:3.3 30:100 X.36 Fluopyram 1:1 30:30 X.36 Benzovindiflupir 1.6:1 100:60 X.36 Benzovindiflupir 5:1 100:20 X.36 Benzovindiflupir 1:2 30:60 X.36 Benzovindiflupir 3:2 30:20 X.36 Pid iflu metof en 1:1 100:100 X.36 Pid iflu metof en 3.3:1 100:30 X.36 Pid iflu metof en 1:3.3 30:100 X.36 Pid iflu metof en 1:1 30:30 X.36 Isoflucipram 1.6:1 100:60 X.36 Isoflucipram 5:1 100:20 X.36 Isoflucipram 1:2 30:60

- 257 046405

X.36 Isoflucipram 3:2 30:20 X.36 Fluindapir 1.6:1 100:60 X.36 Fluindapir 5:1 100:20 X.36 Fluindapir 1:2 30:60 X.36 Fluindapir 3:2 30:20 X.36 Florylpicoxamide 1:1 100:100 X.36 Florylpicoxamide 3.3:1 100:30 X.36 Florylpicoxamide 1:3.3 30:100 X.36 Florylpicoxamide 1:1 30:30 X.36 Metharylpicoxamide 1.6:1 100:60 X.36 Metharylpicoxamide 5:1 100:20 X.36 Metharylpicoxamide 1:2 30:60 X.36 Metharylpicoxamide 3:2 30:20 X.36 Fosetyl aluminum 1:1 100:100 X.36 Fosetyl aluminum 3.3:1 100:30 X.36 Fosetyl aluminum 1:3.3 30:100 X.36 Fosetyl aluminum 1:1 30:30 X.36 Chlorothalonil 1:1 100:100 X.36 Chlorothalonil 3.3:1 100:30 X.36 Chlorothalonil 1:3.3 30:100 X.36 Chlorothalonil 1:1 30:30 X.36 Mankozeb 1:1 100:100 X.36 Mankozeb 3.3:1 100:30 X.36 Mankozeb 1:3.3 30:100 X.36 Mankozeb 1:1 30:30 X.36 Mandipropamide 1:1 100:100 X.36 Mandipropamide 3.3:1 100:30 X.36 Mandipropamide 1:3.3 30:100 X.36 Mandipropamide 1:1 30:30 X.36 Oxathiapiproline 1:1 100:100 X.36 Oxathiapiproline 3.3:1 100:30 X.36 Oxathiapiproline 1:3.3 30:100 X.36 Oxathiapiproline 1:1 30:30 X.36 Fluazinam 1:1 100:100 X.36 Fluazinam 3.3:1 100:30 X.36 Fluazinam 1:3.3 30:100 X.36 Fluazinam 1:1 30:30 X.36 Fludioxonil 1:1 100:100

- 258 046405

X.36 Fludioxonil 3.3:1 100:30 X.36 Fludioxonil 1:3.3 30:100 X.36 Fludioxonil 1:1 30:30 X.36 Cyprodinil 1:1 100:100 X.36 Cyprodinil 3.3:1 100:30 X.36 Cyprodinil 1:3.3 30:100 X.36 Cyprodinil 1:1 30:30 X.36 Metalaxyl-M 1:1 100:100 X.36 Metalaxyl-M 3.3:1 100:30 X.36 Metalaxyl-M 1:3.3 30:100 X.36 Metalaxyl-M 1:1 30:30 X.36 Folpet 1:1 100:100 X.36 Folpet 3.3:1 100:30 X.36 Folpet 1:3.3 30:100 X.36 Folpet 1:1 30:30 X.36 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1.6:1 100:60 X.36 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 5:1 100:20 X.36 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:2 30:60 X.36 LG-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 3:2 30:20 X.36 Ν-π3θπροπππ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1.6:1 100:60 X.36 Ν-π3θπροπππ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 5:1 100:20 X.36 Ν-π3θπροπππ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1 -hydroxy-1 - 1:2 30:60

- 259 046405

phenylethyl)phenyl]-Xmethylformamidine X.36 Ν-Η3θπροπιιπ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 3:2 30:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1:2 30:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 3:2 30:20 X.36 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.36 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20

- 260 046405

X.36 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.36 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.36 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.36 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.36 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.36 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.36 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.36 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.36 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1:2 30:60 X.36 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazole-2- 5:1 100:20

- 261 046405

yl)phenoxy]prop-2-enoate X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 3:2 30:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 5:1 100:20 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:2 30:60 X.36 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

Component A (Connection) Component B A:B ratio Conc, (ppm) (A:B) X.38 Azoxystrobin 1.6:1 100:60 X.38 Azoxystrobin 5:1 100:20 X.38 Azoxystrobin 1:2 30:60 X.38 Azoxystrobin 3:2 30:20 X.38 Trifloxystrobin 1.6:1 100:60 X.38 Trifloxystrobin 5:1 100:20 X.38 Trifloxystrobin 1:2 30:60 X.38 Trifloxystrobin 3:2 30:20 X.38 Methyltetraprole 1.6:1 100:60 X.38 Methyltetraprole 5:1 100:20 X.38 Methyltetraprole 1:2 30:60 X.38 Methyltetraprole 3:2 30:20 X.38 Ciproconazole 1.6:1 100:60 X.38 Ciproconazole 5:1 100:20 X.38 Ciproconazole 1:2 30:60 X.38 Ciproconazole 3:2 30:20

- 262 046405

X.38 Difenoconazole 1:1 100:100 X.38 Difenoconazole 3.3:1 100:30 X.38 Difenoconazole 1:3.3 30:100 X.38 Difenoconazole 1:1 30:30 X.38 Hexaconazole 1:1 100:100 X.38 Hexaconazole 3.3:1 100:30 X.38 Hexaconazole 1:3.3 30:100 X.38 Hexaconazole 1:1 30:30 X.38 Propiconazole 1:1 100:100 X.38 Propiconazole 3.3:1 100:30 X.38 Propiconazole 1:3.3 30:100 X.38 Propiconazole 1:1 30:30 X.38 Prothioconazole 1:1 100:100 X.38 Prothioconazole 3.3:1 100:30 X.38 Prothioconazole 1:3.3 30:100 X.38 Prothioconazole 1:1 30:30 X.38 Mefentrifluconazole 1.6:1 100:60 X.38 Mefentrifluconazole 5:1 100:20 X.38 Mefentrifluconazole 1:2 30:60 X.38 Mefentrifluconazole 3:2 30:20 X.38 Fenpropidine 1:1 100:100 X.38 Fenpropidine 3.3:1 100:30 X.38 Fenpropidine 1:3.3 30:100 X.38 Fenpropidine 1:1 30:30 X.38 Phenpropimorph 1:1 100:100 X.38 Phenpropimorph 3.3:1 100:30 X.38 Phenpropimorph 1:3.3 30:100 X.38 Phenpropimorph 1:1 30:30 X.38 Bixafen 1:1 100:60 X.38 Bixafen 3.3:1 100:20 X.38 Bixafen 1:2 30:60 X.38 Bixafen 3:2 30:20 X.38 Fluxapyroxad 1.6:1 100:60 X.38 Fluxapyroxad 5:1 100:20 X.38 Fluxapyroxad 1:2 30:60 X.38 Fluxapyroxad 3:2 30:20 X.38 Fluopyram 1:1 100:100 X.38 Fluopyram 3.3:1 100:30 X.38 Fluopyram 1:3.3 30:100

- 263 046405

X.38 Fluopyram 1:1 30:30 X.38 Benzovindiflupir 1.6:1 100:60 X.38 Benzovindiflupir 5:1 100:20 X.38 Benzovindiflupir 1:2 30:60 X.38 Benzovindiflupir 3:2 30:20 X.38 Pid iflu metof en 1:1 100:100 X.38 Pidiflumetofen 3.3:1 100:30 X.38 Pid iflu metof en 1:3.3 30:100 X.38 Pid iflu metof en 1:1 30:30 X.38 Isoflucipram 1.6:1 100:60 X.38 Isoflucipram 5:1 100:20 X.38 Isoflucipram 1:2 30:60 X.38 Isoflucipram 3:2 30:20 X.38 Fluindapir 1.6:1 100:60 X.38 Fluindapir 5:1 100:20 X.38 Fluindapir 1:2 30:60 X.38 Fluindapir 3:2 30:20 X.38 Florylpicoxamide 1:1 100:100 X.38 Florylpicoxamide 3.3:1 100:30 X.38 Florylpicoxamide 1:3.3 30:100 X.38 Florylpicoxamide 1:1 30:30 X.38 Metharylpicoxamide 1.6:1 100:60 X.38 Metharylpicoxamide 5:1 100:20 X.38 Metharylpicoxamide 1:2 30:60 X.38 Metharylpicoxamide 3:2 30:20 X.38 Fosetyl aluminum 1:1 100:100 X.38 Fosetyl aluminum 3.3:1 100:30 X.38 Fosetyl aluminum 1:3.3 30:100 X.38 Fosetyl aluminum 1:1 30:30 X.38 Chlorothalonil 1:1 100:100 X.38 Chlorothalonil 3.3:1 100:30 X.38 Chlorothalonil 1:3.3 30:100 X.38 Chlorothalonil 1:1 30:30 X.38 Mankozeb 1:1 100:100 X.38 Mankozeb 3.3:1 100:30 X.38 Mankozeb 1:3.3 30:100 X.38 Mankozeb 1:1 30:30 X.38 Mandipropamide 1:1 100:100

- 264 046405

X.38 Mandipropamide 3.3:1 100:30 X.38 Mandipropamide 1:3.3 30:100 X.38 Mandipropamide 1:1 30:30 X.38 Oxathiapiproline 1:1 100:100 X.38 Oxathiapiproline 3.3:1 100:30 X.38 Oxathiapiproline 1:3.3 30:100 X.38 Oxathiapiproline 1:1 30:30 X.38 Fluazinam 1:1 100:100 X.38 Fluazinam 3.3:1 100:30 X.38 Fluazinam 1:3.3 30:100 X.38 Fluazinam 1:1 30:30 X.38 Fludioxonil 1:1 100:100 X.38 Fludioxonil 3.3:1 100:30 X.38 Fludioxonil 1:3.3 30:100 X.38 Fludioxonil 1:1 30:30 X.38 Cyprodinil 1:1 100:100 X.38 Cyprodinil 3.3:1 100:30 X.38 Cyprodinil 1:3.3 30:100 X.38 Cyprodinil 1:1 30:30 X.38 Metalaxyl-M 1:1 100:100 X.38 Metalaxyl-M 3.3:1 100:30 X.38 Metalaxyl-M 1:3.3 30:100 X.38 Metalaxyl-M 1:1 30:30 X.38 Folpet 1:1 100:100 X.38 Folpet 3.3:1 100:30 X.38 Folpet 1:3.3 30:100 X.38 Folpet 1:1 30:30 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1.6:1 100:60 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 5:1 100:20 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-Xmethylformamidine 1:2 30:60 X.38 X'-[5-bromo-2-methyl-6-(1methyl-2-propoxyethoxy)3-pyridyl]-X-ethyl-X- 3:2 30:20

- 265 046405

methylformamidine X.38 N-H3onponiin-N'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1.6:1 100:60 X.38 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 5:1 100:20 X.38 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:2 30:60 X.38 Ν-Η3θπροπΗΠ-Ν'-[5methoxy-2-methyl-4-(2,2,2trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 3:2 30:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 5:1 100:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:2 30:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[3(trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 3:2 30:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 5:1 100:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(3- 1:2 30:60

- 266 046405

propylpyrazol-1 yl)phenoxy]prop-2-enoate X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(3propylpyrazol-1 yl)phenoxy]prop-2-enoate 3:2 30:20 X.38 methyl (2)-2-(5cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.38 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.38 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.38 methyl-(2)-2-(5- cyclohexyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.38 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1.6:1 100:60 X.38 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 5:1 100:20 X.38 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 1:2 30:60 X.38 methyl (2)-2-(5cyclopentyl-2methylphenoxy)-3 methoxyprop-2-enoate 3:2 30:20 X.38 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 1.6:1 100:60 X.38 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 5:1 100:20 X.38 methyl-(2)-2-[5-(3- 1:2 30:60

- 267 046405

isopropylpyrazol-1-yl)2-methylphenoxy]-3 methoxyprop-2-enoate X.38 methyl (2)-2-[5-(3isopropylpyrazol-1 -yl)2-methylphenoxy]-3 methoxyprop-2-enoate 3:2 30:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1.6:1 100:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 5:1 100:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 1:2 30:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-(4propyltriazol-2yl)phenoxy]prop-2-enoate 3:2 30:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1.6:1 100:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 5:1 100:20 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:2 30:60 X.38 methyl-(2)-3-methoxy-2-[2methyl-5-[4- (trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 3:2 30:20

Example B13. Treatment to prevent infestation / soybean / Phakopsora pachyrhizi / (soybean rust).

Soybean leaf disks were placed on aqueous agar solution in multiwell plates (24-well format) and sprayed with the formulated test compounds diluted in water. One day after application, leaf discs were inoculated by spraying a spore suspension onto the lower surface of the leaf. After an incubation period of 24-36 hours in the climate chamber in the dark at 20°C and 75% relative humidity, the leaf disc was kept at 20°C with 12 hours of light/day and 75% relative humidity. The activity of the mixture composition was assessed as a percentage of disease control compared to untreated material when the corresponding degree of disease damage was observed on untreated control leaf discs (12-14 days after application). The following mixture formulations (A:B) at the indicated concentration (in ppm) provided at least 70% disease control in this test compared to the untreated control, which under the same conditions showed extensive disease development.

- 268 046405

Component A (Connection) Component B A:B ratio Conc. (PPt) (A:B) X.29 Azoxystrobin 2:1 200:100 X.29 Azoxystrobin 6.6:1 200:30 X.29 Azoxystrobin 1:1.6 60:100 X.29 Azoxystrobin 2:1 60:30 X.29 Trifloxystrobin 2:1 200:100 X.29 Trifloxystrobin 6.6:1 200:30 X.29 Trifloxystrobin 1:1.6 60:100 X.29 Trifloxystrobin 2:1 60:30 X.29 Methyltetraprole 2:1 200:100 X.29 Methyltetraprole 6.6:1 200:30 X.29 Methyltetraprole 1:1.6 60:100 X.29 Methyltetraprole 2:1 60:30 X.29 Ciproconazole 2:1 200:100 X.29 Ciproconazole 6.6:1 200:30 X.29 Cyproconazole 1:1.6 60:100 X.29 Ciproconazole 2:1 60:30 X.29 Difenoconazole 2:1 200:100 X.29 Difenoconazole 6.6:1 200:30 X.29 Difenoconazole 1:1.6 60:100 X.29 Difenoconazole 2:1 60:30 X.29 Hexaconazole 2:1 200:100 X.29 Hexaconazole 6.6:1 200:30 X.29 Hexaconazole 1:1.6 60:100

- 269 046405

X.29 Hexaconazole 2:1 60:30 X.29 Prothioconazole 2:1 200:100 X.29 Prothioconazole 6.6:1 200:30 X.29 Prothioconazole 1:1.6 60:100 X.29 Prothioconazole 2:1 60:30 X.29 Mefentrifluconazole 2:1 200:100 X.29 Mefentrifluconazole 6.6:1 200:30 X.29 Mefentrifluconazole 1:1.6 60:100 X.29 Mefentrifluconazole 2:1 60:30 X.29 Fenpropidine 2:1 200:100 X.29 Fenpropidine 6.6:1 200:30 X.29 Fenpropidine 1:1.6 60:100 X.29 Fenpropidine 2:1 60:30 X.29 Phenpropimorph 2:1 200:100 X.29 Phenpropimorph 6.6:1 200:30 X.29 Phenpropimorph 1:1.6 60:100 X.29 Phenpropimorph 2:1 60:30 X.29 Fluxapyroxad 2:1 200:100 X.29 Fluxapyroxad 6.6:1 200:30 X.29 Fluxapyroxad 1:1.6 60:100 X.29 Fluxapyroxad 2:1 60:30 X.29 Fluopyram 2:1 200:100 X.29 Fluopyram 6.6:1 200:30 X.29 Fluopyram 1:1.6 60:100 X.29 Fluopyram 2:1 60:30 X.29 Benzovindiflupir 33.3:1 200:6 X.29 Benzovindiflupir 100:1 200:2 X.29 Benzovindiflupir 10:1 60:6 X.29 Benzovindiflupir 30:1 60:2 X.29 Pidiflumetofen 2:1 200:100 X.29 Pidiflumetofen 6.6:1 200:30 X.29 Pidiflumetofen 1:1.6 60:100 X.29 Pidiflumetofen 2:1 60:30 X.29 Fluindapir 3.3:1 200:60 X.29 Fluindapir 33.3:1 200:6 X.29 Fluindapir 1:1 60:60 X.29 Fluindapir 10:1 60:6 X.29 Florylpicoxamide 2:1 200:100

- 270 046405

X.29 Florylpicoxamide 6.6:1 200:30 X.29 Florylpicoxamide 1:1.6 60:100 X.29 Florylpicoxamide 2:1 60:30 X.29 Metharylpicoxamide 3.3:1 200:60 X.29 Metharylpicoxamide 33.3:1 200:6 X.29 Metharylpicoxamide 1:1 60:60 X.29 Metharylpicoxamide 10:1 60:6 X.29 Chlorothalonil 2:1 200:100 X.29 Chlorothalonil 6.6:1 200:30 X.29 Chlorothalonil 1:1.6 60:100 X.29 Chlorothalonil 2:1 60:30 X.29 Mankozeb 2:1 200:100 X.29 Mankozeb 6.6:1 200:30 X.29 Mankozeb 1:1.6 60:100 X.29 Mankozeb 2:1 60:30 X.29 Mandipropamide 2:1 200:100 X.29 Mandipropamide 6.6:1 200:30 X.29 Mandipropamide 1:1.6 60:100 X.29 Mandipropamide 2:1 60:30 X.29 Oxathiapiproline 2:1 200:100 X.29 Oxathiapiproline 6.6:1 200:30 X.29 Oxathiapiproline 1:1.6 60:100 X.29 Oxathiapiproline 2:1 60:30 X.29 Fludioxonil 2:1 200:100 X.29 Fludioxonil 6.6:1 200:30 X.29 Fludioxonil 1:1.6 60:100 X.29 Fludioxonil 2:1 60:30 X.29 Cyprodinil 2:1 200:100 X.29 Cyprodinil 6.6:1 200:30 X.29 Cyprodinil 1:1.6 60:100 X.29 Cyprodinil 2:1 60:30 X.29 Metalaxyl-M 2:1 200:100 X.29 Metalaxyl-M 6.6:1 200:30 X.29 Metalaxyl-M 1:1.6 60:100 X.29 Metalaxyl-M 2:1 60:30 X.29 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-M-ethyl-Mmethylformamidine 2:1 200:100 X.29 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-X-ethyl-X- 6.6:1 200:30

- 271 046405

methylformamidine X.29 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-M-ethyl-Mmethylformamidine 1:1.6 60:100 X.29 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-T4-ethyl-T4methylformamidine 2:1 60:30 X.29 X-isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine 2:1 200:100 X.29 T4-isopropyl-T4'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine 6.6:1 200:30 X.29 T4-isopropyl-T4'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine 1:1.6 60:100 X.29 T4-isopropyl-T4'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-M-methylformamidine 2:1 60:30 X.29 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.29 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.29 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.29 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 60:30 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 2:1 200:100 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 6.6:1 200:30 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 1:1.6 60:100 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 2:1 60:30 X.29 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100

- 272 046405

X.29 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.29 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.29 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.29 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.29 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.29 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.29 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.29 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 200:100 X.29 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 6.6:1 200:30 X.29 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 1:1.6 60:100 X.29 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop-2enoate 2:1 60:30 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.29 methyl (2)-3 -methoxy-2-[2-methyl-5 -(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.29 methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.29 methyl (2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.29 methyl-(2)-3-methoxy-2-[2-methyl-5-[4- 1:1.6 60:100

- 273 046405

(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate X.29 methyl (7)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 60:30 X.29 TAEGRO® 2:1 200:100 X.29 TAEGRO® 6.6:1 200:30 X.29 TAEGRO® 1:1.6 60:100 X.29 TAEGRO® 2:1 60:30 X.29 Timorex GoldTM 2:1 200:100 X.29 Timorex GoldTM 6.6:1 200:30 X.29 Timorex GoldTM 1:1.6 60:100 X.29 Timorex GoldTM 2:1 60:30 X.29 N-methoxy-N - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxamide 3.3:1 200:60 X.29 N-methoxy-N - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxamide 33.3:1 200:6 X.29 N-methoxy-N - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxamide 1:1 60:60 X.29 N-methoxy-N - [[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxamide 10:1 60:6 X.29 X,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.29 X,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.29 X,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.29 X,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.29 N-ethyl-2-methyl^ - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60

- 274 046405

X.29 N-ethy l-2-methyl l-N - [[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.29 N-ethyl-2-methyl-N - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.29 N-ethyl-2-methyl-N - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.29 1-methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.29 1-methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.29 1-methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.29 1-methoxy-3-methyl-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.29 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.29 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.29 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.29 1,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.29 3-ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.29 3-ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.29 3-ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.29 3-ethyl-1-methoxy-1 - [[4-[5 (trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.29 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate 3.3:1 200:60 X.29 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate 33.3:1 200:6 X.29 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate 1:1 60:60 X.29 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]pyrazole4-carboxylate 10:1 60:6

- 275 046405

Component A Ratio Conc. Component B (ppsh) (Compound) A:B (A:B) X.36 Azoxystrobin 2:1 200:100 X.36 Azoxystrobin 6.6:1 200:30 X.36 Azoxystrobin 1:1.6 60:100 X.36 Azoxystrobin 2:1 60:30 X.36 Trifloxystrobin 2:1 200:100 X.36 Trifloxystrobin 6.6:1 200:30 X.36 Trifloxystrobin 1:1.6 60:100 X.36 Trifloxystrobin 2:1 60:30 X.36 Methyltetraprole 2:1 200:100 X.36 Methyltetraprole 6.6:1 200:30 X.36 Methyltetraprole 1:1.6 60:100 X.36 Methyltetraprole 2:1 60:30 X.36 Ciproconazole 2:1 200:100 X.36 Ciproconazole 6.6:1 200:30 X.36 Ciproconazole 1:1.6 60:100 X.36 Ciproconazole 2:1 60:30 X.36 Difenoconazole 2:1 200:100 X.36 Difenoconazole 6.6:1 200:30 X.36 Difenoconazole 1:1.6 60:100 X.36 Difenoconazole 2:1 60:30 X.36 Hexaconazole 2:1 200:100 X.36 Hexaconazole 6.6:1 200:30 X.36 Hexaconazole 1:1.6 60:100 X.36 Hexaconazole 2:1 60:30 X.36 Prothioconazole 2:1 200:100 X.36 Prothioconazole 6.6:1 200:30

- 276 046405

X.36 Prothioconazole 1:1.6 60:100 X.36 Prothioconazole 2:1 60:30 X.36 Mefentrifluconazole 2:1 200:100 X.36 Mefentrifluconazole 6.6:1 200:30 X.36 Mefentrifluconazole 1:1.6 60:100 X.36 Mefentrifluconazole 2:1 60:30 X.36 Fenpropidine 2:1 200:100 X.36 Fenpropidine 6.6:1 200:30 X.36 Fenpropidine 1:1.6 60:100 X.36 Fenpropidine 2:1 60:30 X.36 Phenpropimorph 2:1 200:100 X.36 Phenpropimorph 6.6:1 200:30 X.36 Phenpropimorph 1:1.6 60:100 X.36 Phenpropimorph 2:1 60:30 X.36 Fluxapyroxad 2:1 200:100 X.36 Fluxapyroxad 6.6:1 200:30 X.36 Fluxapyroxad 1:1.6 60:100 X.36 Fluxapyroxad 2:1 60:30 X.36 Fluopyram 2:1 200:100 X.36 Fluopyram 6.6:1 200:30 X.36 Fluopyram 1:1.6 60:100 X.36 Fluopyram 2:1 60:30 X.36 Benzovindiflupir 33.3:1 200:6 X.36 Benzovindiflupir 100:1 200:2 X.36 Benzovindiflupir 10:1 60:6 X.36 Benzovindiflupir 30:1 60:2 X.36 Pidiflumetofen 2:1 200:100 X.36 Pidiflumetofen 6.6:1 200:30 X.36 Pidiflumetofen 1:1.6 60:100 X.36 Pidiflumetofen 2:1 60:30 X.36 Fluindapir 3.3:1 200:60 X.36 Fluindapir 33.3:1 200:6 X.36 Fluindapir 1:1 60:60 X.36 Fluindapir 10:1 60:6 X.36 Florylpicoxamide 2:1 200:100 X.36 Florylpicoxamide 6.6:1 200:30 X.36 Florylpicoxamide 1:1.6 60:100 X.36 Florylpicoxamide 2:1 60:30

- 277 046405

X.36 Metharylpicoxamide 3.3:1 200:60 X.36 Metharylpicoxamide 33.3:1 200:6 X.36 Metharylpicoxamide 1:1 60:60 X.36 Metharylpicoxamide 10:1 60:6 X.36 Chlorothalonil 2:1 200:100 X.36 Chlorothalonil 6.6:1 200:30 X.36 Chlorothalonil 1:1.6 60:100 X.36 Chlorothalonil 2:1 60:30 X.36 Mankozeb 2:1 200:100 X.36 Mankozeb 6.6:1 200:30 X.36 Mankozeb 1:1.6 60:100 X.36 Mankozeb 2:1 60:30 X.36 Mandipropamide 2:1 200:100 X.36 Mandipropamide 6.6:1 200:30 X.36 Mandipropamide 1:1.6 60:100 X.36 Mandipropamide 2:1 60:30 X.36 Oxathiapiproline 2:1 200:100 X.36 Oxathiapiproline 6.6:1 200:30 X.36 Oxathiapiproline 1:1.6 60:100 X.36 Oxathiapiproline 2:1 60:30 X.36 Fludioxonil 2:1 200:100 X.36 Fludioxonil 6.6:1 200:30 X.36 Fludioxonil 1:1.6 60:100 X.36 Fludioxonil 2:1 60:30 X.36 Cyprodinil 2:1 200:100 X.36 Cyprodinil 6.6:1 200:30 X.36 Cyprodinil 1:1.6 60:100 X.36 Cyprodinil 2:1 60:30 X.36 Metalaxyl-M 2:1 200:100 X.36 Metalaxyl-M 6.6:1 200:30 X.36 Metalaxyl-M 1:1.6 60:100 X.36 Metalaxyl-M 2:1 60:30 X.36 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 2:1 200:100 X.36 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 6.6:1 200:30 X.36 X'-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 1:1.6 60:100

- 278 046405

X.36 LG-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 2:1 60:30 X.36 L>G-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 2:1 200:100 X.36 T\G-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 6.6:1 200:30 X.36 T\G-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:1.6 60:100 X.36 T\G-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 2:1 60:30 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 60:30 X.36 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 2:1 200:100 X.36 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 6.6:1 200:30 X.36 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 1:1.6 60:100 X.36 methyl (2)-3 -methoxy-2-[2-methyl-5 -(3 propylpyrazol-1 -yl)phenoxy]prop-2enoate 2:1 60:30 X.36 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.36 methyl-(2)-2-(5-cyclohexyl-2- 6.6:1 200:30

- 279 046405

methylphenoxy)-3-methoxyprop-2-enoate X.36 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.36 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.36 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.36 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.36 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.36 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.36 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 2:1 200:100 X.36 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 6.6:1 200:30 X.36 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 1:1.6 60:100 X.36 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 2:1 60:30 X.36 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.36 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.36 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.36 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazole-2- 1:1.6 60:100

- 280 046405

yl]phenoxy]prop-2-enoate X.36 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 60:30 X.36 TAEGRO® 2:1 200:100 X.36 TAEGRO® 6.6:1 200:30 X.36 TAEGRO® 1:1.6 60:100 X.36 TAEGRO® 2:1 60:30 X.36 Timorex GoldTM 2:1 200:100 X.36 Timorex GoldTM 6.6:1 200:30 X.36 Timorex GoldTM 1:1.6 60:100 X.36 Timorex GoldTM 2:1 60:30 X.36 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 3.3:1 200:60 X.36 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 33.3:1 200:6 X.36 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 1:1 60:60 X.36 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 10:1 60:6 X.36 X,2-dimethoxy-T4-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.36 X,2-dimethoxy-T4-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.36 X,2-dimethoxy-T4-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.36 X,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.36 X-ethyl-2-methyl-T4-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3 yl]phenyl]methyl]propanamide 3.3:1 200:60 X.36 X-ethyl-2-methyl-T4-[[4-[5- 33.3:1 200:6

- 281 046405

(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide X.36 X-ethyl-2-methyl-X-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.36 X-ethyl-2-methyl-X-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.36 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.36 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.36 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.36 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.36 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.36 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.36 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.36 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.36 3-ethyl-1-methoxy-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.36 3-ethyl-1-methoxy-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.36 3-ethyl-1-methoxy-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.36 3-ethyl-1-methoxy-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.36 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4- 3.3:1 200:60

- 282 046405

oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate X.36 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 33.3:1 200:6 X.36 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 1:1 60:60 X.36 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 10:1 60:6

Component A (Connection) Component B A:B ratio Conc. (PPt) (A:B) X.38 Azoxystrobin 2:1 200:100 X.38 Azoxystrobin 6.6:1 200:30 X.38 Azoxystrobin 1:1.6 60:100 X.38 Azoxystrobin 2:1 60:30 X.38 Trifloxystrobin 2:1 200:100 X.38 Trifloxystrobin 6.6:1 200:30 X.38 Trifloxystrobin 1:1.6 60:100 X.38 Trifloxystrobin 2:1 60:30 X.38 Methyltetraprole 2:1 200:100 X.38 Methyltetraprole 6.6:1 200:30 X.38 Methyltetraprole 1:1.6 60:100 X.38 Methyltetraprole 2:1 60:30 X.38 Cyproconazole 2:1 200:100 X.38 Ciproconazole 6.6:1 200:30 X.38 Ciproconazole 1:1.6 60:100 X.38 Cyproconazole 2:1 60:30 X.38 Difenoconazole 2:1 200:100 X.38 Difenoconazole 6.6:1 200:30 X.38 Difenoconazole 1:1.6 60:100 X.38 Difenoconazole 2:1 60:30 X.38 Hexaconazole 2:1 200:100 X.38 Hexaconazole 6.6:1 200:30 X.38 Hexaconazole 1:1.6 60:100 X.38 Hexaconazole 2:1 60:30

- 283 046405

X.38 Prothioconazole 2:1 200:100 X.38 Prothioconazole 6.6:1 200:30 X.38 Prothioconazole 1:1.6 60:100 X.38 Prothioconazole 2:1 60:30 X.38 Mefentrifluconazole 2:1 200:100 X.38 Mefentrifluconazole 6.6:1 200:30 X.38 Mefentrifluconazole 1:1.6 60:100 X.38 Mefentrifluconazole 2:1 60:30 X.38 Fenpropidine 2:1 200:100 X.38 Fenpropidine 6.6:1 200:30 X.38 Fenpropidine 1:1.6 60:100 X.38 Fenpropidine 2:1 60:30 X.38 Phenpropimorph 2:1 200:100 X.38 Phenpropimorph 6.6:1 200:30 X.38 Phenpropimorph 1:1.6 60:100 X.38 Phenpropimorph 2:1 60:30 X.38 Fluxapyroxad 2:1 200:100 X.38 Fluxapyroxad 6.6:1 200:30 X.38 Fluxapyroxad 1:1.6 60:100 X.38 Fluxapyroxad 2:1 60:30 X.38 Fluopyram 2:1 200:100 X.38 Fluopyram 6.6:1 200:30 X.38 Fluopyram 1:1.6 60:100 X.38 Fluopyram 2:1 60:30 X.38 Benzovindiflupir 33.3:1 200:6 X.38 Benzovindiflupir 100:1 200:2 X.38 Benzovindiflupir 10:1 60:6 X.38 Benzovindiflupir 30:1 60:2 X.38 Pid iflu metof her 2:1 200:100 X.38 Pid iflu metof her 6.6:1 200:30 X.38 Pid iflu metof her 1:1.6 60:100 X.38 Fluindapir 3.3:1 200:60 X.38 Fluindapir 33.3:1 200:6 X.38 Fluindapir 1:1 60:60 X.38 Fluindapir 10:1 60:6 X.38 Florylpicoxamide 2:1 200:100 X.38 Florylpicoxamide 6.6:1 200:30 X.38 Florylpicoxamide 1:1.6 60:100

- 284 046405

X.38 Florylpicoxamide 2:1 60:30 X.38 Metharylpicoxamide 3.3:1 200:60 X.38 Metharylpicoxamide 33.3:1 200:6 X.38 Metharylpicoxamide 1:1 60:60 X.38 Metharylpicoxamide 10:1 60:6 X.38 Chlorothalonil 2:1 200:100 X.38 Chlorothalonil 6.6:1 200:30 X.38 Chlorothalonil 1:1.6 60:100 X.38 Chlorothalonil 2:1 60:30 X.38 Mankozeb 2:1 200:100 X.38 Mankozeb 6.6:1 200:30 X.38 Mankozeb 1:1.6 60:100 X.38 Mankozeb 2:1 60:30 X.38 Mandipropamide 2:1 200:100 X.38 Mandipropamide 6.6:1 200:30 X.38 Mandipropamide 1:1.6 60:100 X.38 Mandipropamide 2:1 60:30 X.38 Oxathiapiproline 2:1 200:100 X.38 Oxathiapiproline 6.6:1 200:30 X.38 Oxathiapiproline 1:1.6 60:100 X.38 Oxathiapiproline 2:1 60:30 X.38 Fludioxonil 2:1 200:100 X.38 Fludioxonil 6.6:1 200:30 X.38 Fludioxonil 1:1.6 60:100 X.38 Fludioxonil 2:1 60:30 X.38 Cyprodinil 2:1 200:100 X.38 Cyprodinil 6.6:1 200:30 X.38 Cyprodinil 1:1.6 60:100 X.38 Cyprodinil 2:1 60:30 X.38 Metalaxyl-M 2:1 200:100 X.38 Metalaxyl-M 6.6:1 200:30 X.38 Metalaxyl-M 1:1.6 60:100 X.38 Metalaxyl-M 2:1 60:30 X.38 LG-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 2:1 200:100 X.38 LG-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 6.6:1 200:30 X.38 LG-[5-bromo-2-methyl-6-(1 -methyl-2- 1:1.6 60:100

- 285 046405

propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine X.38 X'-[5-bromo-2-methyl-6-(1-methyl-2 propoxyethoxy)-3-pyridyl]-N-ethylN-methylformamidine 2:1 60:30 X.38 X-isopropyl-X'-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 2:1 200:100 X.38 L1-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 6.6:1 200:30 X.38 L1-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 1:1.6 60:100 X.38 L1-isopropyl-LG-[5-methoxy-2-methyl-4(2,2,2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Mmethylformamidine 2:1 60:30 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 200:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 6.6:1 200:30 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[3 (trifluoromethyl)pyrazol-1 yl]phenoxy]prop-2-enoate 2:1 60:30 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 200:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-(3 propylpyrazol-1-yl)phenoxy]prop-2enoate 2:1 60:30 X.38 methyl-(2)-2-(5-cyclohexyl-2- 2:1 200:100

- 286 046405

methylphenoxy)-3-methoxyprop-2-enoate X.38 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.38 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.38 methyl (2)-2-(5-cyclohexyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.38 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 200:100 X.38 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 6.6:1 200:30 X.38 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 1:1.6 60:100 X.38 methyl (2)-2-(5-cyclopentyl-2methylphenoxy)-3-methoxyprop-2-enoate 2:1 60:30 X.38 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 2:1 200:100 X.38 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 6.6:1 200:30 X.38 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 1:1.6 60:100 X.38 methyl-(2)-2-[5-(3-isopropylpyrazol-1 yl)-2-methylphenoxy]-3-methoxyprop2-enoate 2:1 60:30 X.38 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 200:100 X.38 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 6.6:1 200:30 X.38 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 1:1.6 60:100 X.38 methyl (2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2enoate 2:1 60:30 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 200:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 6.6:1 200:30

- 287 046405

X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 1:1.6 60:100 X.38 methyl-(2)-3-methoxy-2-[2-methyl-5-[4(trifluoromethyl)triazol-2yl]phenoxy]prop-2-enoate 2:1 60:30 X.38 TAEGRO® 2:1 200:100 X.38 TAEGRO® 6.6:1 200:30 X.38 TAEGRO® 1:1.6 60:100 X.38 TAEGRO® 2:1 60:30 X.38 Timorex GoldTM 2:1 200:100 X.38 Timorex GoldTM 6.6:1 200:30 X.38 Timorex GoldTM 1:1.6 60:100 X.38 Timorex GoldTM 2:1 60:30 X.38 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 3.3:1 200:60 X.38 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 33.3:1 200:6 X.38 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 1:1 60:60 X.38 X-methoxy-T4-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3 yl]phenyl]methyl]cyclopropanecarboxy MID 10:1 60:6 X.38 T4,2-dimethoxy-X-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide 3.3:1 200:60 X.38 T4,2-dimethoxy-T\G-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide 33.3:1 200:6 X.38 T4,2-dimethoxy-T\G-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide 1:1 60:60 X.38 T4,2-dimethoxy-T\G-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]propanamide 10:1 60:6 X.38 Ν-3τηπ-2-μ6τηπ-Ν-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- 3.3:1 200:60

- 288 046405

yl]phenyl]methyl]propanamide X.38 X-ethyl-2-methyl-X-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide 33.3:1 200:6 X.38 X-ethyl-2-methyl-X-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide 1:1 60:60 X.38 X-ethyl-2-methyl-X-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]propanamide 10:1 60:6 X.38 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.38 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.38 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3yl]phenyl]methyl]urea 1:1 60:60 X.38 1-methoxy-3-methyl-1-[[4-[5 (trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.38 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.38 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.38 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.38 1,3-dimethoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6 X.38 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 3.3:1 200:60 X.38 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 33.3:1 200:6 X.38 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 1:1 60:60 X.38 3-ethyl-1-methoxy-1-[[4-[5(trifluoromethyl)-1,2,4-oxad iazol-3 yl]phenyl]methyl]urea 10:1 60:6

- 289 046405

X.38 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 3.3:1 200:60 X.38 ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 33.3:1 200:6 X.38 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3yl]phenyl]methyl]pyrazole-4carboxylate 1:1 60:60 X.38 ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3- yl] phenyl] methyl l] pyrazole-4carboxylate 10:1 60:6

Claims (15)

1. A fungicidal composition containing a mixture of components (A) and (B) as active ingredients, where component (A) is a compound of formula (I): where X represents N; Y represents C-F or C-H; R ¹ represents hydrogen, C1- _C3 alkyl, C1- _C3 alkoxy, _C1 - _C3 haloalkyl, _C1 - _C3 hydroxyalkyl, _C1 - _C3 alkoxy- _C1 - _C4 alkyl , C ₃ -C ₄ -cycloalkyl, C ₁ -C ₂ -alkoxy-C ₁ -C ₂ -alkoxy, C1-C3 alkoxycarbonyl-C1-C ₃ -alkyl, C ₁ -C ₂ -alkoxycarbonyloxy-C ₁ -C ₂ - alkyl, C ₁ -C ₂ -alkycarbonyloxy-C ₁ -C ₂ alkyl, C ₃ -C ₄ -alkynyloxy, C1-C ₃ -alkylsulfanyl, diethylamino, phenyl, benzyl, phenoxy, benzyloxy-C1C ₂ -alkyl, thienyl or furanyl ; R ² represents C1- _C4 alkyl, C1- _C4 alkoxy, C1- _C4 haloalkyl or HC(O)NH-; R ³ represents C ₃ -C ₆ -cycloalkyl, where the cycloalkyl groups are optionally substituted by 1 or 2 groups represented by R ⁴ , or R ³ represents a 6-10 membered non-aromatic spirocyclic carbobicyclyl ring system; R ⁴ represents C1- _C3 alkyl; or a salt or N-oxide thereof; and component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, pyraclostrobin, picoxystrobin, cumoxystrobin, methyltetraprole, cyproconazole, tebuconazole, difenoconazole, hexaconazole, propiconazole, fenhexamide, prothioconazole, mefentrifluconazole, prochloraz, fenpropidine, fenpropimorph, fluxapyroxade , fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, bixafen, pentiopyrad, inpirfluxam, isofetamide, pyrapropone, fluindapyr, fenpicoxamide, florylpicoxamide, acibenzolar^-methyl, trinexepak-ethyl, fosetyl-aluminum, chlorothalone silt, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tebufloquin, tolprocarb, tricyclazole, pyroquilone, cyflufenamide, metrafenone, \'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl] -\-ethyl-\-methylformamidine, N'[4-(2-bromophenoxy)-5-chloro-2-methylphenyl]-\-ethyl-\-methylformamidine, \-(1-benzie-1,3dimethylbutyl)-8 -fluoroquinoline-3-carboxamide, \-(1-benzyl-3,3,3-trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, \-(1-benzyl-3-chloro-1-methylbut-3- enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 4,4 -difluoro-3,3dimethyl-1-(7-methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3yl)-4, 4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 1 -(4,5-dimethylbenzimidazol-1-yl )-4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1-yl)isoquinoline, \'-[5-bromo-2 -methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-\-ethyl-\-methylformamidine, \'-[5-chloro-2-methyl-6-(1-methyl-2propoxyethoxy)-3- pyridyl]-\-ethyl-\-methylformamidine, \'-[5-bromo-2-methyl-6-(1-methyl-2-290 046405 propoxyethoxy)-3-pyrrvdyl]-N-isopropyl-N-methylformamdine, N-isopropyl-H'-[5-methoxy-2-methyl-4(2,2,2-tri(|)tor-1-hydroxy-1-(|)enylethyl)(|)enyl|-H-methyl( |yurmamidine, N-MemoKcu-N-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-guMeTOKCu-N-[[4-[ 5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, N-ethyl-2-methyl-H-||4-|5(trifluoromethyl)-1,2,4-oxadiazole -3-yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[ 5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl ]pyrazole-4-carboxylate, KH-dimethyl-1-||4-|5-(tri(|)tormethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]-1,2,4-triazol-3 -amine, methyl-(Z)-3-methoxy-2-[2-methyl-5-[3-(Ίriforomethyl)pyrazol-1yl]phenoxy]prop-2-enoate, methyl-(Z)-3-methoxy- 2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2enoate, methyl-^)-?-^^-isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop- 2-enoate, methyl-(^)3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(^)-3-methoxy-2 -|2-methyl5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(Z)-2-(5-cyclohexyl-2-methylphenoxy)3-methoxyprop-2-enoate , methyl (Z)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(Z)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy ]-3-methoxyprop-2-enoate, methyl-(Z)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(Z )-2-[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(^)-3-methoxy-2-|2-methyl-5-|5( trifluoromethyl)thiazol-2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide. 2. The fungicidal composition according to claim 1, wherein component (A) is a compound selected from [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]acetate (connection X.01); |2-||4-(cyclobutylcarbamoyl)-5-methylthiazol-2-yl|-(2,6-di(tor-4-pyridyl)amino|-1-methyl-2oxoethyl]ethyl carbonate (compound X.02); [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl|methyl carbonate (connection X.03); [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]ethyl carbonate (connection X.04); 2-[(2,6-difluoro-4-pyridyl)-(2-hydroxypropanoyl)amino]-5-methyl-N-spiro[3.4]octan-3-ylthiazol-4carboxamide (compound X.05); 2-[2-benzyloxypropanoyl-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5-methylthiazol-4carboxamide (compound X.06); N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxypropanoyl)amino]-5-methylthiazol-4carboxamide (compound X.07); [2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2-yl]amino]-2oxoethyl]acetate (compound X.08) ; 2-[(2,6-difluoro-4-pyridyl)-(2-phenylacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.09); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methoxy-N-spiro[3.4]octan-3-ylthiazol-4-carboxamide (compound X.10); 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-N-spiro[3.4]octan-3-ylthiazol-4carboxamide (compound X.11); N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methylthiazole-4-carboxamide (compound X.12); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-cyclobutyl-5-methylthiazole-4-carboxamide (compound X.13); 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.14); 2-[(2,6-difluoro-4-pyridyl)-(2-ethoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.15); 2-[diethylcarbamoyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.16); 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.17); methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-3-oxopropanoate (compound X.18); 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.19); methyl 5-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-5-oxopentanoate (compound X.20); 2-[(2,6-difluoro-4-pyridyl)-(3,3,3-trifluoropropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-291 046405 methylthiazole-4-carboxamide (compound X. 21); methyl 4-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-4-oxobutanoate (compound X.23); 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.24); 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.25); phenyl-H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate (compound X.26); 2-[(2,6-difluoro-4-pyridyl)-(2-fluoroacetyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.27); 2-methoxyethyl-H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5methylthiazol-2-yl]carbamate (compound X.28); 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.29); ethyl H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate (compound X.30); 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.31); methyl-H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate (compound X.32); 2-[(2,6-difluoro-4-pyridyl)formylamino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.33); ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-2-oxoacetate (compound X.34); 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.35); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.36); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-spiro[3.4]octan-3-ylthiazol-4-carboxamide (compound X.37) and 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.38). 3. Fungicidal composition according to claim 1 or 2, where component (A) is selected from: [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]acetate (connection X.01); [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]ethyl carbonate (connection X.04); N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxypropanoyl)amino]-5-methylthiazol-4carboxamide (compound X.07); 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-H-spiro[3.4]octan-3-ylthiazol-4carboxamide (compound X.11); N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methylthiazol-4-carboxamide (compound X. 12); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-H-cyclobutyl-5-methylthiazole-4-carboxamide (compound X.13); 2-[(2-benzyloxyacetyl)-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.14); 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.17); methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-3-oxopropanoate (compound X.18); 2-[(2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.19); 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.24); phenyl-H-(2,6-difluoro-4-pyridyl)-H-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]carbamate (compound X.26); 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.29); 2-[(2,6-difluoro-4-pyridyl)-(thiophene-2-carbonyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.31); - 292 046405 2-[(2,6-difluoro-4-pyridyl)formylamino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.33); ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-2-oxoacetate (compound X.34); 2-[benzoyl-(2,6-di(|)tor-4-pyridyl)amino|-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.35); 2-[acetyl-(2.6-di((()tor-4-pyridyl)amino|-H-(2.2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.36); 2-[acetyl-(2.6-di(()tor-4-pyridyl)amino|-5-methyl-H-spiro[3.4|octan-3-ylthiazol-4-carboxamide (compound X.37) and 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.38). 4. Fungicidal composition according to any one of claims 1 to 3, where component (A) is selected from: [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]acetate (connection X.01); [2-[(2,6-difluoro-4-pyridyl)-[5-methyl-4-(spiro[3.4]octan-3-ylcarbamoyl)thiazol-2-yl]amino]-1methyl-2-oxoethyl]ethyl carbonate (connection X.04); 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methyl-H-spiro[3.4]octan-3-ylthiazol-4carboxamide (compound X.11); N-cyclobutyl-2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-5-methylthiazol-4-carboxamide (compound X. 12); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-H-cyclobutyl-5-methylthiazole-4-carboxamide (compound X.13); 2-[(2-chloroacetyl)-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.17); methyl 3-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-3-oxopropanoate (compound X.18); 2-[2,6-difluoro-4-pyridyl)-(furan-2-carbonyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.19); 2-[cyclopropanecarbonyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5methylthiazole-4-carboxamide (compound X.24); 2-[2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazol-4carboxamide (compound X.29); 2-[(2,6-difluoro-4-pyridyl)formylamino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.33); ethyl 2-[(2,6-difluoro-4-pyridyl)-[4-[(2,2-dimethylcyclobutyl)carbamoyl]-5-methylthiazol-2yl]amino]-2-oxoacetate (compound X.34); 2-[benzoyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.35); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole-4carboxamide (compound X.36); 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-5-methyl-H-spiro[3.4]octan-3-ylthiazol-4-carboxamide (compound X.37) and 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-H-(2,2-dimethylcyclobutyl)-5-methylthiazole4-carboxamide (compound X.38). 5. Fungicidal composition according to any one of claims 1 to 4, where component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole, hexaconazole, propiconazole, prothioconazole, me(entri(luconazole, (enpropidine) , (enpropimor(a, (luxapyroxade, (luopyram, isopyrazam, sedaxana, benzovindi(lupyra, pidi(lumeto(ene), iso(lucipram, iso(etamide, pyrapropone, (luindapyra, (enpicoxamide, (lorylpicoxamide, acibenzolar^-methyl, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifen, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, cyflufenamide, metrafenone, K'-[2-chloro-4-(2-fluorophenoxy)- 5methylphenyl]-N-ethyl-N-methylformamidine, K'-[4-(2-bromophenoxy)-5-chloro-2-methylphenyl|-K-ethyl-Kmethylformamidine, N-(1-benzyl-1,3-dimethylbutyl )-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3trifluoro-1-methylpropyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3-chloro-1-methylbut -3-enyl)-8-fluoroquinoline-3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3dimethylisoquinoline, 4, 4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5-a|pyridin-3-yl)isoquinoline, 1 (6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl )-4,4,6-trifluoro-3,3-dimethylisoquinoline, 1-(4,5dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline, 1-(4,5-dimethylbenzimidazole -1-yl)4,4-difluoro-3,3-dimethylisoquinoline, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4-methylbenzimidazol-1 yl)isoquinoline, N'-[5 -bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl| -K-ethyl-K- 293 046405 methylformamidine, No.-[5-chloro-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-No.ethyl-No. methylformamidine, No.-[5- bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridyl]-Nisopropyl-N methylformamidine, N-isopropyl-N-[5-methoxy-2-methyl-4-(2,2, 2-trifluoro-1-hydroxy-1 phenylethyl)phenyl]-Nmethylformamidine, Nmethoxy-N[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]cyclopropanecarboxamide, K2- dimethoxy^-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3yl]phenyl]methyl]propanamide, ^ethyl-2-methyl^-[[4-[5-(trifluoromethyl)-1.2.4 -oxadiazol-3yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 1, 3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, 3-ethyl-1-methoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3yl]phenyl]methyl]urea, ethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl ]pyrazol-4carboxylate, K^dimethyl-1-[[4-[5-(trifluoromethyl)-1.2.4-oxadiazol-3-yl|phenyl|methyl|-1.2.4-lriazol3-amine, methyl-(2) -3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl -5 -(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl-(2)-2-[5-(3isopropylpyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2- enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-(4propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl-(2)-3-methoxy-2-[2 -methyl-5-[4(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl-(2)-2-(5-cyclohexyl-2-methylphenoxy)-3methoxyprop-2-enoate, methyl- (2)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate, methyl(2)-2-[5-(4-cyclohexylthiazol-2-yl)-2-methylphenoxy]-3 -methoxyprop-2-enoate, methyl-(2)-2-[5-[4(ethoxymethyl)thiazol-2-yl]-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-2 -[5-(4-bromothiazol-2yl)-2-methylphenoxy]-3-methoxyprop-2-enoate, methyl-(2)-3-methoxy-2-[2-methyl-5-[5(trifluoromethyl)thiazole -2-yl]phenoxy]prop-2-enoate, TAEGRO®, Timorex Gold™ and methylpicoxamide. 6. Fungicidal composition according to any one of claims 1 to 5, where component (B) is a compound selected from the group consisting of azoxystrobin, trifloxystrobin, methyltetraprole, difenoconazole. hexaconazole. propiconazole. prothioconazole. mefentrifluconazole. phenpropidine. fenpropimorph, fluxapyroxad, fluopyram, isopyrazam, sedaxane, benzovindiflupyr, pidiflumetofen, isoflucipram, isofetamide, pyrapropone, fluindapir, fenpicoxamide, florylpicoxamide, chlorothalonil, mancozeb, mandipropamide, oxathiapiproline, fluazinam, fludioxonil, cyprodinil, metalaxyl-M, aminopyrifene, folpet, ipflufenoquin, quinofumeline, tricyclazole, pyroquilone, N-(1-benzyl-1,3-dimethylbutyl)-8-fluoroquinoline-3-carboxamide, N-(1-benzyl-3,3,3-trifluoro1-methylpropyl)-8-fluoroquinoline- 3-carboxamide, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5trifluoro-3,3-dimethylisoquinoline, 4,4-difluoro-3,3-dimethyl- 1-(7-methylpyrazolo[1,5-a]pyridin-3yl)isoquinoline, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethylisoquinoline and 1- (4,5dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethylisoquinoline. 7. Fungicidal composition according to any one of claims 1 to 6, where the weight ratio of component (A) and component (B) is from 100:1 to 1:100. 8. Fungicidal composition according to any one of claims 1 to 7, where the weight ratio of component (A) and component (B) is from 20:1 to 1:40. 9. Fungicidal composition according to any one of claims 1 to 8, where the weight ratio of component (A) and component (B) is from 12:1 to 1:25. 10. Fungicidal composition according to any one of claims 1 to 9, where the weight ratio of component (A) and component (B) is from 5:1 to 1:15. 11. Fungicidal composition according to any one of claims 1 to 10, where the weight ratio of component (A) and component (B) is from 2:1 to 1:5. 12. A fungicidal composition according to any one of claims 1 to 11, where the composition contains one or more additional pesticides selected from the group consisting of a fungicide selected from etridiazole, fluazinam, benzovindiflupir, pidiflumetofen, benalaxyl, benalaxyl-M (kyralaxyl), furalaxyl , metalaxyl, metalaxyl-M (mefenoxam), dodicine, N-[(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylformamidine, I-[4-(4.5-dichlorothiazol-2yloxy)-2, 5-dimethylphenyl]-N-ethyl-N-methylformamidine, I-[4-[[3-[(4-chlorophenyl)methyl|-1.2.4thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-H -ethyl-N-methylformamidine, ethirimol, 3'-chloro-2-methoxy-N[(3RS)-tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (closilacone), cyprodinil, mepanipyrim , pyrimethanil, dithianone, aureofungin, blasticidin-S, biphenyl, chloroneb, dichlorane, hexachlorobenzene, quintozene, tecnazene (TCNB), tolclofos-methyl, metrafenone, 2,6-dichloro-N-(4trifluoromethylbenzyl)benzamide, fluopicolide (flupicolide), thioximide, flusulfamide, benomyl, carbendazim, carbendazim hydrochloride, chlorphenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, betoxazine, pyriophenone (IKF-309), acibenzolarA-methyl. pyribencarb (KIF-7767), butylamine, 3-iodo-2-propynyl-n-butylcarbamate (IPBC), iodocarb (isopropanylbutylcarbamate), isopropanylbutylcarbamate (iodocarb), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-No( 7-fluoro-1,1,3,3-tetramethylindan-4-yl)1-methylpyrazole-4-carboxamide, diclocimet, N[(5-chloro-2-isopropylphenyl)methyl]-Ncyclopropyl-3(difluoromethyl)- 5-fluoro-1-methylpyrazole-4-carboxamide, N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N[(2isopropylphenyl)methyl|-1-methylpyrazole-4-carboxamide, carpropamide, chlorothalonil, flumorph, ok- 294 046405 copper sina, cymoxanil, fenamacryl, cyazofamide, flutianil, thithiophene, chlozolinate, iprodione, procymidone, vinclozolin, bupirimate, dinoctone, dinopentone, dinobutone, dinocap, meptyldinocap, diphenylamine, phosdiphene, 2,6-dimethyl-[1,4]dit foreign [2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)tetraone, azithiram, ethem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc , nabama, propineba, tiram, vapam (sodium metam), cineba, cyram, dithioether, isoprothiolane, ethaboxam, fosetyl, fosetyl aluminum (fosetyl-A1), methyl bromide, methyl iodide, methyl isothiocyanate, cyclofuramide, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2-(bromomethyl)glutaronitrile (bromotalanil), dodine, doguadine, guazatin, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethylrimol, fenhexamide, hymexazole, hydroxyisoxazole , imazalil, imazalyl sulfate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone, Bordeaux mixture, calcium polysulfide, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulfate, copper tallate , copper oxide, sulfur, carbaryl, phthalide (phthalide), dingjunezuo (Jun Si Qi), oxathiapiproline, fluoroimide, mandipropamide, KSF-1002, benzamorph, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, hydroxycarboxine, drazoxolone, famoxadone, mphenylphenol, p-phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6fluorophenyl]propan-2-ol, 2 -[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol, cyflufenamide, ofuras, oxadixil, flutolanil, mepronil, isofetamide, fenpiclonil, fludioxonil, pencycuron, edifenphos, iprobenphos, pyrazophos, phosphoric acids, teclophthalam, captafol, captan, dithalymphos, triforin, fenpropidine, piperaline, osthole, 1-methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipine, endothal, ethephon, flumetralin, forchlorfenuron, gibber Hellenic acid, gibberellins, hymexazole, maleic hydrazide, mepiquat, naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-calcium, thidiazuron, tribufos (tributylfopsfortrithioate), trinexapac, uniconazole, a-naphthaleneacetic acid, polyoxin D (polyoxrim), BLAD, chitose na, fenoxanil, folpeta , 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-methyl-2(2,4,6-trichlorophenyl)ethyl]pyrazole-4-carboxamide, bixafen, fluxapyroxad, furamethpyr, isopyrazam, penflufen, pentiopyrad, sedaxane, fenpyrazamine, diclomezine, pyrifenox, boscalid, fluopyram, diflumetorim, fenarimol, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, ferimzone, dimethachlon (dimethaclone), pyroquilone, proquinazide, ethoxyquin, quinoxifene, 4,4,5-trifluoro-3,3dimethyl-1-(3-quinolyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1-(3-quinolyl)isoquinoline, 5-fluoro-3,3, 4,4tetramethyl-1 -(3-quinolyl)isoquinoline, 9-fluoro-2,2-dimethyl-5 -(3-quinolyl)-3H-1,4-benzoxazepine, tebufloquin, oxolinic acid, quinomethionate (hydroxythioquinox, quinoxymethionate) , spiroxamine, N-N-methyl-p-CA-dimethylphenoxymethyl-enylN-methoxyiminoacetamide (mandestrobin), azoxystrobin, cumoxystrobin, dimoxystrobin, enestroburin, pyriotrobin, fenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, methaminostrobin, met ominostrobin, orysastrobin , picoxystrobin, pyraclostrobin, pyramethostrobin, pyroxystrobin, trichloropyricarb, trifloxystrobin, amisulbrom, dichlofluanid, tolylfluanid, but-3-ynyl-N-[6[[(2)-[(1-methyltetrazol-5-yl)-phenylmethylene]amino] hydroxymethyl]-2-pyridyl]carbamate, dazomet, isothianil, thiadinil, tifluzamide, benthiazole (TCMTB), silthiopham, zoxamide, anilazine, tricyclazole, (+-)-cis-1-(4-chlorophenyl)-2-(III- 1,2,4-triazol-1-yl)-cycloheptanol (Huanjunzuo), 1 -(5-bromo-2pyridyl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1,2 ,4-triazol-1-yl)propan-2-ol, 2-(1-tert-butyl)-1 -(2chlorophenyl)-3-(1,2,4-triazol-1-yl)propan-2- ol (TCDP), N-[5-bromo-2-methyl-6-(1-methyl-2propoxyethoxy)-3-pyridyl]-N-ethyl-N-methylformamidine, azaconazole, bitertanol (biloxazole), bromuconazole, climbazole, cyproconazole, difenoconazole, dimethconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole a, prothioconazole, mefentrifluconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, 2-[[(N^)-5-[(4-fluorophenyl)methyl]-1-hydroxy-2,2dimethylcyclopentyl]methyl]-4H-1,2,4-triazol-3-thione , 2-[[3 -(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazol-3-thione, amethoctradine (imidium), iprovalicarb, valifenalate, 2-benzyl-4-chlorophenol (chlorophen), allyl alcohol, azaphenidine, benzalkonium chloride, chloropicrin, cresol, daracid, dichlorophen (dichlorophen), diphenzoquat, dipyrithione, Na(2-p-chlorobenzoylethyl)hexaminium chloride, NNF-0721 , octilinone, oxasulfuron, Timorex Gold™ (a plant extract containing tea tree oil), propamidine and propionic acid; or an insecticide selected from abamectin, acephat, acetamipride, amidofluomet (S-1955), Avermectin, Azadihitin, Azinfos-Meadiel, bifentrin, bifenazate, bupophysin, carbofurane, cardpeap, chlorrantiliprol (DPX-E2Y45), chlorfenapir, chlorfenapir, chlorfinapine, chlorflower, chlorfino-chloride Pyrifose, chlorpyricthos -methyl, cromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambdacyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diophenolan, emamectin, endosulfan, esfenvalerate, ethiprole, phenothiocarb , fenoxycarb, fenpropatrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucitrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonofos, - 295 046405 halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathione, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitene pyrama, nithiazine, novaluron, noviflumuron (XDE-007 ), oxamyl, parathion, parathion-methyl, permethrin, phorate, fosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazone, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifene (BSN 2060), spirotetramate, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultapsodium, tralomethrine, triazamate, trichlorfon and triflumuron; or a bactericide selected from streptomycin, or an acaricide selected from amitraz, quinomethionate, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, phenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridabene and tebufenpyrad ; or a biological agent selected from Bacillus thuringiensis, Bacillus thuringiensis delta-endotoxin, baculovirus and entomopathogenic bacteria, virus and fungi. 13. A fungicidal composition according to any one of claims 1 to 12, wherein the composition further comprises an agriculturally acceptable carrier and optionally a surfactant and/or formulation auxiliaries. 14. A method for controlling or preventing phytopathogenic diseases of useful plants or their propagation material, especially those caused by phytopathogenic fungi, which includes the use of a fungicidal composition according to any one of claims 1 to 12 in relation to useful plants, their habitat or their propagation material. 15. The method according to claim 14, wherein components (A) and (B) of the composition are applied in a sequential manner.